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ALWAYS LAUGH WHEN YOU CAN. IT IS CHEAP MEDICINE. 
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Summary 
Elaboration of new generations of more effective and safer metal-based anticancer 
agents, has been stimulated by the severe side effects encountered by patients 
undergoing chemotherapeutic treatments. In this search, ruthenium complexes have 
shown encouraging potential, demonstrating a wide antiproliferative profile against 
cancer cells. Seminal studies conducted in our labs have resulted in the development 
of ruthenium(II)-based new anticancer agents, which showed distinct cytotoxicity 
mechanisms. 
First, a substitutionally-inert bis(dppz)-Ru(II) complex has been synthetized that 
impairs the mitochondrial membrane potential of cells leading to apoptosis. A follow-
up structure-activity relationship analysis investigating the impact of lipophilicity, 
charge and size-based modification revealed the presence of carboxylic acid 
functionality as indispensable to confer cytotoxicity to the Ru(II) complex. This 
complex was successfully inactivated by protecting the carboxylate functionality with 
a photolabile protecting group. The anticancer activity could be regained by UV-A 
irradiation (2.58 J/cm2). 
Second, a seemingly harmless ruthenium(II) complex was prepared. It targets the 
cell nucleus and causes significant damage to DNA, such as single-strand breaks 
(SSBs) and purines oxidation upon UV-A irradiation (1.29 J/cm2). After 24 h, double-
strand breaks (DSBs) are also created that lead overall to cell death. 
Collectively, these findings are an important progress towards developing a new 
class of metal-based anticancer agents, which have the potential to overcome the 
drawbacks of the current platinum-based drugs. 
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Zusammenfassung 
Die Ausarbeitung einer neuen Generation von effizienteren und sichereren 
Antikrebswirkstoffen auf Metallbasis wurde von den starken Nebenwirkungen, die 
Patienten erleiden, welche mit Medikamenten auf Platinbasis behandelt werden, 
angeregt. In dieser Suche haben sich Rutheniumkomplexe durch ihr grosses Potential 
hervorgetan und ein weites Spektrum an antiproliferativer Wirkung auf Krebszellen 
gezeigt. Bahnbrechende Studien unseres Labors haben zur Entwicklung von 
neuartigen, auf Ruthenium(II) basierenden Antikrebsmitteln geführt, welche 
ausgeprägte zytotoxische Mechanismen aufweisen, sobald sie durch Licht aktiviert 
wurden. 
Als erstes wurde ein substitutionell-inerter bis(dppz)-Ru(II) Komplex synthetisiert, 
welcher auf Mitochondrien abzielt und deren Membranpotential beeinträchtigt, was 
zur Apoptose führt. Eine darauf folgende Struktur-Aktivitätsanalyse, welche die 
Auswirkung von Lipophilie, Ladung und Grössenmodifikation untersuchte, hat 
gezeigt, dass das Vorhandensein einer funktionellen Carbonsäure unabdingbar für 
eine zytotoxische Wirkung des Ru(II) Komplexes ist. Dieser Komplex konnte 
inaktiviert werden durch das Verdecken des funktionellen Carboxylats mit einer 
photolabilen Schutzgruppe, wobei die Antikrebswirkung durch Bestrahlung mit UV-
A (2.58 J/cm2) wiederhergestellt werden konnte.  
Als zweites wurde ein scheinbar harmloser Ruthenium(II) Komplex konstruiert, 
welcher den Zellnukleus zum Ziel hat, wo er, nach erfolgter UV-A Bestrahlung (1.29 
J/cm2), signifikanten Schaden an der DNS anrichtet, beispielsweise “single-strand 
breaks“ und Purinoxidation. Nach 24h entstehen zusätzlich DNS “double-strand 
breaks“, was schliesslich zum Zelltod führt.  
Zusammenfassend sind diese Erkenntnisse ein wichtiger Schritt in Richtung einer 
neuen Klasse von Antikrebsmitteln auf Metallbasis, welche das Potential haben, die 
Nachteile der derzeitigen Medikamente auf Platinbasis zu überwinden. 
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1. Introduction 
 
 
 
 
 
 
 
An overview about the effects of cisplatin on DNA and how cells cope with DNA 
damages: repair and resistance mechanisms; and highlight on the use of Ruthenium 
complexes in phototherapy.  
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1.1. CISPLATIN 
1.1.1. SERENDIPITOUS DISCOVERY 
 The accidental discovery made by Rosenberg and colleagues in the 1960s, that the 
reaction product of a platinum electrode and ammonium chloride, cisplatin (Figure 1), 
was able to halt bacterial cell division, revolutionized few years later the field of 
cancer treatment.1, 2 While severe side effects encountered by patients almost stopped 
clinical trials in phase I, the stunning amount of partial and complete remissions 
reported on patients who previously exhausted all possible treatments in phase I and 
inter alia on early testicular cancer in phase II, led to drug approval in 1978.3 
Cisplatin has a potent effect on treating several types of solid cancers, among which 
feature testes, ovaries, bladder, head and neck, lung and breast.4-6 Although actions 
have been taken to tackle the most common side effects (e.g. anti-nausea drugs and 
hydration to take care of the kidney),3, 7 cisplatin treatment remains aggressive for 
most of the tissues.8-10 The main goal of anticancer research is now two-pronged: 
overcoming side effects (i.e. carboplatin)11, 12 and preventing resistance (i.e. 
oxaliplatin on colorectal cancer) (structures in Figure 1).12, 13 Combination therapies 
are frequently used, but research towards other metal complexes is also ongoing.  
  
 
Figure 1. Structures of cisplatin and platinum derivatives. 
 
1.1.2. MECHANISM OF ACTION AND REPAIR: FOCUS ON DNA INTERACTION 
A lot of efforts have been invested in order to clearly understand the mechanism of 
action of cisplatin. Even if the DNA is the undeniable major target of the drug, effects 
have been reported on protein or mitochondrial function for example.14, 15 By itself, 
cisplatin is a neutral compound. To interact with DNA, cisplatin follows spontaneous 
aquation in cells, corresponding to the replacement of cis-chloro groups with water 
molecules. The mono- and bi-activated forms are both reactive with purine at position 
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N7, leading to the formation of DNA-protein crosslink as well as inter-strand and 
intra-strand DNA crosslinks (Figure 2).16 However only bi-adduct are responsible for 
toxicity, since transplatin (Figure 1) lesions on DNA are not cytotoxic.12 
HN
N N
N
O
H2N
NH
NN
N
O
NH2
Pt
H3N NH3
dsDNA
Intrastrand 1,2-d(GpG) crosslink
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Figure 2. Majors DNA interaction of cisplatin. 
Intra-strand DNA crosslinks account for about 90 % of the cisplatin-DNA 
crosslinks and are mainly repaired by the Nucleotide Excision Repair (NER) 
machinery.17 On the other hand, the only 10% remaining inter-strand crosslinks are 
the most toxic ones, since covalent lesions are formed on both strands of DNA, 
thereby blocking replication forks.18 They require the Fanconi Anemia (FA) and 
Homologous recombination (HR) pathway for repair. Repair mechanisms of cisplatin 
induced DNA crosslinks are detailed in chapter 1.3. Taken together, these intra- and 
inter-strand crosslinks represent a massive burden for the cell, in a way that overloads 
both repair pathways and ultimately leads to cell death. 
 
1.1.3. MECHANISM OF RESISTANCE IN CELL 
Resistance to chemotherapeutics results in an insufficiency trigger of apoptosis. The 
mechanisms observed to play a role in resistance, spontaneously occurring or linked 
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to chronic drug exposure, include (i) decreased accumulation of the drug in cells, (ii) 
increased efflux and (iii) increased activation of repair machinery.12, 16 
Specifically to point (i), once injected in the blood, thiol-containing molecules, such 
as glutathione (GSH) or cysteinylglycine, play an important role in cisplatin 
resistance, as high level of metallothioneins correlates with decrease sensitivity to 
cisplatin. GSH acts as a redox-regulator, inhibiting the pool of the active form of the 
drug through thiol-conjugation.19 Therefore, increased production of GSH or thiol-
containing molecules in general, for instance by over activation of factors involved in 
the synthesis, will reduce the pool of functional cisplatin. Decreased accumulation of 
cisplatin can also arise from decreased amount of drug entering cells. Most of the 
drug enters the cell by passive diffusion, although a portion of cisplatin enters cells by 
active transport. Decreased expression of membrane transporters CTR1, reduces the 
portion of cisplatin.20  
Regarding point (ii), as cofactor of the multidrug resistance protein 2 (MRP2), GSH 
also facilitates the efflux of cisplatin. Overexpression of MRP2 has been shown to 
promote cisplatin insensitivity.  
Finally, regarding point (iii), overexpression of members of DNA repair 
machineries, leading to efficient repair (i.e., as in this case NER and HR), or 
inhibition of factors involved in apoptosis, such as p53,21 Bcl members or caspases, 
will contribute to cell survival and hence resistance.16 
 
1.1.4. RUTHENIUM COMPLEXES AS PROMISING PLATINUM SUBSTITUTES IN CANCER 
In the quest for anticancer drugs with increased potency and reduced side effects, 
other metal complexes than platinum have been examined, with ruthenium complexes 
being one of the best candidates.22, 23 While the mode of action of platinum derivatives 
is related to DNA targeting, Ru compounds have been reported to target different 
cellular organelles such as the nucleus and the mitochondria, for example. The 
differences in the biological activity of ruthenium compounds lie in the different 
coordination states and the wide range of ligands that can be coordinated to the metal 
centre. Ruthenium complexes differ from other metal complexes in the fact that under 
physiological conditions, ruthenium can reach three oxidation states, namely Ru(II), 
Ru(III) and Ru(IV). The oxidation potential of Ru complexes in general can be 
INTRODUCTION	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exploited to target their activity towards cancer or infected areas. Indeed, cancer and 
diseased tissue in general, produce a reduced environment which is prompt to convert 
relatively inert Ru(III) into active Ru(II).24 Such strategy is generally referred to as 
"activation by reduction". The Ru(III) complex acts therefore as prodrug. In other 
words, the product injected to the patient is not the active form.  
Moreover, the Ru oxidation states (II) and (III) are both prone to ligand exchange. 
Importantly, it has been now postulated that Ru complexes are mimicking iron in 
binding to protein that usually bind to iron such as albumin or transferrin.25 This 
phenomenon would explain why usually Ru complexes have a lower systemic toxicity 
compared to platinum drugs. However, it has been established that cancer cells, by 
continuously dividing, require more iron, and thereby, increase the expression of the 
transferrin receptor at their cellular membrane. The latest peculiarity will allow for a 
more specific delivery of the Ru complexes to cancer over healthy cells via transferrin 
transportation.  
Worthy of note, two ruthenium compounds namely, NAMI-A and KP1339, are now 
in phase II clinical trial and a third one, RAPTA-C is proceeding towards clinical trial 
(structures in Figure 3).24, 26, 27 
 
 
 
 
Figure 3. Structures of NAMI-A, KP1019, KP1339 and RAPTA-C. 
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1.2. RU(II) COMPLEXES AND LIGHT: TARGETED THERAPY 
1.2.1. AIM AND SCOPE  
The severe systemic side effects encountered by patients treated with cisplatin have 
driven the research to elaborate more targeted strategies.21 Light-activated therapy has 
become an attractive strategy in the clinic since temporal and spatial control is 
possible. In photodynamic therapy (PDT), light, oxygen and innocuous 
photosensitizers (PS) are combined to produce cytotoxic reactive oxygen species 
(ROS), which ultimately kill nearby cells. This therapy is currently used in the clinic, 
especially for the treatment of skin diseases, but is more and more applied for the 
treatment of cancer, typically for skin, head and neck and cavity-located cancers. 
Among all the photosensitizers approved, only two bear a metal ion.28 This is 
surprising since platinum-based anticancer compounds are the most used drugs in 
chemotherapy.  
Another light-triggered approach using metal complexes, namely photo-activated 
chemotherapy (PACT), relies on different mechanisms to provoke cell death (e.g. 
ligand ejection, DNA crosslinking and caging approaches). The advantage of the 
latter technique is its oxygen independency, fundamental since the internal core of 
tumor are generally hypoxic.29 
In the following perspective article, the use of Ru(II) complexes as photosensitizers 
and photoactivatable prodrugs in the treatment of cancer is presented. 
 
1.2.2. CONTRIBUTIONS TO THE PERSPECTIVE ARTICLE 
V.P.: wrote the Ruthenium complexes in PACT chapter of the first draft. This 
perspective article as been accepted for publication in Chem. Sci. 
(DOI:10.1039/C4SC03759F).  
 
1.2.3. PERSPECTIVE ARTICLE: COMBINATION OF RU(II) COMPLEXES AND LIGHT NEW 
FRONTIERS IN CANCER THERAPY30  
Reproduced by permission of The Royal Society of Chemistry. 
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Combination of Ru(II) complexes and light: new
frontiers in cancer therapy
Cristina Mari,†a Vanessa Pierroz,†ab Stefano Ferrarib and Gilles Gasser*a
The synergistic action of light, oxygen and a photosensitizer (PS) has found applications for decades in
medicine under the name of photodynamic therapy (PDT) for the treatment of skin diseases and, more
recently, for the treatment of cancer. However, of the thirteen PSs currently approved for the treatment
of cancer over more than 10 countries, only two contain a metal ion. This fact is rather surprising
considering that nowadays around 50% of conventional chemotherapies involve the use of cisplatin and
other platinum-containing drugs. In this perspective article, we review the opportunities brought by the
use of Ru(II) complexes as PSs in PDT. In addition, we also present the recent achievements in the
application of Ru(II) complexes in photoactivated chemotherapy (PACT). In this strategy, the presence of
oxygen is not required to achieve cell toxicity. This is of signiﬁcance since tumors are generally hypoxic.
Importantly, this perspective article focuses particularly on the Ru(II) complexes for which an in vitro
biological evaluation has been performed and the mechanism of action (partially) unveiled.
Introduction
The biological activity of ruthenium (Ru) compounds has been
known for decades.1–3 Two Ru complexes are currently in phase
II clinical trials (NAMI-A and KP1339) as anticancer drug
candidates and a third one, RAPTA-C, is progressing towards
clinical trials (see Fig. 1 for the structures of these
compounds).4–10 The increasing interest in the biological
behavior of Ru compounds is due to their appealing physico-
chemical properties. Among others, such complexes can have
diﬀerent geometries (e.g. tetrahedral or octahedral) allowing for
the design of compounds with a specic cellular target (e.g.
proteins). Hence, the rigid and well-dened spatial arrange-
ment of a series of Ru complexes has enabled the preparation of
highly potent and selective enzyme inhibitors. The group of
Meggers has notably demonstrated such a concept with kinase
inhibitors.2,11,12 Other attractive features of Ru complexes
include their generally lower systemic toxicity compared to
platinum complexes and their higher cellular uptake, thanks to
the specic transport of ruthenium inside cells by transferrin.13
Of utmost importance, ruthenium complexes can easily be
obtained in two oxidation states (II and III) and are prone to
ligand exchange. Such properties have been found to play a
pivotal role in the mode of action of both NAMI-A and KP1339.14
Ru(III) complexes are thus prodrugs – meaning that the
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compound which is administered to the patient is not the active
species. Ru(III) complexes are reduced into a more active Ru(II)
form when localized in an hypoxic environment, which is a
property characteristic of tumors.6 This phenomenon is nor-
mally referred to as “activation by reduction” and was also
exploited for the in situ activation of Pt-based anticancer drug
candidates, like satraplatin.15
Nowadays, the use of the “prodrug approach” is very
appealing to reduce the systemic toxicity of a drug candidate.16
In order to activate the prodrugs, two diﬀerent kinds of stimuli
can be employed, namely an internal stimulus (reducing
cellular conditions, hypoxia, enzymatic reactions, etc.) or an
external stimulus (magnetic eld, temperature, light, etc.). The
rst approach, however, presents a signicant disadvantage, in
that it completely relies on intracellular parameters. In other
words, once the prodrug is injected into the patient, physicians
have no more control over the fate of the compound. On the
contrary, this is exactly the kind of control that can be achieved
using an external stimulus. The latter indeed provides complete
spatial and temporal control over the generation of the toxic
molecule. As of today, the most commonly applied technique to
induce the formation of active species is via light
irradiation.15,17,18
The light-mediated activation of prodrugs in the eld of
anticancer research can be generally divided into two cate-
gories: photodynamic therapy (PDT) and photoactivated
chemotherapy (PACT). PDT relies mainly on the generation of
the toxic reactive oxygen species (ROS) singlet oxygen (1O2). On
the other hand, PACT exploits diﬀerent mechanisms to induce
cell death such as ligand ejection, DNA crosslinking and caging
approaches. In this perspective article, we intend to give an
overview of recent progress in the application of ruthenium
Fig. 1 Structures of NAMI-A, KP1339, KP1019 and RAPTA-C.
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complexes in both PDT and PACT, focusing particularly on
those compounds for which an in vitro evaluation of the bio-
logical activity has been performed and the mechanism of
action (partially) unveiled. Notably, these topics have been
partially reviewed in the past but an article covering all subjects
is, to the best of our knowledge, currently missing.17–26
Ruthenium complexes as
photosensitizers in PDT
Photodynamic therapy is an approved medical technique,
which is applied in dermatology for the treatment of several
diseases such as acne or psoriasis and in ophthalmology for
age-related macular degeneration. Since relatively recently, this
technique has been used for the treatment of some types of
cancer. For example, Photofrin® (Fig. 2), the only FDA-approved
PDT drug, is employed to treat esophageal and non-small cell
lung cancers. In the UK, on the other hand, there are several
photoactive agents which are clinically approved (i.e. Foscan®,
Fig. 2) to treat a wide range of cancer types, from skin to internal
organs.27,28
More specically, PDT relies on the synergistic activity of an
ideally non-toxic molecule called a photosensitizer (PS), light
and molecular oxygen. The PS is administrated to the patient
either locally or systemically. Upon light irradiation at a wave-
length in its range of absorption, the PS is able to reach its
singlet excited state 1PS* (Fig. 3). Very importantly, the PS must
then undergo an intersystem crossing (ISC) so that the excited
state has a triplet character (3PS*). At this point, PDT relies on
two diﬀerent mechanisms called Type I and Type II. A Type I
reaction consists of an electron or proton transfer from the
triplet excited state of the PS to the surrounding biological
substrates (or the other way around). This leads to the forma-
tion of radicals that can further interact with molecular oxygen
to form ROS such as superoxide, hydroxyl radicals or peroxides.
At the same time, an energy transfer from the triplet excited
state of the PS to molecular oxygen in its ground triplet state
(3O2) can occur (a Type II reaction). In this case, singlet oxygen
(1O2) is generated. 1O2 is a very reactive form of oxygen with an
estimated half life of 40 ns in a biological environment.27
Consequently, it will rapidly react just with the surrounding
biomolecules, generating topical cellular damage that can
ultimately lead to cell death. PSs which are nowadays applied in
clinics mainly rely on the Type II mechanism of action.29
PDT is a very appealing medical technique due to its intrinsic
selectivity. The toxic species are generated just at the site of light
irradiation, with complete spatial and temporal control.
Furthermore, due to the very fast reactivity of 1O2, damage is
limited to the irradiated areas. The outcomes of PDT treatment
depend on the performance of the PS but also on other very
important factors (e.g. the light component, the in vivo dosim-
etry or the oxygen tension). To be clinically applicable, a PS
should, among other requirements, (i) localize mainly (ideally
only) in cancer cells; (ii) should be non-toxic in the absence of
light, while displaying strong phototoxicity. This behavior is
normally described by the so-called phototoxic index (PI),
dened for a compound as the ratio of its IC50 in the dark to its
IC50 upon light irradiation. Finally, the PS (iii) should be excited
in the red or near-IR region of the spectrum (>600 nm). This last
requirement is very important to avoid cytotoxicity deriving
from high energy light irradiation. In addition, the use of long
wavelength light allows for a deeper penetration through the
human tissues.21,30
The great majority of PSs that are currently applied in clinics
are based on a cyclic tetrapyrrolic scaﬀold. The photophysical
and biological characteristics of porphyrins, phthalocyanines
and chlorins match the requirements for a PDT agent relatively
well. On the other hand, their performances are also limited by
important side-eﬀects. As an example, treatment with Photo-
frin® results in light sensitivity for several weeks due to slow
clearance of the drug from the body.31 As a consequence, an
Fig. 2 Structures of porphyrin-based approved PDT agents.
Fig. 3 Mechanisms of action of PDT.
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
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important eﬀort has been undertaken to improve the perfor-
mances of the current PSs following two approaches: the
modication of a conventional porphyrin-based PS or the
optimization of entirely new systems that can outperform
porphyrins in their PDT activity. In this specic section, we
present a description of the inuence of the insertion of
ruthenium fragments into porphyrin-based PSs, focusing our
attention on the works that report on the biological behavior of
these new systems. Furthermore, we present the recent
achievements in the use of ruthenium polypyridyl complexes as
novel PSs in the innovative attempt to move away from the
traditional porphyrin-as-PS paradigm.
Ruthenium-containing porphyrin PSs
The derivatization of the porphyrin core with metal complexes
is an appealing opportunity to improve the activity of a PS. This
functionalization was exploited for the rst time een years
ago by Brunner and coworkers.32,33 They synthesized hemato-
porphyrin–platinum conjugates to combine the strong anti-
cancer activity of platinum-based drugs with the phototoxic
eﬀect of porphyrins. The metal derivatization of a porphyrin
core can enhance the intrinsic properties of a PS by modifying
its physico-chemical characteristics. For example, the metal
fragment can change the lipophilicity of the PS, increase its
water solubility or improve its cellular uptake. As mentioned
above, ruthenium complexes display very promising biological
behavior. Consequently, several research groups have recently
evaluated the possibility of introducing Ru(II) moieties on the
periphery of porphyrins. For instance, Therrien et al. synthe-
sized a wide range of Ru-modied porphyrin systems and
studied their biological performances.34 More specically, they
appended a number of Ru-arene fragments to the meso-40-tet-
rapyridylporphyrin scaﬀold to evaluate the inuence of the
diﬀerent aromatic moieties (1a–e, Fig. 4, top). All the
compounds were found to induce 60–80% mortality in human
Me300 melanoma cells at a 10 mM concentration, using light at
652 nm with a dose of 5 J cm!2. The photoactivity of the metal-
functionalized systems was found to be independent of the
nature of the arene. This exibility can give access to the use of
arenes which are derivatized with targeting agents or chemo-
therapeutic compounds. Fig. 5, which shows the phototoxicity
evaluation of the compounds synthesized by Therrien et al.,
demonstrates that the improved behavior of their systems
required the presence of the Ru fragment, since the Rh analog 3
was not internalized by cells and was therefore not toxic. In
addition, the Os derivative 2 exerted just a weak phototoxic
eﬀect (see Fig. 4 for the structures of the latter compounds).
The same authors also studied the inuence of tetra- vs.
mono-metallic derivatization (4a-b/6a–b vs. 5a–b/7a–b, Fig. 6),
Fig. 4 Structures of Ru–porphyrin conjugates (top, 1a–e), and Os and Rh analogs (bottom, 2 and 3).34
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
Chemical Science Perspective
Op
en
 A
cc
ess
 A
rti
cle
. P
ub
lis
he
d o
n 1
3 J
an
ua
ry 
20
15
. D
ow
nlo
ad
ed
 on
 13
/02
/20
15
 11
:00
:27
. 
 T
his
 ar
tic
le 
is 
lic
en
sed
 un
de
r a
 C
rea
tiv
e C
om
mo
ns
 A
ttr
ibu
tio
n 3
.0 
Un
po
rte
d L
ice
nc
e.
View Article Online
as well as the nature of the pyridylporphyrin isomers, by
comparing 40-pyridylporphyrin or 30-pyridylporphyrin derivatives
(4a–b/5a–b vs. 6a–b/7a–b, Fig. 6).35 Several conclusions could be
drawn from this small structure–activity relationship (SAR) study.
For example, the type of pyridylporphyrin isomer was shown to
play a major role in the observed activity, since the 30-pyridyl
substituted compounds showed a greater phototoxic eﬀect than
the 40-pyridyl analogs. On the other hand, the number of Ru
atoms or the arene derivatization seemed to have less inuence
on the biological activity.
In more detail, upon the 652 nm light irradiation of human
Me300 melanoma cells, a LD50 of 5 mM was reached with a light
dose of 0.5 J cm!2 for compounds 6a and 6b and with a light
dose of 2.5 J cm!2 for 7a and 7b. For the 4-pyridyl derivatives, 5
or even 10 J cm!2 were necessary to achieve the same potency.
This diﬀerence in biological activity was explained by lumi-
nescence microscopy studies, where 4a (more hydrophobic) was
shown to form aggregates inside the cytoplasm (Fig. 7A),
although the authors did not discuss further about accumula-
tion in a specic organelle. This aggregation could lead to a
quenching of the ROS production. On the contrary, compound
Fig. 6 Structures of the Ru–porphyrin conjugates evaluated in the SAR study by Schmitt et al.35
Fig. 7 Fluorescence microscopy images of human Me300 melanoma
cells incubated for 24 h with 5 mM of 4a (A) and 6a (B), displaying red
luminescence. The blue luminescence in the nuclei derives from DAPI
co-staining. With kind permission from Springer Science and Business
Media.35
Fig. 5 Phototoxicity evaluation of compounds 1a–e, 2 and 3 on
Me300 melanoma cells. Cells were incubated with 10 mM of the
compounds, incubated for 24 h, then irradiated at 652 nm with 0 J
cm!2 (white bar), 5 J cm!2 (light grey bar), 15 J cm!2 (dark grey bar) or
30 J cm!2 (black bar) light doses. Adapted with permission from ref.
34. Copyright 2008 American Chemical Society.
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
Perspective Chemical Science
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6a was shown to be evenly distributed in the cytoplasm, where it
could exert its phototoxic activity (Fig. 7B).
The two best compounds in this study, namely [Ru(h6-
p-iPrC6H4Me)(PMP)Cl2] (PMP ¼ 5-(3-pyridyl)-10,15,20-triphe-
nylporphyrin) and [Ru4(h6-p-iPrC6H4Me)4(PTP)Cl8] (PTP ¼
5,10,15,20-tetra(3-pyridyl)porphyrin) (6b and 7b) were evaluated
in vivo on nude mice xenograed with human head and neck
carcinoma KB cells.36 Since PDT is a synergistic cooperation of
diﬀerent components (PS, light and O2), the evaluation of its in
vivo eﬃcacy depends on the combination of a complex system
of parameters, which reciprocally aﬀect each other. As a conse-
quence, the authors determined that crucial factors to be opti-
mized during in vivo studies were not just the concentration of
the drug, but also the interval between PS administration and
light treatment (the drug-light interval, DLI), light uence and
the uence rate.36 They therefore adopted a statistical approach
to nd the combination of parameters that would yield the best
therapeutic outcomes, thereby reducing as much as possible the
number of required experiments. The study showed that, if PS
concentration and light uence were not crucial parameters, a
long DLI and the use of the tetranuclear species led to statistically
signicant tumor growth stabilization up to at least 30 days.
Since the study on these systems highlighted that the
number of ruthenium modications is correlated with an
increase in phototoxicity, the authors synthesized two cationic
octanuclear metalla-cubes 8 and 9 (Fig. 8). These compounds,
thanks to their higher ruthenium content, showed better
activities when compared to their tetranuclear analogs.37 An
LD50 of 1 mM was reached upon irradiation with 652 nm light
and a 2–7 J cm!2 light dose for both compounds, whereas for
the tetranuclear analogs, a light dose of 5–10 J cm!2 at the same
wavelength resulted in a LD50 of 5 mM.
Another interesting approach used by this group for the
combination of Ru complexes and PDT is the application of
Ru-cages as carriers for porphyrin photosensitizers inside
cancer cells. The authors developed the two cages presented in
Fig. 9, namely hexa- (10) and octanuclear (11), which were
characterized by diﬀerent mechanisms of release.38 In the case
Fig. 9 Ruthenium cages 10 and 11 applied as carriers of a porphyrin PS inside cancer cells.38
Fig. 8 Polynuclear metalla-cubes 8 and 9 synthesized by Therrien to increase phototoxicity.37
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
Chemical Science Perspective
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of 10, the cage must be disrupted to allow the release of the PS,
whereas for 11, the PS can diﬀuse through the sides of the cage.
As a consequence of this diﬀerence, 11 was found to be 10 times
more photoactive than 10. The authors obtained phototoxicity
in the submicromolar range and a PI of about 20 for 11 on
cervical cancer HeLa cells, upon irradiation at 455 nm with an
impressively weak light dose (0.2 J cm!2). This result demon-
strated the release of the porphyrin aer cellular internaliza-
tion, as was also shown by luminescence microscopy (Fig. 10).
In these pictures, it is possible to notice the red luminescence
from the free PS and the blue emission originating from the
empty cage. This also indicates that the two systems are local-
izing in diﬀerent cellular compartments aer release. Further-
more, the internalization of the porphyrin in both cages
resulted in a hypochromic eﬀect on the porphyrin. This means
that when the PS is trapped, its emission is dramatically
reduced and consequently also the phototoxic eﬀect. This
phenomenon leads to a safe delivering agent that does not
display undesired phototoxicity outside of cells.
With the same idea in mind, namely to obtain a synergistic
biological eﬀect owing to the conjugation of porphyrin and
ruthenium fragments, Alessio and coworkers synthesized a
library of compounds where meso-tetraphenylporphyrin or
meso-40-tetrapyridylporphyrin cores were modied on their
peripheries with Ru complexes.39 The authors then selected ve
cationic species for biological evaluation.40 The most active
compounds 13 and 14 (Fig. 11) contain four rutheniummoieties
and their coordination sphere is a slight modication of the
[Ru([9]aneS3)(en)Cl]+ complex (12, Fig. 11, top le, [9]aneS3 ¼
1,4,7-trithiacyclononane, en ¼ ethylenediamine), which was
already shown by the same group to be characterized by a strong
cytotoxicity.41,42
As expected, the ruthenium fragments strongly improved the
physicochemical behavior of the porphyrin core. This resulted
in a clear increase in cytotoxicity of the compounds, most
likely, as speculated by the authors, due to higher cellular
accumulation. Furthermore, the potency of the systems in
human breast cancer cells MDA-MB-231 was improved by one
order of magnitude upon exposure to 5 J cm!2 of 590–700 nm
light, thus reaching the nanomolar range. Following the same
strategy, Swavey et al. explored a range of possible modications
of porphyrins to improve their activity and selectivity.43 In
particular, they introduced a Ru(bipy)2 moiety (bipy ¼ 2,20-
bipyridine) with a labile Cl ligand to obtain additional DNA
binding and light-induced DNA cleavage. Two pentauoroaryl
groups, which are known to increase the excited state lifetime of
a PS, were also linked to the porphyrin, to give compound 15
(Fig. 12, le). The authors obtained a very strong aﬃnity for
DNA and consequent photocleavage of plasmid supercoiled
DNA. Furthermore, they demonstrated that the compound
exerted a higher phototoxicity on melanoma cells when
compared to normal skin broblast cells.
To improve the eﬃcacy and the selectivity of their system,
the same authors removed one pentauoroaryl group and
evaluated the eﬀect of the insertion of a metal into the
porphyrin ring (16a–d, Fig. 12, right).44 Upon coordination of a
metal ion in the porphyrin, the photophysical properties of the
system undergo an important change due to the metal per-
turbing the energy levels of the free ligand. For instance, it was
noticed that the complexation of Zn(II) increases the lifetime of
the excited state of the porphyrin.19 In this work, they demon-
strated that all three metal-coordinated systems were able to
nick plasmid DNA upon induction with light, with the Zn(II)
system 16d also generating double strand breaks. In cellular
studies, Ni(II) and Cu(II)–porphyrins were inactive as photosen-
sitizers. On the other hand, the Zn(II) system at a concentration
of 5 mM induced cell death very eﬃciently on a melanoma cell
line upon white light irradiation (Fig. 13, bottom). Interestingly,
the same treatment did not show any eﬃcacy on normal skin
broblast cells (Fig. 13, top), providing indications of a very
selective system.
Of utmost interest, the authors performed in vivo studies
with compound 16d on Drosophila melanogaster to assess its
general toxicity in the dark as well as biodistribution.45 The
compound was found to be harmless for the larvae and during
their development. Cellular localization studies were also per-
formed by feeding the larvae with the compound. Confocal
microscopy revealed that the molecule was able to accumulate
in the cytosol, but also in the nuclei at higher concentration.
This suggests that the compound is not readily metabolized.
Another interesting class of compounds includes the coor-
dinatively saturated ruthenium polypyridyl complexes. These
compounds are known to be kinetically inert and substitu-
tionally stable. Therefore, they do not have a labile ligand that
can covalently bind DNA. Nevertheless, it was shown that, with
the use of appropriate ligands such as dipyrido[3,2-a:20,30-c]-
phenazine (dppz) or tetrapyrido[3,2-a:20,30-c:30 0,200-h:20 0 0,30 00-j]-
phenazine (tpph), these complexes can interact very strongly
with double-stranded DNA via intercalation or groove binding.
Thanks to these interesting characteristics, these compounds
were extensively studied as DNA intercalating probes46,47 or as
cytotoxic agents.48–51 Furthermore, it was demonstrated that
these compounds are also able to produce 1O2 (see next para-
graph for more information on this topic). To exploit this
property, Wong and co-workers conjugated a [Ru(bipy)2phen]2+
(phen ¼ 1,10-phenanthroline) moiety to a porphyrin core via
three diﬀerent linkers on the phen (Fig. 14) and evaluated the
biochemical behavior of the resulting systems 17a–c.52 The
ruthenium conjugation was also introduced here to improve the
two-photons absorption (TPA) characteristics of the
compounds. As a consequence, by virtue of the simultaneous
absorption of two photons, the molecule can be excited at 800
nm, a more tissue penetrating and less harmful wavelength.
Therefore, this interesting characteristic allows for the devel-
opment of bifunctional PDT and tumor imaging agents.
Interestingly, the authors could achieve a diﬀerent cellular
localization based on the type of linker used to connect the
porphyrin core to the ruthenium moiety. This diﬀerence allowed
for studying the eﬀects of PDT in diﬀerent cellular compart-
ments. Compounds 17a and 17b were characterized by the best
cellular uptake, as demonstrated by ow cytometry analysis.
Comparably, they also displayed the best phototoxic behavior
with a toxicity of 118 and 175 mM on HeLa cells in the dark and
LD50 of 1 mM upon yellow light irradiation with doses of 6.5 and
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
Perspective Chemical Science
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2.0 J cm!2, respectively. Compound 17b also showed its activity
as a TPA-PDT agent, causing cell shrinkage upon irradiation at
850 nm. The compound, which localized in the mitochondria
before light exposure, was found to relocate in the nuclei aer
light irradiation. The authors therefore assumed that 17b
induced light-mediated damage to mitochondria, from which it
is then released. Once in the cytosol, the compound can damage
the nuclear membrane and cause cell death. Interestingly, they
also showed that the presence of the Zn atom in their conjugates
had a detrimental eﬀect on the emission quantum yields of the
systems in DMSO, going from values of 1.93–5.3% for the free
base compounds to <1% when Zn(II) was inserted in the
porphyrin ring. The authors considered this diﬀerence in the
photophysical behavior to be related to an energy transfer from
the Soret band of Zn–porphyrins to the ruthenium fragment.
Ruthenium complexes as PSs
As discussed above, porphyrins certainly have good character-
istics as PSs due to their intrinsic physico-chemical properties.
On the other hand, the PSs available on the market still display
a number of drawbacks such as their low solubility in biological
media, lack of selective cancer accumulation and the frequently
encountered photosensitivity in patients undergoing PDT
treatments. Over the last few years, several research groups have
explored the possibility to move away from tetrapyrrolic
systems, studying the potential of metal complexes as PSs
themselves. The application of ruthenium complexes as PSs is a
reasonable approach due to their tunable photophysics and the
aforementioned advantages for biological applications (see
Introduction). As an example of this approach, our group
synthesized six [Ru(bipy)2dppz]2+ complexes 18a–f with
diﬀerent functional groups on the dppz ligand (Fig. 15).53
As highlighted before, the presence of the dppz intercalative
ligand was meant to increase the aﬃnity of the compounds for
DNA, so that a targeted delivery of singlet oxygen to the genetic
material can be achieved. All Ru complexes were found to be
non-toxic (up to 100 mM) to both normal fetal lung broblast
cells (MRC-5) and cervical cancer HeLa cells in the dark.
Nevertheless, the amino- and methoxy-substituted Ru
complexes showed impressive photoactivities. When HeLa cells
were irradiated with a light dose of 9.27 J cm!2 at 420 nm, IC50
values in the low micromolar range were obtained for 18a and
18b. An impressive PI of 43 for the latter and even >150 for the
former were obtained. Cellular distribution studies were per-
formed on both compounds by means of confocal microscopy
and high-resolution continuum source atomic absorption
spectrometry (HR-CS AAS) and the results are reported in
Fig. 16. These techniques indicated a very good cellular uptake
of both compounds. Furthermore, HR-CS AAS analysis
conrmed the nuclear localization for both complexes aer 4 h
incubation, allowing for target delivery of 1O2 to DNA.
Compounds 18a and 18b also showed good eﬃciency in
generating strand breaks of supercoiled plasmid DNA upon
light irradiation. This feature strongly suggested the involve-
ment of DNA in the mechanism of phototoxicity. Further
studies are ongoing to investigate the interaction of 18b with
DNA, and the exact mechanism of cell death engendered by
light activation.
With the similar goal of targeting and photocleaving DNA,
Brewer et al. studied mono-metallic or supramolecular
complexes of Ru, Pt, Rh and their abilities to interact with DNA
upon light irradiation in depth (see also the PACT section
below). In particular, they demonstrated the ability of three
[(TL)2Ru(dpp)]2+ compounds (dpp ¼ 2,3-bis(2-pyridyl)pyrazine,
with TL ¼ bipy, phen or Ph2phen ¼ 4,7-diphenyl-1,10-phenan-
throline) to eﬃciently photocleave supercoiled pUC18 plasmid
DNA upon irradiation at l ¼ 450 nm thanks to the formation of
1O2.54 However, the biological activity of compounds of the type
[(TL)2Ru(dpp)]2+ in cells was not evaluated. Turro and coworkers
are also very active in the eld of light-activated ruthenium
complexes. They synthesized and characterized many
compounds and studied their photophysics, and light-mediated
interactions with DNA and proteins due to the formation of
singlet oxygen,55,56 or to other mechanisms (see also the PACT
section below). To further highlight the mode of action of these
photoactivated compounds, these researchers investigated their
light-induced eﬀects on DNA and proteins in broblasts.57 The
two complexes, [Ru(tpy)(pydppn)]2+ (19) and [Ru(pydppn)2]2+
(20) reported in Fig. 17, with tpy ¼ [2,20;60,200]-terpyridine and
pydppn ¼ 3-(pyrid-20-yl)-4,5,9,16-tetraaza-dibenzo[a,c]naph-
thacene,56 displayed very long lifetimes of the excited states (20–
24 ms), thanks to the pydppn ligand, which allows for singlet
oxygen generation with an eﬃciency of almost 100%.
The authors were then able to demonstrate that 19 and, to a
lesser extent, 20 induced photodynamic damage to the tumor
suppressor p53 and the DNA polymerase processivity factor
PCNA (proliferating cell nuclear antigen), both of them being
key components of DNA maintenance and repair pathways.
Upon light irradiation of cells and cell lysates (3.15 J cm!2 of
visible light), the compounds induced covalent crosslinking of
the protein subunits, the formation of DNA–protein adducts
and, as a consequence, the inhibition of DNA replication. p53
crosslinking was previously demonstrated to correlate with the
formation of singlet oxygen,58 and the work of Turro and
colleagues57 demonstrated a strong reduction in the eﬃciency
of p53 photodamage by the presence of sodium azide, a known
singlet oxygen quencher. In addition, protein–DNA crosslinking
was demonstrated to depend on singlet oxygen-mediated
formation of 8-oxo-7,8-dihydroguanine and its further reaction
with amino groups in the protein. Also in this case though, the
evaluation of the phototoxic prole of the compounds on cells
was not explored.
Fig. 10 Fluorescence microscopy of HeLa cells incubated with 11 (2
mM, 2 h): (A) white light and (B) ﬂuorescence. Reprinted with permis-
sion from ref. 38. Copyright 2012 American Chemical Society.
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
Chemical Science Perspective
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Ruthenium polypyridyl complexes also have an excellent
record of performance in the eld of dye-sensitized solar cells
(DSSCs)59 due to their absorption in the visible range and very
long lifetimes. Interestingly, and as previously noted, these
characteristics are also of extreme importance in the eld of
PDT. Consequently, our group decided to explore the photo-
dynamic behavior of two derivatives of ruthenium complexes
bearing a benzenedithiol (21) and a tridentate polypyridyl
ligand (22), respectively (Fig. 18), which were previously
employed in the eld of DSSCs.60
Fig. 11 Structures of Ru([9]aneS3)(en)Cl]
+ (top, left) and of the ruthenium-derivatized porphyrin systems 13 and 14.40
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
Perspective Chemical Science
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Both compounds were characterized by moderate uptake by
HeLa cells, as indicated by inductively coupled plasma mass
spectrometry (ICP-MS) analysis performed aer 4 h incubation.
21 accumulated preferentially in mitochondria (67% of the
entire Ru uptake) as also conrmed by uorescence confocal
microscopy (Fig. 19). 22, on the other hand, was shown to target
Fig. 12 Porphyrin with pentaﬂuoroaryl and Ru(bipy)2Cl fragments to give 15 (left) and Ru–porphyrin conjugates containing diﬀerentmetals in the
ring (16a–d, right).43,44
Fig. 13 Phase contrast microscopy images of cells irradiated with a 60 W tungsten lamp for 30 min. Normal ﬁbroblast cells (top) and melanoma
cells (bottom) without 16d (control) and in the presence of 5 and 10 mM concentrations of 16d. Reproduced from ref. 44 with permission from
The Royal Society of Chemistry.
Fig. 14 Structures of Ru–porphyrin conjugates 17a–c, with three diﬀerent bridging linkers.52
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
Chemical Science Perspective
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the nuclei, where 50% of the total Ru that entered cells was
localized.
Phototoxicity was evaluated on HeLa cells. 21 was found to
be most active upon irradiation at 420 nm with 6.95 J cm!2. Its
PI was equal to 80, with an IC50 of 620 nM upon light irradia-
tion. It is important to notice that although the uptake of 21 was
not as high as those reported for similar complexes, the amount
of compound present in cells was suﬃcient to produce a strong
phototoxic eﬀect. On the contrary, 22 displayed a lower photo-
toxicity against HeLa with an IC50 of 25.3 mM under the same
irradiation conditions. Of utmost interest, the compounds were
also evaluated for their potential activity as PSs in antibacterial
PDT (aPDT). The use of PDT to kill bacteria was recently
exploited to overcome the problematic occurrence of resistance
to available antibiotics. This is essentially due to the fact that a
resistance mechanism is far more diﬃcult to develop for
bacteria since PDT does not have a specic target but can aﬀect
the entire cell. The antibacterial activities of 21 and 22 were
tested on the Gram-(!) Staphylococcus aureus and on the Gram-
(+) Escherichia coli. Surprisingly, 22 was active against both
strains, with a reduction of >6 log10 of the viability of the S.
aureus and >4 log10 of that of E. coli at a concentration of 50 mM
and with a dose of 8 J cm!2 of light at 420 nm. Under the same
Fig. 15 Structures of the six diﬀerent DNA intercalating Ru complexes
18a–f.53
Fig. 16 Left: Confocal microscopy images of HeLa cells treated for 2 h with 100 mM of complex 18b (excitation at 488 nm, emission above 600
nm, bottom left) and stained with DAPI (nuclear staining, top left) and with Mitotracker green (mitochondrial staining, middle left); in the yellow
circle a representative example of the diﬀerent localization of 18b andMitotracker green is found (picture on the right). Right: Cellular uptake into
HeLa cells treated for 4 h with 20 mM solutions of the complexes 18a–f. Results are expressed as the mean# error of independent experiments.
In the inset: nuclear uptake for complexes 18a and 18b. Reproduced with permission from ref. 53. © 2014 Wiley-VCH Verlag GmbH & Co. KGaA,
Weinheim.
Fig. 17 Structures of the Ru complexes 19 and 20 bearing the tri-
dentate pydppn ligand, which confers very long excited state
lifetimes.57
Fig. 18 Structures of the ruthenium complexes 21 and 22 which have
PDT and aPDT activity.60
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
Perspective Chemical Science
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conditions, 21 displayed the same activity towards S. aureus,
while being completely non-toxic towards E. coli. The very good
performance of 22 is particularly promising considering that it
is reported that normally Gram-(!) bacteria are less sensitive to
PDT treatment.
In the last few years, Glazer and coworkers have thoroughly
investigated the application of Ru polypyridyl complexes as
PACT agents (see also PACT section). However, they also
recently performed an in-depth biological characterization of
two potential PDT agents. In particular, they evaluated
[Ru(Ph2phen)3]2+ (23) and [Ru(Ph2phen-SO3)3]4! (24) (Fig. 20),
which are known dyes for solar cells or biological staining, but
which were never investigated as PDT agents.61 The two
compounds have very similar structures but extremely diﬀerent
physical properties, mainly due to their diﬀerent charges,
namely +2 for 23 and!4 for 24. This, along with the subsequent
diﬀerence in hydrophilicity of the two molecules, was expected
to induce distinct cellular responses. Nonetheless, both mole-
cules were found to be able to produce singlet oxygen when
photo-irradiated.
Toxicity experiments were performed on three diﬀerent cell
lines (A549 human non-small lung cancer cells, HL60 human
promyelocytic leukemia cells and Jurkat human T lympho-
blastoid cells) in the dark and upon irradiation with 7 J cm!2 of
>400 nm light. 23 showed a very good cytotoxic eﬀect on all cell
lines studied. Irradiation brought a further increment in
potency, with IC50 values ranging from 0.075 mM to 0.35 mM,
depending on the cell lines employed. However, the PI was just
around 10–20. Surprisingly, 24 appeared to be non-toxic in the
dark (up to 300 mM) on all cell lines studied. Nevertheless,
irradiation induced strong toxicity with IC50 values in the low
micromolar range, resulting in a larger therapeutic window
compared to 23. The compounds also displayed a diﬀerent
subcellular localization, with 23 accumulating in mitochondria
and lysosomes and 24 displaying a non-specic accumulation
in the cytoplasm (Fig. 21). Interestingly, mitochondrial uptake
of 23 was proposed by the authors as the cause of toxicity in the
dark. Upon light irradiation, 23 relocalized from mitochondria
and lysosomes to the nucleus. This phenomenon was explained
by the authors as the consequence of damage to the nuclear
membrane induced by 23 upon light irradiation. On the other
hand, when cells incubated with 24 were irradiated, the
compound was mainly observed in lysosomes, suggesting that
no damage occurred to the nuclear membrane in this case.
Investigation of the mechanism of cell death using distinct
assays and read-outs revealed a role for light-induced apoptotic
pathways in the case of 24. On the other hand, initial necrotic
cell death in the dark, followed by a combination of necrotic
and apoptotic pathways, was observed for 23 upon light
irradiation.
Fig. 19 Fluorescence confocal microscopy images of HeLa cells
incubated with 40 mM of 21 for 4 h: (a) DAPI staining, (b) Mitotracker
green FM staining, (c) visualization of 21 by excitation at 405 nm, (d)
overlay of a–c. Reprinted with permission from ref. 60. Copyright 2014
American Chemical Society.
Fig. 20 Structures of the Ph2phen complexes 23 and 24 with diﬀerent charges investigated by Glazer and co-workers.61
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
Chemical Science Perspective
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While one of the main problems of PDT is its reliance on
oxygen, which is oen present at low concentrations in the
tumor environment (hypoxic conditions), the application of
metal complexes as PSs also has its drawbacks, which are due to
the need for light at a high energy (blue or green) for the exci-
tation of the PS. McFarland and co-workers addressed both
issues by taking advantage of the possibility to ne tune the
photophysical characteristics of coordination compounds.
More specically, by modifying the structures of the ligands
coordinated to the metal centre, the authors developed Ru
polypyridyl PSs characterized by a triplet intraligand (3IL)
excited state with remarkably long lifetimes. Oxygen was
reported to be able to quench this excited state even when
present at very low concentrations (3.5%). Furthermore, the
strong photosensitizing ability of this excited state allowed PDT
eﬀects to be achieved in the red and NIR regions where
compounds have marginal absorptions (3 values in the order of
10 M!1 cm!1). The rst series of compounds bearing a pyr-
enylethynyl moiety on the phenathroline ligand was strongly
eﬀective on the cell line Malme-3M, a malignant melanoma
lung metastasis.62 Melanoma cells are able to grow at very low
oxygen concentrations and have a remarkable ability to resist
the outburst of ROS.63 Nevertheless, compound 25 (Fig. 22, le)
could induce cell death in a melanoma cell line, with a toxicity
increase of two orders of magnitude upon irradiation with white
light at 7 J cm!2. In these conditions, EC50 went from 62 mM in
the dark to 200 nM upon irradiation.
A second class of compounds studied by the same group
contained the extensively conjugated benzo[i]dipyrido[3,2-
a:20,30-c]phenazine ligand (dppn, Fig. 22, right).64 The authors
could exploit the 3IL excited state of these compounds with very
long lifetimes to obtain a remarkable PDT eﬀect. Impressively,
EC50 values in the low micromolar range were obtained upon
irradiation with 100 J cm!2 light at 625 nm, where the
compounds have marginal absorption. This eﬃcacy demon-
strated that it is possible to achieve good photoactivity with
compounds that mainly absorb in the blue-green region of the
light spectrum. Furthermore, the same authors developed a
system where the Ru polypyridyl complexes are connected to
polythiophene chains of variable lengths (Fig. 23). This conju-
gation gave access to a low-lying 3IL excited state and to a strong
non covalent DNA association.65 Gel electrophoresis experi-
ments were performed on the complexes to elucidate the
interaction with plasmid DNA. These analyses suggested that
compounds bearing more than one thiophene unit are able to
induce light-mediated damages to plasmid DNA via an oxygen-
independent pathway. This was indicated by the fact that
compound 27c was still able to induce single strand breaks
when the experiment was performed under argon atmosphere.
Therefore, the authors speculated that these thiophene conju-
gates could act via photoinitiated Type II reaction in the case of
Fig. 21 ApoTomemicroscopy showing subcellular localization of 23 and 24 at 8 h. Co-localization of 23 and 24 in mitochondria or lysosomes is
indicated by the apparent yellow emission. (A) Mitotracker green FMwas used to imagemitochondria. (B) Lysotracker green DND-26was used to
image lysosomes. Red color denotes intrinsic emission of 23 and 24, whereas blue color denotes Hoechst staining of the nucleus. The yellow
color results from overlap of the red emission from the ruthenium complexes and green emission of the organelle-speciﬁc dyes, indicating co-
localization. Compound 23 localizes in both the mitochondria and the lysosomes, while 24 was not predominantly found in either organelle.
Reprinted with permission from ref. 61. Copyright 2014 American Chemical Society.
Fig. 22 Structures of ruthenium complexes 25 and 26 studied by McFarland, characterized by 3IL excited states.62,64
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
Perspective Chemical Science
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high oxygen tension. On the contrary, under low oxygen
concentration, the compounds induced damage to DNA via a
Type I pathway. This behavior was already observed for this
class of compounds in the photoinactivation of bacteria.66 A PS
with the ability to act via a dual Type I/II photosensitization
could allow for the treatment of hypoxic tissues, broadening the
spectra of applicability of PDT.
The in vitro PDT eﬀect of these compounds was found to be
directly proportional to the polythiophene chain length, with a
PI of > 200 when 4 thiophene units were present in the complex.
The two best compounds 27c and 28c, bearing three thiophene
units, were also tested in vivo on mice, which were inoculated
with colon carcinoma cells (CT26.WT). In animals treated with
compound 28c (53 mg kg!1), administration of 525 nm
continuous wave light (192 J cm!2) resulted in complete tumor
regression, with no recurrence up to 52 days aer the end of the
treatment. These compounds are currently under optimization
for clinical phase I trials.65
A very elegant approach to eﬀectively increase the selectivity
of PDT treatment is the so-called CALI (chromophore-assisted
light inactivation). This technique is based on the functionali-
zation of a modest protein inhibitor with a PS, allowing for
strong enhancement of the inhibitory properties through
photo-triggered 1O2 generation in close proximity to the active
site (see the mechanism in Fig. 24). The Kodadek group recently
explored this technique using a [Ru(bipy)3]2+ derivative,67
demonstrating the feasibility of this technique on both
membrane and intracellular proteins.
Furthermore, the authors showed selective inhibition of
RBBP9 serine hydrolase, which is implicated in pancreatic
cancer, in protein-enriched cell lysate.68 The limitation of this
approach is related to the choice of PS, since [Ru(bipy)3]2+
derivatives do not allow eﬃcient photosensitization due to the
short wavelengths required for excitation. A careful optimiza-
tion of the system could provide a very useful tool for future
targeted PDT applications.
Ruthenium complexes in PACT
As mentioned above, PDT relies on the presence of oxygen to
induce cell death. However, most tumors are hypoxic in their
internal core,69 limiting the eﬃcacy of PDT. Hence, increasing
eﬀorts are devoted to the optimization of novel photo-activation
strategies that do not rely on an oxygen-dependent mechanism,
but which would still allow for spatial and temporal control of
the toxicity engendered to cells. Strategies of this type are nor-
mally referred to as photoactivated chemotherapy. In this
section of the review, we describe the recent eﬀorts in the use of
ruthenium complexes for PACT. We have divided this section
into two main parts depending on the photo-activation strategy
employed. In the rst part, we will focus on ruthenium-based
DNA photobinders acting (1) in a cisplatin-like mode of action
resulting in DNA helix distortion; (2) via intercalation yielding
DNA cleavage; and (3) via conjugated oligodeoxyribonucleotides
(ODNs) to allow for gene silencing. In the second part, we will
discuss photo-activated release approaches involving Ru(II)
complexes. In this part, we will rst introduce the use of Ru(II)
complexes as caging agents for the selective release of bioactive
molecules upon light activation. We will then present a parallel
approach consisting of the photorelease of cytotoxic Ru(II)
complexes rendered inactive upon caging.
Photo-activated Ru complexes targeting DNA
Cancer cells diﬀer from their original healthy precursor cells by
their ability, inter alia, to continuously proliferate.70 This
feature, conferred by mutations in tumor suppressor genes or
by the altered expression/activity of proto-oncogenes, implies
continuous activation of DNA replication, which is not the case
in healthy cells, which rather display the ability to enter
quiescence aer a certain number of cell divisions. This hall-
mark of cancer has been extensively exploited to selectively
target cancer cells by means of chemotherapeutic drugs,
inhibiting components of the DNA replication/transcription
machineries, such as topoisomerase I (e.g. camptothecin)71 or
covalently binding to DNA (e.g. cisplatin)72. In this section, we
will introduce photo-triggered strategies designed to target
DNA.
Ligand photo-dissociation and DNA target. The best known
metal complex used in cancer treatment is undoubtedly
cisplatin, a metal-based drug that targets growing cells by
interfering with DNA replication. Cisplatin is a prodrug that
rst undergoes a process called aquation, by which chloride
ligands are displaced by water. The cytotoxic activity of cisplatin
Fig. 23 Structures of Ru polypyridyl complexes conjugated with
diﬀerent polythiophene moieties to achieve dual Type I/II
photosensitization.65
Fig. 24 Mechanism of the CALI strategy to inhibit enzymes, applied by the Kodadek group.
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
Chemical Science Perspective
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results from interaction of the highly reactive hydrated form of
the drug with DNA, preferentially with the N7 atoms of purine
residues.73 Themajority of lesions generated by cisplatin consist
of intra-strand cross-links at two consecutive purines that are
promptly addressed by the Nucleotide Excision Repair pathway.
On the other hand, the far smaller proportion of inter-strand
crosslinks causes distortions of the double helix and inhibits
replication,74 transcription74,75 and translation,76 representing a
serious threat to cell survival. Furthermore, although replica-
tion fork stalling at inter-strand crosslinks does not compro-
mise the completion of S-phase, as it is compensated for by
incoming forks from the opposite site of the lesion, the real
threat consists of the persistence of the inter-strand crosslink
until mitosis, leading to apoptosis.77 The broad spectrum of
action of cisplatin, as well as its lack of specicity for cancer
cells, is evidenced by the severe side eﬀects observed in patients
treated with the drug (e.g. nephrotoxicity, ototoxicity, etc.).72
Hence, a signicant eﬀort has been directed towards more
targeted strategies, involving the use of an external trigger such
as light to induce cytotoxicity. As an example, Sadler and
coworkers have designed and characterized photoactivatable
cisplatin derivatives with clear potential for use in PACT.78–80 In
particular, they showed that irradiation of Pt(IV) diazido deriv-
atives with UV-A or blue light induced photoejection of the
azido ligands and reduction of the metal to Pt(II). As a conse-
quence, the photoproduct can covalently bind DNA in a similar
way to cisplatin, generating a potent cytotoxic eﬀect on cells in
culture.20,81
In contrast to square planar Pt(II) compounds, Ru(II)
complexes oﬀer octahedral conformations. It was shown that
complexes with distorted octahedral geometry can undergo
ligand dissociation aer photo-irradiation,82,83 which is fol-
lowed by the formation of an aqua complex that can bind to
DNA in a manner similar to cisplatin. To exploit this concept,
Glazer and coworkers recently investigated the potential use of
methyl substituents on one polypyridyl ligand to obtain highly
distorted geometries.84 To this end, an unstrained [Ru(bipy)2-
phen]2+ (29) and two methylated derivatives of [Ru(bipy)2(2,20-
bypiridyl)]2+ (30) and [Ru(bipy)2(dipirido[3,2-f:20,30-h]-quinoxa-
line)]2+ (31) were synthesized (see Fig. 25 for structures). As
expected, aer >450 nm light irradiation using a 200 W
projector, the authors could monitor the photoejection of the
methylated ligand of 30 and 31, with half-lives (t1/2) of 2 and 60
min, respectively. Since photoejection of the latter ligand
resulted in the formation of a similar aqua species to cisplatin,
the authors naturally explored the activity of the photo-product
on biologically relevant molecules. In the presence of plasmid
DNA pUC19, only irradiated (>450 nm, 200 W, 1 h) products
showed DNA damage. Complex 29 produced DNA photo-
cleavage, 30 showed only DNA photobinding whilst 31
combined both properties. To verify if the DNA damage
observed in vitro would reect in decreased viability in cancer
cells in culture, the authors treated HL60 leukemia and A549
lung cancer cells for 12 h with the complexes in the dark prior to
>450 nm irradiation for 3 min at 410 W, followed by a further 72
h of incubation (see Table 1 for complete IC50 values). As a
control, they used aminolevulinic acid (ALA) which is a clini-
cally available PS. Complexes 30 and 31 showed no toxicity in
the dark with IC50 values of > 100 mM. However, a strong eﬀect
aer irradiation on both cells with IC50 on HL60 cells of 1.6 and
2.6 mM, respectively, and of 1.1 and 1.2 mM, respectively, on
A549 cells, was observed. In order to eﬃciently mimic the three-
dimensional tumor environment, the authors also assessed the
photo-toxicity of the compounds on A549 spheroids. As repor-
ted for the monolayer cell culture, complex 30 was conrmed to
be eﬃcient with an IC50 of 21 mM upon light irradiation, a value
that corresponds to twice the potency of cisplatin on the same
spheroids. Worthy of note, glutathione (GSH), responsible for
cisplatin inhibition in cells, had no deleterious eﬀect on DNA
binding or cleavage eﬃciency nor on the toxicity of the ruthe-
nium complexes 30 and 31.
More recently, Glazer et al. applied the same methylation
strategy to a novel strained Ru(bipy)2 complex bearing a 2,3-
dihydro-1,4-dioxino[2,3-f]-1,10-phenanthroline (dop) (32)
ligand.85 The methylated form of 32 is 2,3-dihydro-1,4-dioxino
[2,3-f]-2,9-dimethyl-1,10-phenanthroline (dmdop) (33, Fig. 26).
To further increase the straining, the authors also synthesized a
[Ru(dmphen)2(dop)]2+ (dmphen ¼ 2,9-dimethyl-1,10-phenan-
throline) (34, Fig. 26). As anticipated by the authors, aer irra-
diation at >400 nm with a 200 W projector at a distance of 12
inches from the cuvette, both methylated analogs showed
photoejection. The process was found to be 10-fold faster for
complex 34 (t1/2 ¼ 4 min) than for 33 (t1/2 ¼ 42 min). The
authors further analyzed photo-induced DNA damage. Upon the
same irradiation settings, complex 32 created single strand
breaks (SSBs) in pUC19, likely via 1O2 production. In compar-
ison, complex 34 showed covalent binding while 33 showed a
combination of both mechanisms. Regarding cell photo-
Fig. 25 Structures of the strained Ru complexes 30 and 31 that undergo ligand photoejection and the inert control 29.84
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
Perspective Chemical Science
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toxicity, complex 34 exerted the highest toxicity against
leukemia cells HL60 with a PI of >1880. The IC50 was 300 mM in
the dark while the value was 0.16 mM aer 12 h incubation, 3
minutes irradiation at >400 nm with 410 W projector and 72 h
recovery. This impressive PI was explained by the fact that 34
binds and distorts DNA, whereas the mechanism of action of
complex 33 is characterized by a dual mode of action including
SSBs formation via 1O2 production and DNA distortion, which
possibly lowers its distortion eﬃciency.
Following a similar distortion strategy, the same group
studied the coordination of biquinoline (biq) to ruthenium-
based complexes. Such a ligand would act as a potent geometry
distorter, and at the same time, improve the light activation
process by pushing the absorption maximum to higher wave-
lengths. Indeed, the resulting strained Ru(II) 2,20-biquinoline
complexes (see Fig. 27 for structures) were shown to be active in
the PDT therapeutic window. 35, which bears one biq, and 36,
which contains two biq ligands, can absorb light up to 700 and
800 nm, respectively.86 Both complexes induced decreased
electrophoretic migration of the DNA plasmid pUC19 only upon
illumination (samples were placed at 12 inches from a 200 W
lamp equipped with either blue, green, red or near-IR cut-oﬀ
lters and irradiated for 1 h or 3 h). Since the appearance of
open circular or linear DNA was not observed, the mechanism
involved clearly coincides with photobinding. Maximal activity
has been observed with blue light irradiation, which is consis-
tent with the absorption prole of the Ru(II) complex. Cytotox-
icity against HL60 leukemia cells followed the same light-dose/-
wavelength prole as DNA photo-cleavage. Aer 12 h incubation
followed by 7 J cm!2 light irradiation and 72 h recovery, a cell
viability assay revealed that complex 36 had the best photo-
toxicity prole with IC50 values of between 2.3 and 5.1 mM
among the diﬀerent wavelengths used, compared to 47.3 mM in
the dark (see Table 2 for IC50 values). The interesting PIs (blue:
Table 1 Cytotoxicity IC50 values in 2D and 3D cellular assays
a
IC50 (mM)
Compounds
Light Dark PI
HL60 A549 A549 spheroid HL60 A549 A549 spheroid HL60 A549
Cisplatin 3.1 # 0.2 3.4 # 0.6 n. d. 3.1 #0.1 3.5 # 0.6 42 # 3.6 1 1
29 8.1 # 1.9 40 # 4 >300 240 # 9 250 # 5 >300 3 6.3
30 1.6 # 0.2 1.1 # 0.3 21.3 # 2.3 >300 150 # 7 >300 >188 136
31 2.6 # 1.0 1.2 # 0.1 64.6 # 4.7 108 # 1.9 250 # 5 >300 42 208
ALA 16.2 # 3.2 21 # 3.5 >300 >300 87.8 # 5.5 >300 >18 4.2
a n. d. ¼ not determined. ALA ¼ aminolevulinic acid.
Fig. 26 Structures of the photostable control compound 32 and the strained 33 and 34 that undergo ligand photoejection.85
Fig. 27 Structures of the two Ru(II) complexes 35 and 36 with the biq
ligands that are exchanged upon irradiation.86
Table 2 Photobiological activities of 35 and 36 on HL-60 cellsa
IC50 (mM) PI
Compounds Dark
Blue
(3 min)
Red
(3 min)
Red
(6 min)
IR
(25 min) Blue IR
35 52.5 1.2 13.8 7.6 15.8 43.8 3.32
36 47.3 2.4 4.5 2.3 5.1 19.2 9.2
Cisplatin 3.1 3.1 n. d. n. d. n. d. 1
a n. d.¼ not determined.
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
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19.7, IR: 9.2) obtained for complex 36 hold great promise for
this type of Ru(II) complex, which can be activated with red light
or even with near-IR wavelengths. Interestingly, a complex
similar to compound 36 but bearing a 2-phenylpyridine (phpy)
instead of the phen, had diﬀerent photophysical properties.
Indeed, Dunbar, Turro and coworkers found that the latter
complex had enhanced phototoxicity against HeLa cells.87
Nevertheless, its mode of action remains unclear, since no
ligand dissociation was observed. Moreover, the short lifetime
of the compound rules out any singlet oxygen mechanism.88
Another manner to shi the MLCT absorption of a Ru(II)
complex to the red (PDT window) is by insertion of a cyclo-
metallating ligand.89 For this purpose, Turro and coworkers
focused on the ligand phpy. More specically, they investigated
the photo-induced ligand release of cis-[Ru(phpy)(phen)(CH3-
CN)2]2+ (37, Fig. 28), a complex known to decrease tumor growth
inmice,90 but whose photo-induced ligand release potential had
never been evaluated. First, they observed that 3 min of irradi-
ation at 690 nm were suﬃcient to eject one CH3CN, while 30
min were needed to release the second acetonitrile ligand. They
could also observe an enhancement of cytotoxicity upon light
irradiation (100 s irradiation at 690 nm, 5 J cm!2). As expected,
the compound displayed a potent cytotoxicity on human
advanced ovarian epithelial cancer cells (OVCAR-5) in the dark,
with an IC50 of 1 mM (15 h incubation followed by rinsing and
then by 24 h recovery). Upon light irradiation, the IC50 reached
70 nM, a 14-fold increase compared to dark conditions.
According to agarose gel shi assay, this increase in toxicity
upon light illumination is due to photobinding of the complex
to DNA. Of note, the authors could demonstrate that GSH
enhanced the photo-dissociation process, but still further
analyses are needed to fully understand its role.91
Fig. 28 Structure of the Ru(II) complex 37 with labile CH3CN ligand.91
Fig. 29 Schematic representation of the photo-dissociation process. Left branch: pre-irradiated Ru–peptide conjugates followed by addition of
the oligonucleotide. Right branch: irradiation of a mixture of peptide-conjugated Ru(II) complex and the oligonucleotide.94
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
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Although light-activated prodrugs oﬀer an already high
temporal and spatial selectivity per se, they still suﬀer from the
recurrent problem of photosensitivity. Despite the fact that Ru
complexes may be mimicking Fe uptake and thereby accu-
mulate in cancer cells overexpressing transferrin,92,93 and
assuming an intravenous administration, the light-activatable
prodrugs presented above are supposed to be transported
everywhere in the body without special selectivity for cancer
cells. This implies that surrounding healthy tissues are not
free from deleterious eﬀects. To tackle this important draw-
back, several groups have envisaged coupling a targeting
moiety to light-activatable prodrugs. In this perspective,
Marcha´n et al. coupled two diﬀerent receptor-binding
peptides, which are known to target receptors overexpressed
on the membrane of some cancer cells, to a photoactivated
Ru(II) arene complex (Fig. 29).94 Since tumor endothelial cells
overexpress two types of integrins, anb3 and anb5, the authors
attached the specic targeting peptide sequence Arg-Gly-Asp
(RGD). On the other hand, they decided to target the
somatostatin receptor sst2, which is located at the membranes
of malignant cells in supernumerary copies, using the peptide
octreotide, a somatostatin agonist. The authors reported
interesting and promising in vitro studies. First, they showed
that conjugation to the peptides did not aﬀect the photo-
activation process, since the reactive aqua species was formed
aer pyridine ligand loss upon visible light irradiation
(420 nm lamps). Second, they reported that DNA binding of
the Ru-conjugates was not compromised by the presence of
the peptides. When pre-irradiated (8 h) peptide-conjugated
Ru(II) complexes 38-octreotide or 38-RGD were incubated
overnight with the 9-ethylguanine, monofunctional adducts
were formed. The same was true for the incubation with a
short oligonucleotide sequence (5
0
dCATGGCT), as shown in
Fig. 29, le branch. The formation of monofunctional adducts
41a and 41b was due to the release of the pyridyl ligand 39-
octreotide or 39-RGD (depending on the compound used)
upon irradiation, followed by formation of the aqua species
[Ru(h6-p-cymene)(bpm)(H2O)]2+ (bpm ¼ 2,20-bipyrimidine) 40.
This intermediate then reacted with one guanine present in
the sequence, yielding the isomers 41a and 41b. On the other
hand, when the solution containing the Ru–peptide conju-
gates and the oligonucleotide was intensively irradiated (9 J
cm!2, 9 h irradiation), the bifunctional adduct 41c appeared,
due to consequent arene release (see Fig. 29, right branch).
Encouragingly, the authors demonstrated the specicity of
the ruthenium complex for guanine over other potential bio-
logical ligands present in octreotide such as histidine or
methionine, since no interactions between the ruthenium
complex and these amino acids were observed. Nevertheless,
these promising results and targeted strategy still need to be
veried in cell-based assays.
DNA intercalation and photo-cleavage. Covalent binding to
guanine is not the only manner by which a (metal-based) drug
can interfere with DNA replication. Diﬀerent compounds have
indeed been shown to interact with DNA in a non-covalent
fashion. Flat aromatic structures (e.g. dppz or PHEHAT ¼ 1,10-
phenanthrolino[5,6-b]1,4,5,8,9,12-hexaazatriphenylene; TAP ¼
1,4,5,8-tetraazaphenanthrene; IPPBA ¼ 3-(1H-imidazo[4,5-f]-
[1,10]phenanthrolin-2yl)phenylboronic acid) are known to
intercalate between two DNA bases. These DNA intercalative
moieties place the metal in close proximity to the bases, facili-
tating direct photo-induced oxidation of guanines or DNA
cleavage, for instance. To this end, de Feyter's group evaluated
the eﬀect of at aromatic ligands on DNA conformation upon
intercalation and upon photo-irradiation of [Ru(TAP)2-
PHEHAT]2+ (42) (Fig. 30).95 However, since no biological evalu-
ation in cells or mice has been performed, only the important
ndings will be mentioned in this section. The authors could
demonstrate that the main binding motif of the complex to
DNA occurred via intercalation of the PHEHAT ligand. They
could also highlight the importance of hydrogen bond-medi-
ated TAP intercalation in DNA in the nicking activity upon
visible light irradiation, since a decrease in nicking activity was
observed when hydrogen bonds were prevented by urea.
Nevertheless, urea treatment had no eﬀect on the second type of
DNA damage observed upon irradiation, namely adduct
formation between the complex and DNA.
Recently, Wang et al. succeeded to shi the absorption of a
Ru complex to longer wavelengths in order to obtain ligand
photorelease in the PDT window. At the same time, the authors
achieved an increase of the lifetime of the excited state, which
facilitates 1O2 production, thus combining PDT and PACT
mechanisms. The authors undertook the latter by introduction
of a 2,3-bis(2-pyridyl)-benzoquinoxaline (dpb) ligand into the
structure of the Ru(II) complex, whose delocalized p system was
able to shi 1MLCT absorption to lower energy.96 The authors
observed the formation of several photoproducts when [Ru(h6-
p-cymene)(dpb)(py)]2+ (py ¼ pyridine) (43) (Fig. 30) was irradi-
ated with visible light (>400 nm) with the moieties (py) and
(dpb) released in a 3.4 : 1 ratio. Moreover, the authors showed
that the complex was a modest 1O2 generator with a 1O2
quantum yield of 0.25 in CH3CN. Further investigation of the
direct eﬀects on DNA revealed the photo-binding and photo-
cleaving ability of the complex. These behaviors were subse-
quently examined in cell-based assays. Aer 4 h incubation in
A549 cells, followed by 1 h irradiation at >400 nm and an
additional incubation of 20 h in the dark, the complex showed
enhanced toxicity aer light irradiation, although with a
moderate PI of about 7 (IC50 in the dark: 27.6 mM, upon light
Fig. 30 Structures of [Ru(TAP)2PHEHAT]
2+ 42 studied for DNA inter-
calation and nicking by de Feyter and [Ru(h6-p-cymene)(dpb)(py)]2+
43 synthesized by Wang, characterized by high wavelength absorption
and ligand release.95,96
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
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exposure: 4.0 mM). Brewer and co-workers also aimed to tune
the absorption of the Ru(II) complexes to lower energy wave-
lengths and to not be, at the same time, dependent on the
presence of oxygen to achieve cell killing. To this end, they
designed a mixed-metal supramolecular complex [{(bipy)2-
Ru(dpp)}2RhCl2]5+ (44, Fig. 31) containing two Ru(II) centers to
absorb visible light and one Rh(III) atom.97 Complexes contain-
ing Rh(III) have previously been shown to photo-cleave DNA.98 By
agarose gel shi assays, the authors were able to characterize
the structural requirements for the photo-cleavage process.
First, they could show that the presence of rhodium in the
molecule is needed for the DNA cleavage to occur. Indeed, when
DNA was irradiated for 10 min at >475 nm, no cleavage was
observed in the presence of the analog compounds lacking
Rh(III), both in the presence and absence of oxygen. Second, they
could demonstrate that the process followed metal-to-metal
charge transfer (MMCT) and not the ordinary MLCT process. To
show this, the authors compared the DNA photo-cleavage eﬃ-
ciency of two analogs with inaccessible Rh(ds*) and Ir(ds*)
orbitals, namely [{(bipy)2Ru(bpm)}2RhCl2]5+ and [{(bipy)2-
Ru(dpp)}2IrCl2]5+ (45 and 46 in Fig. 31). As expected, both
analogs failed to cleave DNA. The same group then tested the
photo-triggered impact of their Ru–Rh mixed-metal complex
on African green monkey kidney epithelial cells (vero cells)
replication.99 The authors demonstrated that when cells were
pretreated with 44 and exposed to >460 nm light, limited
growth was observed up to 12 mM (conditions: 48 h incubation
with compounds, then removal of the medium and 4 min
irradiation at >460 nm, followed by 48 h recovery). At higher
concentrations, cell death was observed. Interestingly, cell
death was not observed with cells pretreated with the osmium
analog complex 47, shown in Fig. 31. This last observation
highlighted the fundamental role of the Ru atoms in 44 in
triggering cell death.
Gene silencing (ODN strategy)
Another attractive approach to target DNA is the use of oligo-
deoxyribonucleotides (ODNs) to inhibit gene expression. ODNs
can act on diﬀerent kinds of targets, namely double-stranded
DNA by triple helix formation (antigene strategy) or mRNA
(antisense strategy). However, these strategies suﬀer from the
low stability of ODNs, their ineﬀective delivery into cells and
from the low aﬃnity of the ODNs for the target sequence. To
overcome these drawbacks, chemically modied ODNs have
been investigated with diﬀerent moieties, including ruthenium
complexes. In the last few years, the group of Kirsch-De Mes-
maeker focused its attention on the detection of nucleic acids
using metal complexes.100 As an example, they employed highly
photo-reactive Ru complexes to irreversibly crosslink ODNs to a
DNA target sequence. A photoinduced electron transfer (PET)
takes place between a Ru complex and the guanine present in
close vicinity in the complementary DNA sequence. This results
in covalent binding between the Ru complex and the guanine,
forming a crosslink (see Fig. 32). The authors rst examined the
diﬀerent geometric factors inuencing adduct formation using
[Ru(TAP)2dip]2+ (dip ¼ 4,7-diphenylphenanthroline) (48,
Fig. 33). They demonstrated that guanines at the 30 side of the
complementary strand, compared to the ruthenium complex
anchoring position, are more favorable for the recombination of
radicals formed by PET (irradiation settings: 1 h at 4 $C with a
mercury/xenon lamp (200 W) using a lter (2M KNO3
solution)).101
In a follow-up study, the same group explored the impor-
tance of the anchoring position of the Ru complex with respect
to the ODN sequence. To do so, the photo-reactive poly-
azaaromatic complex [Ru(TAP)2(dppz)]2+ was coupled to the
ODN sequence either via the dppz (alias Ru(D) (49) in Fig. 34) or
the TAP moiety (alias Ru(T) (50) in Fig. 34). Adduct formation
eﬃciencies and DNA interactions were evaluated. The authors
found that both versions of anchored Ru complexes had the
same DNA photo-ligation eﬃciency upon light irradiation (442
nm, 50 mW, 60 min) but, interestingly, they interacted with
DNA in a diﬀerent fashion. Whilst Ru(T) interacts by
Fig. 31 Structures of the mixed-metal supramolecular complexes;
(44) [{(bipy)2Ru(dpp)}2RhCl2]
5+, (45) [{(bipy)2Ru(bpm)}2RhCl2]
5+, (46)
[{(bipy)2Ru(dpp)}2IrCl2]
5+, and (47) [{(bipy)2Ru(dpp)}2OsCl2]
5+.97,99
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
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intercalation with the dppz ligand, Ru(D) interacts via TAP
without intercalation. On one hand, dppz intercalation places
the ruthenium center in direct contact with the guanine,
favoring the PET process and back electron transfer. However,
this geometrical conformation secludes the reduced TAPc! and
oxidized G+c, thus reducing the photo-crosslinking eﬃciency.
On the other hand, the TAP interaction puts TAPc! and oxidized
guanine in an optimal orientation for the photo-crosslinking
reaction.102
This Ru–ODN strategy was examined in cell-based assays.103
In their study, Delvenne and co-authors coupled the comple-
mentary sequence of the oncogene E6, stimulated aer HPV16
infection and responsible for the silencing of p53, to a poly-
azaaromatic complex [Ru(TAP)2(phen)]2+ (51, Fig. 35). With this
tool in hand, they tested the eﬃciency of the conjugate for
impairing HPV16 positive cervical cancer cell (SiHa) prolifera-
tion upon visible illumination. They could demonstrate an
irreversible crosslink between the target and the Ru-conjugated
probe. The authors could not only show reduced cell prolifera-
tion (45–50% growth inhibition on SiHa cells, 24 h post
Fig. 32 (a) Schematic representation of the Ru–ODN strategy, (b) explanation of the adduct formation. Adapted from ref. 102.
Fig. 33 Structure of the [Ru(TAP)2dip]
2+ conjugated to the ODN sequences.101
Fig. 34 Structures of the Ru(II) complexes with an ODN sequence
coupled either on the dppz (49) or on the TAP (50) moiety.102
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
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illumination at 380–480 nm for 2 h 30), but also a restored
amount of p53, which is the principal target of E6, as well as a
reduced E6 protein level. The use of photo-reactive Ru
complexes for conjugation to ODN sequences oﬀers, in light of
the studies presented above, an attractive tool in the eld of
gene silencing. On one hand, the presence of a metal complex
can enhance cell delivery of the Ru–ODN due to the positive
charge brought by the Ru complex. On the other hand, the
aﬃnity of the probe for the target is improved since an irre-
versible crosslink is induced upon light irradiation. Moreover,
undesired non-specic interactions are avoided if the DNA
target sequence is not present, since the complex is capable of
auto-inhibition (the ‘seppuku eﬀect’), thus eliminating any
collateral inhibition or crosslink (see Fig. 32).
Photo-release strategy
Modication of the activity of a compound can be achieved by
masking the functional groups involved in the toxicity with a
cleavable moiety, acting as a cage. The idea of using light-
responsive cages to deliver biologically active compounds into
living cells or organisms is extremely appealing, oﬀering control
over the cytotoxicity and improved cellular uptake thanks to the
modulation of the lipophilicity or the insertion of a charge.
However, to date, there are only a few examples reported in the
literature. Those are described below.
Ruthenium complexes as caging moieties. The rst study
mentioned in this part of the perspective does not actually deal
with cancer therapy, but presents for the rst time the concept
of using a Ru complex as a suitable cage for molecules bearing
nitrogen atoms. Indeed, the [Ru(II)(bipy)2] fragment was the rst
ruthenium cage used to release a molecule. Etchenique et al.
caged the neurocompound 4-aminopyridine (4-AP) (52, Fig. 36),
which is known to promote neuronal activity by blocking
specic K+ channels.104 The authors were able to monitor the
electrical activity of a neuron within an isolated ganglion aer
photo-release of 4-AP. First, as expected, they conrmed that the
caged 4-AP did not change the electric pulse when kept in the
dark. A similar behavior was found for the cage itself. Never-
theless, upon pulsed irradiation (pulsed Xe lamp, 0.5 J per
pulse, low pass lter at 480 nm), a signal similar to the one of
the free 4-AP was detected, demonstrating the photo-release of
the neuro-compound. Of note, Etchenique and coworkers pre-
sented the release of other bioactive compounds upon light
activation such as GABA,105–107 glutamate,108,109 nicotine110 and
dopamine.111 However, this impressive work is not discussed
herein since it is not related to anticancer research.
Kodanko and collaborators, in turn, considered the latter
study and the opportunity oﬀered by Ru complexes to act as an
eﬀective photo-caging group for nitriles. They synthesized a
Ru(II)tris(2-pyridylmethyl)amine complex 53, functionalized
with two molecules of a known cathepsin K inhibitor 54 con-
taining a nitrile group (Cbz-Leu-NHCH2CN) (Fig. 37).112 In
healthy tissue, cathepsin K is a proteinase secreted by osteo-
clasts to degrade bones. It was shown to be expressed by breast
cancer metastasized to bones as well. The authors were able to
demonstrate the inhibition of the enzymatic activity of
cathepsin K upon light activation (365 nm for 15 min) even if
only one molecule of the inhibitor was released (IC50 values of
5.6 mM in the dark vs. 63 nM upon light irradiation).
Driven by these promising in vitro results, the same authors
chose a diﬀerent Ru cage and a second cathepsin K inhibitor 55,
yielding the compounds 56 and 57 reported in Fig. 38.113
The new inhibitor 55 was chosen because of its better inhi-
bition potency than 54 (reported IC50: 35 and 9 nM for 54 and
55, respectively). Moreover, using the Ru(bipy)2 fragment as a
cage, they could demonstrate that both nitrile ligands could be
photoreleased. However, complex 57 required a longer exposure
time to release the inhibitor (up to 60 min of irradiation) than
complex 56 (15 min). Using the same experimental conditions
(tungsten lamp, 250 W, >395 nm, H2O lter), 56 and 57 showed
signicantly enhanced inhibition activities compared to the
parent inhibitors 54 and 55 (IC50 values are 36 nM and 28 nM,
Fig. 35 Structure of [Ru(TAP)2(phen)]
2+.103
Fig. 36 Structure of the Ru(II) caged neuroactive 4-AP.104
Fig. 37 Structures of caged cathepsin K inhibitor (Cbz-Leu-NHCH2-
CN) (RCN).112
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
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respectively). Complex 56 showed a dark to light IC50 improve-
ment from 560 nM to 16 nM (PI ¼ 35). The photo-activated
inhibition of cathepsin K is twice as eﬀective as the parent
inhibitor alone, correlating with the two molecules of inhibitor
released. In the case of complex 57, the dark to light IC50
enhancement was from 2.2 mM to 25 nM (PI ¼ 88). The light-
triggered inhibition is in good agreement with the slow release
rate of the second inhibitor molecule, reaching a similar value
to the free parent molecule 55. In order to verify that none of the
drugs or photoproducts were toxic in cells, the authors tested
the viability of Bone Marrow Macrophages (BMM) and PC3 cells
aer 30 min incubation with the complexes, followed by a dark
environment or 15 min irradiation for 56 or 40 min for 57 and
24 h additional incubation. They were able to conrm that no
toxicity was found in murine BMM or PC3 cells up to 10 mM for
complex 56 and up to 1 mM for 57. Since 56 showed the most
promising features, the authors evaluated its enzymatic inhi-
bition ability in a cell-based assay. Enzymatic activity in osteo-
clasts decreased by 25% and 50%when treated with 100 nM and
1 mM, respectively, either with 54 or with the photo-activated 56
(see the enzymatic inhibition studies in mouse osteoclasts in
Fig. 39 for 54 and Fig. 40 for 56). These ndings suggest that the
photo-released enzyme inhibitors can play a potent role in the
treatment of diseases where increased enzymatic activity is
observed, sparing normal activity in surrounding tissues. These
studies widen the perspective on the use of Ru(II) complexes as
caging groups for the release of a large variety of biomolecules,
from the pioneering Ru(II)(bipy)2 fragment as a neurotrans-
mitter releaser, to nitrile-based protease inhibitors.
Kodanko and colleagues applied the Ru(bipy)2 fragment as a
cage. However, compared to this, the Ru(II)tpy fragment oﬀers a
lower energy 1MLCT absorption, tting within the PDT window
Fig. 38 Structures of the Ru(II) complexes containing cathepsin K
inhibitors.113
Fig. 39 Confocal microscopy images of mouse osteoclast cells treated with 54. Cells were pre-incubated with 54 (10–1000 nm) for 30 min at
37 $C in the presence of cathepsin B inhibitor CA074Me (1 mm). Cells were treated with the cathepsin K substrate Z-LR-4MbNA (0.25 mm) and
nitrosalicylaldehyde (1.0 mm, a precipitating agent), leading to the release of 4MbNA (green ﬂuorescent precipitate indicative of cathepsin
activity, arrows). Cells were ﬁxed and imagedwith a confocal laser scanningmicroscope (Zeiss LSM 780) using a 40% oil immersion lens. For each
of the conditions at least six images of individual osteoclast cells were acquired, and ﬂuorescence intensity per osteoclast area wasmeasured and
quantiﬁed using ImageJ software (NIH). The intensity of green ﬂuorescence is a direct measure of the quantity of hydrolyzed and precipitated
substrate (A–D), also visible on DIC images (E–H). The quantiﬁed data are shown as column (I) and dot (J) plots; *p < 0.05, **p < 0.001. Results are
representative of at least three experiments. Reproduced with permission from ref. 113. © 2014Wiley-VCH Verlag GmbH &Co. KGaA, Weinheim.
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
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(600–850 nm). Turro et al. took this opportunity and designed a
Ru(II)tpy complex able to induce the release of 5-cyanouracil
(5CNU), a known pyrimidine catabolism inhibitor, upon irra-
diation with visible light (>400 nm). Since it was shown that the
bis-aqua Ru derivative can bind DNA, the following
[Ru(tpy)(5CNU)3]2+ complex (59, Fig. 41) can potentially be used
as a dual-action therapeutic agent.114
Indeed, the authors demonstrated that similarly to its analog
complex bearing (CH3CN)3 (58, Fig. 41), the complex eﬃciently
released the two axial ligands when irradiated with visible light
(150 W Xe lamp housed in a Milliarc compact arc lamp
housing), concomitantly producing the bis-aqua species. Only
the latter photoproduct was then able to bind to DNA as
observed by a reduction in the plasmid pUC19 mobility, when
complexes 58 and 59 were irradiated for 5 or 15 min, respec-
tively. However, extending these observations to cellular studies
was revealed to be more challenging. Indeed, when human
cervical cancer HeLa cells were treated with 100 mM of the Ru
complexes for 2 h in the dark, followed by 1 h light irradiation,
only complex 59 was shown to be capable of generating damage
(no damage was observed in non-irradiated cells for 58 and 59).
Moreover, cells treated with 100 mM of free 5CNU showed the
same extent of damage as for complex 59 upon light irradiation,
coinciding with only one molecule of 5CNU being released. The
latter observation was conrmed when the LC50 value of irra-
diated 59 matched the one of free 5CNU (156 and 151 mM,
respectively). In both cases, the mono-aqua photoproduct
formed was not able to bind DNA. Accordingly, no decreased
mobility was observed in agarose gel shi assay. This was also
conrmed by the absence of cytotoxicity upon irradiation in the
case of 58 or increased toxicity for 59.
Ruthenium complexes as photo-released drug candidates.
The photo-cleavage of a cage to release bioactive components is
not a novel strategy since this method has been successfully
used to release small organic molecules.115 However, to the best
of our knowledge, the specic release of a cytotoxic metal
complex has never been reported before the work of our group.
Indeed, we could recently successfully inactivate a previously
characterized cytotoxic ruthenium complex (61)116 by attach-
ment to a photo-labile protecting group (PLPG) (60, Fig. 42).
UPLC-MS experiments conrmed that, upon UV-A exposure, the
original complex was released from the PLPG. As previously
suggested by SAR studies,50 we could demonstrate that caging
reduced the toxicity of the Ru complex (IC50 > 100 mM in the
dark) and that the original toxicity could be regained upon
irradiation at 350 nm (2.58 J cm!2) (17 mM). This value coincides
with the value of the original non-caged complex (61).51 We also
Fig. 40 Confocal microscopy images of mouse osteoclast cells treated with the ruthenium-caged inhibitor 56 (A–D) or cis-[Ru(bpy)2-
(MeCN)2](PF6)2 (E–H). Cells were pre-incubated with either complex (0–1000 nm) for 30 min at 37 $C in the presence of cathepsin B inhibitor
CA074Me (1 mm), then exposed to dark (no irradiation) or light (irradiation at 250 W, 395–750 nm) conditions for 15 min. Cells were treated with
the cathepsin K substrate Z-LR-4MbNA (0.25 mm) and nitrosalicylaldehyde (1.0 mm, a precipitating agent), leading to the release of 4MbNA
(green ﬂuorescent precipitate indicative of cathepsin activity). Cells were ﬁxed and imaged with a confocal laser scanningmicroscope (Zeiss LSM
780) using a 40% oil immersion lens. For each of the conditions at least six images of individual osteoclast cells were acquired, and ﬂuorescence
intensity per osteoclast area was measured and quantiﬁed using ImageJ (NIH) software as described for Fig. 39 above; **p < 0.001. Results are
representative of at least three experiments. Reproduced with permission from ref. 113. © 2014Wiley-VCH Verlag GmbH &Co. KGaA, Weinheim.
Fig. 41 Structures of the Ru-inhibitor complexes synthesized by
Turro.114
This journal is © The Royal Society of Chemistry 2015 Chem. Sci.
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investigated the fate of the Ru complexes by confocal micros-
copy. We could show that the caged complex was probably
relocalizing from the cytoplasm and nucleoli (before light irra-
diation) to mitochondria, which were previously shown to be
the preferential target of this complex.116 Our group recently
demonstrated that such a concept could be applied to a rhe-
nium(I) organometallic complex.51 Although there are a few
advantages to use UV-A light as a trigger in the context of light-
activated drugs, this type of light is only able to penetrate up to
the derma, which protects tissues in the lower layers. Therefore,
it would be of high interest to push the light activation of these
drug candidates to the PDT or near-IR window.
Conclusions
As shown in this perspective article, Ru(II) complexes oﬀer several
opportunities as light-activated drug candidates. Although very
promising in vitro results have been achieved so far, the lack of in
vivo studies (to the best of our knowledge, there have only been
three reported so far) undoubtedly does not allow for a full
assessment of the suitability of such compounds in a clinical
context. However, we are condent that more such studies will be
reported in the near future, shedding light on the full potential of
these compounds.
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1.3. DNA DAMAGE AND REPAIR 
1.3.1. SHORT OVERVIEW OF DNA DAMAGES AND RESPONSE MECHANISMS 
 The genomic integrity is continuously challenged by endogenous (oxygen radicals, 
replication errors, etc) and exogenous (UV light, alkylating and crosslinking agents, 
etc) stresses that cause DNA damage as represented in Figure 4. Each type of DNA 
lesions is processed by a specific repair pathway according to a common scheme: 
detection of the lesion, recruitment of the repair machinery to the site of damage and 
repair of the lesion.31  
  
Figure 4. Overview of DNA damage and repair. Adapted from ref 31. 
 
1.3.2. CISPLATIN INDUCED DNA DAMAGES AND REPAIR MECHANISM 
1.3.2.1. INTRA-STRAND DNA CROSSLINK  
Cisplatin induced intra-strand DNA crosslinks produce a kink in the DNA structure, 
which is recognized and repaired by the NER pathway.17 This pathway is also 
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responsible for the repair of DNA bulky lesions caused by UV damage, mostly 
thymine dimers and 6-4 PP (Figure 5). Two NER pathways are distinguished, the 
global genomic NER (GG-NER) and the transcription coupled NER (TC-NER). The 
principal difference is that in the case of TC-NER, the lesion is recognized by the 
RNA polymerase, whereas in the GG-NER, XPC-HR23B, XPA and RPA are 
involved in sensing the lesion. After lesion recognition, the transcription factor TFIIH 
is recruited to the site of damage. The TFIIH subunits XPB and XPD, two helicases, 
open the DNA surrounding the lesion. This conformational change allows then the 
recruitment of other factors, such as XPG. The role of RPA in this context is to 
protect the single stranded DNA from nucleases, while the endonuclease XPG, make 
the first 3' incision. The role of XPA in this process is still unclear. The ERCC1-XPF 
endonuclease is recruited to perform the 5' incision, liberating a 24-32 oligomer. In 
the presence of PCNA, polymerases δ or ε can then refill the gap, which will be 
closed by DNA Ligase I.32, 33 Defects in the NER reaction lead to xeroderma 
pigmentosum, a disease characterized by severe sensitivity to sunlight with high risk 
to develop cancer. This is due to the deficiency in the repair of UV-mediated 
damage.34 
Figure 5. Cisplatin intra-strand DNA crosslink repair by GG-NER. Adapted from ref 32. 
 
1.3.2.2. INTER-STRAND DNA CROSSLINK  
The minor in number but major in effect are inter-strand DNA crosslinks. Such 
lesions require the Fanconi Anemia (FA) protein complex as well as the Homologous 
recombination (HR) pathway for repair (Figure 6). Inter-strand crosslink are highly 
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toxic because they interfere with fundamental cellular processes like DNA replication 
and transcription that necessitate strand separation.35 The recognition of inter-strand 
crosslinks is operated by FANCM and associated proteins (FAAP20, FAAP24, 
FAAP100) and promotes the recruitment and activation of the FA core complex 
(FANC-A, B, C, E, F, G, L). FANCL, an E3-ligase, monoubiquitinates the FANCI-
D2 heterodimer. The latter can then recruit the nuclease FAN1 and with the 
cooperation of other structure specific nucleases, such as MUS81-EME1, SNM1A, 
XPF-ERCC1 and SLX1-SLX4, the inter-strand DNA crosslink is incised and 
unhooked. Fork stabilization and complete repair is now undertaken by Homologous 
recombination (HR) machinery.  Briefly, RPA DNA coating protein is replaced by 
RAD51 with the help of factor such as BRCA2, which control the search for 
homology and strand invasion. RAD54, a DNA-dependent ATPase stabilizes the 
RAD51-ssDNA complex. The polymerase ζ fills the gap and Holiday junctions are 
resolved by specific endonucleases mentioned above.36 
Figure 6. Cisplatin inter-strand DNA crosslink repair during replication. Adapted from ref 36. 
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1.3.3. OXIDATIVE DNA BASE LESIONS: 8-OXO-GUANINES 
Oxidative stress and resulting base oxidation such as 8-oxo-Guanine, are repaired in 
cells by the Base Excision Repair (BER) pathway (Figure 7). The key protein in this 
repair is 8-oxoguanine DNA glycosylase 1 (OGG1) that removes 8-oxo-G lesions, 
leaving an abasic apurinic/apyrimidinic (AP) site. AP endonuclease 1 (APE1) can 
then cut at the 5' site of the sugar, leaving either a native or an oxidized 5'-sugar 
phosphate. In the case of the native sugar, polymerase β will remove the sugar thanks 
to its 5′-deoxyribose phosphate (dRP) lyase activity and refill the gap before ligation 
(Single Nucleotide Excision). In the second case, where the sugar is oxidized, two or 
more nucleotides can be excised. Two nucleotides are removed by the help of the flap 
endonuclease FEN1, that substitutes for the (dRP) lyase activity deficiency of 
polymerase β. In this case we talk of long-patch BER. More than two nucleotides are 
removed by DNA strand-displacement synthesis mediated by polymerase β or δ/ɛ, 
FEN1 operates the cleavage and the strand is religated.37 
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Figure 7. Oxidized base repair by BER pathway. Taken from ref 37. 
In the situation of OGG1 overload, non-excised 8-oxo-Gs can persist and are 
addressed in the next cell cycle (Figure 8). In this case, the Mismatch Repair (MMR) 
machinery is involved. Indeed, polymerase β will recognize an 8-oxo-G as a thymine 
(T) and mispairs it with an adenine (A). If this error is not resolved before the next 
cell cycle, a transversion mutation CG -> AT will occur. The role of MUTYH is then 
crucial in this process. MUTYH will excise the mismatched A, leaving an apurinic 
site to be processes by APE1 with the help of FEN1, PCNA, RPA, polymerase λ and 
the ligase.38 MUTYH can give then a second chance to OGG1 to remove the oxidized 
base, but if the latter is still overloaded, it can give rise to a futile cycle, that will lead 
ultimately to apoptosis.39 Recently, MutSβ, a protein involved in the mismatch 
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recognition in MMR, has been found to recognize cisplatin inter-strand DNA 
crosslinks.40 
 
 
Figure 8. 8-oxo-G repair outcome. Taken from ref 38. 
 
UV-induced SSBs and photosensitization: repair mechanism 
It has been reported that SSBs can be produced by UV and visible wavelengths in 
the 240-546 nm range.41 It is also possible to induce SSBs by means of intermediate 
molecules that will act as photosensitizers. These photosensitizing molecules will 
transfer the energy of the light absorbed via electron transfer or energy transfer to 
surrounding molecules, such as water or bases, thereby creating SSBs.42 The case of 
Ruthenium based photosensitizers is discussed in section 1.2. SSBs will be recognized 
by PARP1 and repaired by BER excision repair pathway.  
 
  
 
 
2. Results 
 
 
 
Project 1: Photo-uncaging of Ru(II) complex in living cells using UV-A irradiation 
as trigger. 
This study is divided into 3 articles. In the first one, the promising biological effects 
of a Ru(II) complex on cancer cells have been investigated. The following SAR study 
revealed that the carboxylic function of the complex is crucial for toxicity. Finally, the 
biological deactivation of this complex by coordination of a photo-protecting group 
and its efficient release upon light irradiation is depicted in the last study. 
Project 2: Investigation of the mechanisms of action and repair of an efficient 
photosensitizer Ru(II) complex upon UV-A irradiation. 
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2.1. PHOTO-ACTIVATED UNCAGING OF RU(II) COMPLEXES IN CANCER 
CELLS (PACT) 
The aim of this study is to specifically deliver metal complexes to living cells using 
light as an external trigger. We could show that such concept is potentially relevant 
for cancer therapy and PACT in general. We used a substitutionally-inert bis(dppz)-
Ru(II) complex as anticancer drug candidate and UV-A light as trigger. 
 
2.1.1. CONTRIBUTIONS TO THE ARTICLES 
V.P.: performed all the biological experiments; viability assays, microscopy, MMP 
assay, FACS, mitochondria extraction.  
 
2.1.2. MOLECULAR AND CELLULAR CHARACTERIZATION OF THE BIOLOGICAL EFFECTS 
OF RUTHENIUM(II) COMPLEXES INCORPORATING 2-PYRIDYL-2-PYRIMIDINE-4-
CARBOXYLIC ACID 
After identification of a promising anticancer drug candidate, namely 
[Ru(dppz)2(CppH)]2+, showing cytotoxic activity in the range of cisplatin, 
investigation of its behavior in cells and mechanism of action of the complex have 
been unveiled. Briefly, the complex targets mitochondria, impairs their membrane 
potential, leading to apoptosis.  
This chapter has been published in J. Am. Chem. Soc. in 2012. Reused with 
permission from 43. Copyright (2012) American Chemical Society. 
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ABSTRACT: A great majority of the Ru complexes currently
studied in anticancer research exert their antiproliferative activity,
at least partially, through ligand exchange. In recent years,
however, coordinatively saturated and substitutionally inert
polypyridyl Ru(II) compounds have emerged as potential
anticancer drug candidates. In this work, we present the synthesis
and detailed characterization of two novel inert Ru(II)
complexes, namely, [Ru(bipy)2(Cpp-NH-Hex-COOH)]
2+ (2)
and [Ru(dppz)2(CppH)]
2+ (3) (bipy = 2,2′-bipyridine; CppH =
2-(2′-pyridyl)pyrimidine-4-carboxylic acid; Cpp-NH-Hex-COOH = 6-(2-(pyridin-2-yl)pyrimidine-4-carboxamido)hexanoic acid;
dppz = dipyrido[3,2-a:2′,3′-c]phenazine). 3 is of particular interest as it was found to have IC50 values comparable to cisplatin, a
benchmark standard in the ﬁeld, on three cancer cell lines and a better activity on one cisplatin-resistant cell line than cisplatin
itself. The mechanism of action of 3 was then investigated in detail and it could be demonstrated that, although 3 binds to calf-
thymus DNA by intercalation, the biological eﬀects that it induces did not involve a nuclear DNA related mode of action. On the
contrary, confocal microscopy colocalization studies in HeLa cells showed that 3 speciﬁcally targeted mitochondria. This was
further correlated by ruthenium quantiﬁcation using High-resolution atomic absorption spectrometry. Furthermore, as
determined by two independent assays, 3 induced apoptosis at a relatively late stage of treatment. The generation of reactive
oxygen species could be excluded as the cause of the observed cytotoxicity. It was demonstrated that the mitochondrial
membrane potential in HeLa was impaired by 3 as early as 2 h after its introduction and even more with increasing time.
■ INTRODUCTION
The phenomenal success of the chemotherapeutic drug
cisplatin has boosted the research directed at novel metal-
based drugs, especially since severe side eﬀects including
nephrotoxicity can be encountered during treatment with this
compound.1−7 Among the potential metal-based candidates,
ruthenium complexes have emerged as leading players by
showing extremely promising results.8−18 Two Ru(III)
candidates, namely, imidazolium trans-[tetrachloro-
(dimethylsulfoxide)-(1H-imidazole)ruthenate(III) (NAMI-
A)19,20 and indazolium trans-[tetrachlorobis(1H-indazole)-
ruthenate(III)] (KP1019),21 have even entered clinical trials
(Figure 1).22 Despite their structural similarities, these two Ru
complexes exert their cytotoxic action diﬀerently. While
KP1019 exhibits promising eﬀects against a variety of tumor
models including colorectal carcinomas and primary explanted
human tumors,23 NAMI-A only has a minor activity against
primary tumor cells but an impressive eﬃcacy against the
formation of metastases.23,24 For both NAMI-A and KP1019,
and generally speaking for the majority of the Ru complexes
investigated for medicinal purposes, the complexes usually
undergo ligand exchange to exert their antiproliferative
activities, as cisplatin does. There are, however, exceptions
such as the Ru(II) based enzyme inhibitors of Meggers et
al.25−27 and the coordinatively saturated and substitutionally
inert polypyridyl Ru(II) compounds.28,29 For the latter, the
cytotoxic eﬀects were at least partially attributed to noncovalent
interactions with nucleic acids, particularly DNA.30−37 In recent
years, however, several studies have shown that other factors,
such as modiﬁcation of cell membrane and cell adhesion
properties,38 topoisomerase I and II inhibition39 or mitochon-
dria-mediated apoptosis,32,33,40−43 could be responsible for
cytotoxicity.
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Inspired by these ﬁndings, we have decided to thoroughly
investigate the in vitro behavior of four Ru(II) complexes
bearing a derivative of the 2-(2′-pyridyl)pyrimidine (Cpp)
ligand,44 namely, [Ru(bipy)2(CppH)]
2+ (1),44 [Ru-
(bipy)2(Cpp-NH-Hex-COOH)]
2+ (2), [Ru(dppz)2(CppH)]
2+
(3), and [Ru(dppz)2(Cpp-NH-Hex-COOH)]
2+ (4)45 (bipy =
Figure 1. Structures of NAMI-A, KP1019, and the Ru(II) complexes (isolated as hexaﬂuorophosphate salts) studied in this work.
Scheme 1. Syntheses of 2 and 3a
aConditions: (a) (i) bipy, Me3NO, 2-methoxyethanol, Δ, 4 h; (ii) CH3CN/H2O/H2SO4 (45:45:10), Δ, 24 h, 75%; (b) (i) dppz, Me3NO, 2-
methoxyethanol, Δ, 4 h; (ii) CH3CN/H2O/H2SO4 (45:45:10), Δ, 24 h, 66%.
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2,2′-bipyridine; CppH = 2-(2′-pyridyl)pyrimidine-4-carboxylic
acid; Cpp-NH-Hex-COOH = 6-(2-(pyridin-2-yl)pyrimidine-4-
carboxamido)hexanoic acid; dppz = dipyrido[3,2-a:2′,3′-c]-
phenazine) (Figure 1). Complex 4 was recently prepared in our
laboratories with a view to the development of electro-
chemiluminescent Ru(II)-peptide nucleic acid bioconjugates
as either DNA/RNA biosensors or cellular uptake en-
hancers.45−47 Herein, we also describe the synthesis and
characterization of the two Ru(II) complexes 2 and 3 (Figure
1), including the X-ray crystal structure of 2. This work, to the
best of our knowledge, presents one of the most detailed
biological evaluations of a polypyridyl Ru(II) complex, 3, which
was found extremely cytotoxic on diﬀerent cancer cell lines.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of the Ru(II) Com-
plexes. The two Ru(II) complexes 1 and 4 presented in Figure
1 were prepared as previously reported by our groups.44,45
Compounds 2 and 3 were synthesized in an analogous manner
by reacting [Ru(Cpp-NH-Hex-COOH)(CO)2Cl2],
45 and [Ru-
(CppH)(CO)2Cl2],
44 with bipy and dppz, respectively
(Scheme 1). All Ru(II) complexes were unambiguously
characterized by 1H NMR spectroscopy, ESI mass spectrom-
etry, and elemental analysis (see Experimental Section for
further details and Figures S1−S4 in Supporting Information
for the 1H NMR spectra of 2 and 3 as well as the absorption
and emission spectra of 1−4).
X-ray Crystal Structures. During the preparation of 1−4,
single crystals of 1 and 2 were obtained and their structures
were elucidated by X-ray crystallography. The asymmetric unit
(ASU) of 1 consists of a [Ru(bipy)2(CppH)]
2+ cation,
hexaﬂuorophosphate anions, and noncoordinated water mole-
cules (Figure S5 in the Supporting Information) {A related
structure in which the CppH ligand is deprotonated was
published recently by our group}.44 As for 1, a [Ru-
(bipy)2(Cpp-NH-Hex-COOH)]
2+ unit, perchlorate counter-
anions, and noncoordinated water molecules deﬁne the ASU
for 2 (Figure S6 in the Supporting Information). The X-ray
structural analysis showed Ru(II) center to reside in a distorted
octahedral geometry in both complexes, with bond distances
and angles typical of Ru(II) diimine complexes.44,48 The trans-
N−Ru−N angles and N−Ru−N bite angles, formed between
the nitrogen atoms of the 2,2′-bipyridine and 2-(2′-pyridyl)-
pyrimidine (Cpp) rings and the Ru(II) center, are in the typical
range (172.29(14)−175.40(13)° and 78.60(15)−79.03(14)°,
respectively), as reported for other tris(diimine)Ru(II)
complexes (Table S1 in Supporting Information).44,48 Coordi-
nation of the Cpp unit to the Ru(II) center in 1 and 2 involves
the N4 and N3 nitrogen atoms and the carboxylate group
points away from the Ru(II) center as previously observed for
other Ru(II)-2-(2′-pyridyl)pyrimidine-4-carboxylic acid com-
plexes.44 The crystal structure for 2 (see Figure S7 in the
Supporting Information) also shows hydrogen-bonding of the
N−H and O−H (protonated carboxylate) groups with the
perchlorate counteranions present in the crystal lattice along
with C−H....pi interactions between the aromatic protons and
pi-electron rich bipyridyl ring.
Cytotoxicity Studies. The cytotoxicity of complexes 1−4
toward human cervical cancer HeLa, breast carcinoma MCF7,
osteosarcoma U2OS, ovarian carcinoma A2780, and cisplatin-
resistant ovarian carcinoma A2780-CP70 cell lines was
investigated using a ﬂuorometric cell viability assay (Resazur-
in).49 As a control, the toxicity of the compounds was also
tested toward human lung ﬁbroblasts MRC-5. Furthermore, for
the purposes of comparison the toxicities of cisplatin and
dequalinium chloride hydrate, a known antiproliferative
compound with a mitochondrial implication in cell death,50,51
were also determined on the same cell lines (see Figures S8−
S10 in the Supporting Information for the graphs of the
Resazurin assays of compound 3, cisplatin and dequalinium
chloride hydrate). As shown in Table 1, the Ru(II) bipyridyl
derivatives 1 and 2 did not present cytotoxcity in any of the cell
lines tested. These observations are in contrast to the results
obtained for the Ru(II) dppz derivatives 3 and 4, which were
cytotoxic toward all the six cell lines employed in this study. Of
particular interest is the observation that the IC50 values
determined for 3 are close, or even lower, than those for
cisplatin and in a similar range to dequalinium chloride hydrate.
Notably, 3 was found to be more active on a cisplatin-resistant
cell line than cisplatin itself, an observation that points to its
therapeutic potential, particularly in light of the worrying
emergence of cisplatin resistance in tumors.52 Moreover, the
ﬁnding that 3 was found to be less cytotoxic than cisplatin on
the healthy cell line studied in this work is suggestive of a better
therapeutic proﬁle than cisplatin. Another striking result is that
4, the structurally similar derivative of 3, displayed much higher
IC50 values than 3 (>12-fold on the A2780 cell line). This
rather surprising ﬁnding clearly indicates that subtle structural
changes have an important impact on the toxicity and
prompted us to further investigate the origin of this behavior.
Cellular Localization. As a ﬁrst step toward elucidating the
mechanism of action of 3, the favorable photophysical
properties of 1−4 have been used to evaluate their localization
in HeLa cells. It was anticipated that the cellular localization of
the complexes bearing the dppz moieties (3 and 4) could be
possible if they were directed to a hydrophobic environment as
the ﬂuorescence of these compounds is quenched in aqueous
media. On the contrary, the ﬂuorescence properties of 1 and 2
should not be so signiﬁcantly solvent-dependent and it was
expected that they could be detected in any cellular
Table 1. Cytotoxicities (IC50) of 1−4 Dequalinium Chloride Hydrate and Cisplatin towards Human (Cancer) Cell Linesa
IC50 (μM)
HeLa MCF7 U2OS A2780 A2780-CP70 MRC-5
1 >100 >100 >100 >100 >100 >100
2 >100 >100 >100 >100 >100 >100
3 10.0 ± 1.3 4.3 ± 0.1 13.5 ± 2.5 2.8 ± 0.1 4.0 ± 1.2 15.1 ± 2.2
4 57.5 ± 4.8 22.0 ± 3.8 83.2 ± 5.6 26.8 ± 7.6 49.6 ± 5.0 66.3 ± 8.1
cisplatin 11.5 ± 2.9 1.8 ± 0.3 11.8 ± 1.7 2.9 ± 0.6 13.8 ± 3.0 7.9 ± 1.2
dequalinium chloride hydrate 21.9 ± 3.6 2.9 ± 0.5 13.4 ± 2.5 1.0 ± 0.1 1.7 ± 0.7 48.9 ± 7.6
aCells were treated with diﬀerent concentrations of the ruthenium complexes, cisplatin, and dequalinium chloride hydrate for 48 h. The cell viability
was determined by using the resazurin reduction test.
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compartments. The localization of the complexes was then
assessed by ﬂuorescence microscopy (see Figure S11 in the
Supporting Information). The presence of 1 and 2 in living
cells or after ﬁxation in formaldehyde was very diﬃcult to
evaluate. Only a weak ﬂuorescence could be detected which we
have assumed indicates that these compounds were poorly
taken up by the cells. However, very clear confocal microscopy
images were obtained for 3 and 4 after cell ﬁxation with
formaldehyde (Figure 2). The most important ﬁnding to
emerge from these studies is that, even though 3 and 4 are
structurally quite similar, their cellular localization was
extremely diﬀerent. Compound 4 diﬀused throughout the
cell, including the nucleus. In addition, the outer cellular
membrane also seemed to be a primary target of 4. On the
contrary, 3 localized mainly to the cytoplasm with only weak
ﬂuorescence detectable in the nucleus. This signiﬁcant
diﬀerence in localization is likely to be responsible for the
disparity in cytotoxicity observed for these Ru(II) complexes.
To obtain further information on the exact localization of 3,
colocalization experiments were performed. Mitotracker green
FM was employed for this purpose as it was anticipated that 3
could be localized in the mitochondria. As shown in Figure 3,
an excellent superimposition pattern between the commercially
available dye and 3 could be observed (see also the online video
in Supporting Information). To the best of our knowledge,
there are only a handful of reports which so clearly demonstrate
by ﬂuorescence microscopy that mitochondria are the target of
inert polypyridyl Ru complexes,40,41,53 although these organ-
elles have only recently been considered as target of such
compounds.32,33,40−42,54 Of particular relevance here is the fact
that mitochondria are critical targets of cytotoxic gold
compounds.55−59
As 3 mainly exhibits ﬂuorescence in a hydrophobic
environment, it could also be localized in another cellular
organelle hampering visualization by ﬂuorescence microscopy.
High-resolution continuum source atomic absorption spec-
trometry (HR-CS AAS) is an analytical method of choice in
this situation, as it allows the detection of trace metal
concentrations in biological tissues.60−62 In previous studies,
it has been reported that the amount of ruthenium taken up by
cancer cells can be a deciding factor in obtaining active
ruthenium compounds.33,38,63 In this study, we decided to go
one step further by endeavoring to ascertain that 3 mainly
targets mitochondria. Therefore, we incubated HeLa cells with
50 μM of 3 for 2 h and isolated the mitochondria from the cells.
The uptake of 3 into whole cells and into their mitochondrial
fractions was quantiﬁed by determination of the ruthenium
content by HR-CS AAS (Figure 4). The cellular and
mitochondrial protein content of the same samples was
determined by the method of Bradford64 and the measured
Figure 2. Fluorescence confocal microscopy images of HeLa cells incubated with (a) 3 (20 μM) and (b) 4 (60 μM) for 2 h. Images show DAPI
staining, cellular staining of ruthenium compounds, and the overlay.
Figure 3. Fluorescence confocal microscopy images of HeLa cells
incubated with 3 (20 μM) for 2 h and Mitotracker green FM for 45
min: (a) DAPI staining; (b) cellular staining of 3; (c) Mitotracker
green FM staining; and (d) the overlay image.
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ruthenium levels were correlated to the respective protein
content. The analysis revealed a high mitochondrial uptake of 3
with a concentration of 29.3 nmol Ru/mg mitochondrial
protein. This corresponds to 68% of the total cellular uptake of
3 into HeLa cells.
All in all, ﬂuorescence microscopy and high-resolution
continuum source atomic absorption spectrometry indicate
that uptake into the mitochondria may be a major pathway for
the biodistribution of 3.
Stability in Human Plasma. To determine whether 3 was
stable in biological media, its stability in human plasma was
assessed following an experimental protocol that we have
recently used in the study of ferrocenyl derivatives.65 As clearly
evident from the LC−MS traces (Figure S12 and Table S2 in
the Supporting Information), 3 shows no signiﬁcant decom-
position in human plasma when monitored over a period of
three days. This observation is an excellent indication that the
intact Ru(II) complex is responsible for the observed cytotoxic
activity.
Cellular Uptake Mechanism. To obtain more insight into
the mechanism of the cellular entry of compound 3, we ﬁrst
assessed whether cellular uptake is energy dependent. As nicely
explained in a recent review by Pucket and Barton,66
endocytosis and active transport proteins require energy
while passive diﬀusion through the membrane and diﬀusion
are energy independent. In this respect, 3 was incubated into
HeLa cells at 4, 23, and 37 °C for 6 h, and the relative uptake of
3 was assayed by ﬂow cytometry (see Figure S13 in the
Supporting Information). As shown in Figure S14a in the
Supporting Information, the uptake of 3 increased with
temperature, indicating that it was energy-dependent. With
no signiﬁcant perturbation observed in mitochondrial mem-
brane potential of untreated HeLa cells between 4 and 37 °C
(Supporting Information, Figure S14b), it implies that the
uptake of 3 into HeLa cells is not only due to passive diﬀusion
as it could have been ﬁrst anticipated.
Distribution Coeﬃcient (logD) and Electrochemical
Studies. The lipophilicity of a compound is well-known to
have a strong inﬂuence on its cellular uptake and local-
ization,66−68 and it has been shown that lipophilic cations
accumulate in mitochondria as a result of the negative potential
diﬀerence across the mitochondrial membrane.66,69,70 With this
in mind, we have evaluated the lipophilicity of the Ru
complexes by determining the distribution coeﬃcients at pH
= 7.01, a good approximation of physiological conditions, using
the “shake-ﬂask” method. The distribution coeﬃcient (logD) is
a measure of partitioning of a compound, in its ionized form,
between organic and water phases, and consequently it is pH
dependent. As shown in Table 2, compounds 3 and 4 are the
most lipophilic compounds of the series due to the presence of
the two dppz ligands. Of note, the logD7.01 values correlate well
with the solubility of 1−4 in buﬀer, namely, 1 and 2 are
comparatively more soluble in buﬀer than 3 and 4 (up to 50
μM). As expected, addition of an alkyl chain in 2 and 4 also
increases the lipophilicity of the compounds compared to the
parent compounds 1 and 3, respectively.
To evaluate whether a correlation exists between the
electrochemical behavior of the Ru complexes and their
cytotoxicities, the midpoint potentials Em for the Ru(II)/
Ru(III) couple of 2−4, namely, the average of the oxidation
and reduction peak potentials, were determined from the cyclic
voltammograms (see Table S3 and Figures S15−S18 in
Supporting Information). The Em values are equal to the
reversible potentials, provided the diﬀusion coeﬃcient of the
oxidized Ru(III) and reduced Ru(II) form are equal. Although
the Em values of the compounds are similar, complex 3, which is
the hardest to oxidize, is the most cytotoxic compound of the
series. However, there is no clear trend between the potential
and cytotoxicity. As expected, the oxidation process is diﬀusion
controlled (plot of peak current vs scan rate is linear), as is
generally the case with tris(diimine) Ru(II) complexes,45,46,48
and diﬀusion coeﬃcients of 1−4 could be determined (see
Table S3 in the Supporting Information) by applying the
Randles−Sevcik relationship.71−73
DNA and Protein Binding Experiments. The ability of
transition metal polypyridyl complexes to reversibly bind DNA
through intercalation or groove binding is well docu-
mented.74−76 Depending on the type of metal complexes, this
feature was employed to develop imaging agents in living
cells.77 As mentioned in the introduction, however, non-
covalent binding to DNA of these coordinatively saturated and
substitutionally inert polypyridyl Ru(II) compounds was also
assumed to be responsible for the cytotoxic eﬀects observed for
some of these complexes. We therefore investigated the binding
of complexes 3 and 4 to calf-thymus DNA (CT-DNA).78,79
The absorption spectra shown in Figures S19 and S20 in the
Supporting Information conﬁrm an intercalative mode of DNA
binding for 3 and 4 rather than groove binding or electrostatic
binding interactions. A signiﬁcant change in absorbance
(hypochromism for 3 and 4 as well as a supplementary red
shift for 4) ascribable to stacking of the aromatic chromophore
between the DNA nucleobase pairs is indeed noticed.76 In
comparison, as expected, no change in absorption is observed
for complexes 1 and 2 (Figures S21 and S22 in the Supporting
Information). The intrinsic binding constants (Kb) for
intercalation of 3 and 4 into DNA were obtained by ﬁtting
the absorption and emission titrations data to the non-
cooperative model for DNA binding80−82 (Figures S23 and
Figure 4. Ruthenium absorption signal of a mitochondrial fraction
measured by HR-CS AAS.
Table 2. Distribution Coeﬃcients between Octanol and
Phosphate Buﬀer 10 mM (pH 7.01) Obtained Using the
“Shake-Flask” Method and Midpoint Potentials (Em)
a
Determined from Cyclic Voltammetry at a Glassy Carbon
Electrode Using a Scan Rate of 100 mV s−1 in MeCN (0.1 M
nBu4NPF6) at (20 ± 2) °C
logD7.01
b Em/mV
1 −1.81 98044
2 −1.58 970
3 −0.21 1100
4 −0.05 1065
aMidpoint potential = Em = (Ep
ox + Ep
red)/2, quoted versus Fc0/+
bComplex concentrations range between 37 and 50 μM.
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S24 in Supporting Information) and are presented in Table 3.
The obtained values (>106 M−1 range) indicate a high binding
aﬃnity for DNA and correlate well with other dppz-containing
Ru(II) complexes (Table 3). The less than unity binding site
size(s) obtained from the Kb ﬁts for 4 also shows an extent of
cooperativity for intermolecular stacking of the dppz ligands on
the DNA surface.83,84 Such pi-stacking and aggregation of
cationic Ru(II) complex can be further facilitated by
polyanionic DNA backbone.83 The stronger binding of 4,
compared to 3, was further examined by DNA gel experiments
(Figure S25 in the Supporting Information), which revealed a
stronger interaction with DNA for 4 than for 3. Thus, a
contribution from such surface aggregation of 4 on DNA
surface to its binding aﬃnity cannot be ruled out. Given that
the charge of the two complexes at pH = 7.0 is identical (+1),
we speculate that the slightly higher binding aﬃnity for 4 could
be reﬂecting the ability of the more “ﬂexible” anionic
carboxylate group in 4 to hydrogen-bond with protons present
on the DNA, and its slightly greater hydrophobicity. As
proteins can be the targets of metallo-drugs,27 we incubated the
ruthenium complexes with proteins of varying molecular weight
resolved by SDS-polyacrylamide gel electrophoresis (Figure
S26 in the Supporting Information). Similar to DNA, complex
4 was found to bind more strongly to the proteins than 3. A
possible explanation to this observation could be that the
carboxylate group in 4 is likely to bind more to protonated
amino acids due to its “ﬂexibility”. Regardless of the origin of
the greater binding aﬃnity of 4, it is important to highlight the
fact that the most cytotoxic compound is not the one binding
most strongly to DNA or proteins.
Mechanism of Cytotoxicity. To assess whether 3 causes
cell death by apoptosis or necrosis, the YO-PRO and the
annexin-V assays were performed. For the former, cytoﬂuoro-
metric analysis of programmed cell death (apoptosis) allows
detection of cell membrane permeabilization, an event taking
place during apoptosis.86 Hence, HeLa cells were treated with
20 μM of either 3 or cisplatin for 2, 24, 48, or 72 h before being
incubated with the dye YO-PRO (2.5 μM). As shown in Figure
5, 3 does induce apoptosis during the ﬁrst 48 h but only
slightly, with the percentage of apoptotic cells increasing by a
factor of ∼5 after 72 h. In comparison, cisplatin induced
apoptosis in a more gradual manner. The data showed that,
after 48 h of treatment with 3 at a dose corresponding to the
IC50, only 20% of the cells were apoptotic, indicating that
apoptosis is triggered at a later stage. As expected, the annexin-
V assay conﬁrmed the results obtained with the YO-PRO assay
as it was again found that 3 induced apoptosis (see Figure S27
in the Supporting Information). In the case of the annexin-V
assay, apoptosis was found to occur at a slightly faster rate than
for the YO-PRO assay.
To clarify the mechanism by which 3 induces apopotosis, the
activity of caspases 3/7 was examined using the Caspase-Glo 3/
7 assay. These caspases are known to be the apoptosis
executers, to which extrinsic and intrinsic pathway converge.87
The data showed a higher caspase activity upon incubation of
cells with 3 (20 μM, 24 h). The low-speciﬁcity kinase inhibitor
staurosporin (150 nM, 6 h) was used as positive control,
conﬁrming that 3 induced cell death by apoptosis (see Figure
S28 in the Supporting Information).
Another important factor which could explain the cytotox-
icity exerted by 3 is the production of reactive oxidative species
Table 3. DNA Binding Constants Obtained by DNA Titrations of All the Complexes in Phosphate Buﬀer at pH 7.01a
absorbance data emission data
Kb (M
−1 per nucleotide) binding site size(s) Kb (M
−1 per nucleotide) binding site size(s)
3 (3.95 ± 0.40) × 106 (at 1.25 ± 0.30 (2.13 ± 0.60) × 106 1.17 ± 0.10
(at 364 nm) (at 628 nm)
4 (9.29 ± 0.60) × 106 0.65 ± 0.05 (2.47 ± 0.40) × 106 0.89 ± 0.03
(at 364 nm) (at 623 nm)
[Ru(L)(dppz)2]
4+ 85 (2.2 ± 0.5) × 106 1.2 NAb NAb
(at 447 nm)
[Ru(bipy)2dppz]
2+ 81 2.9 × 106 0.84 1 × 107 0.95
(at 369 nm)
aMeasurement buﬀer contained 10 mM phosphate buﬀer and 50 mM NaCl. Abbreviations: L = 5,5′-di(1-(trimethylammonio)methyl)-2,2′-dipyridyl
cation; bipy = 2,2′-bipyridine; dppz = dipyrido[3,2-a:2′,3′-c]phenazine]. bNot Available.
Figure 5. Quantiﬁcation of apoptotic cells using the YO-PRO assay. HeLa cells were incubated with 3 (20 μM) and cisplatin (20 μM) for 2, 24, 48,
or 72 h at 37 °C.
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(ROS). This was recently observed with ruthenium-Norharman
and ruthenium β-carboline complexes as well as ruthenium
containing bis-benzimidazole derivatives complexes.32,33,88 In
this respect, HeLa cells were treated with 3 in the presence or
absence of N-acetylcysteine (NAC), which is known to
scavenge ROS. As can be seen in Figure S29 in the Supporting
Information, ROS were not produced during treatment with 3
at concentrations up to 2-fold the IC50.
Very recently, Meggers, Xu, Wong, Zheng and co-workers
reported that Ru(II) complexes could induce cell death by
interferring with the membrane potential ﬁnally leading to cell
apoptosis.32,33,40,42,43,88 To assess whether 3 displays a similar
behavior, the mitochondrial membrane potential (ΔΨm) was
evaluated in HeLa using JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolylcarbocyanine iodide) and valinomycin
as positive control. As shown in Figure 6, the impairment
induced by 3 (which is reﬂected in ΔΨm) is clearly time-
dependent (see Figure S30 in Supporting Information for the
ﬂow cytometry dot blots). On the contrary, within the
temperature range investigated and considering that complex
3 aﬀects the mitochondrial membrane potential of HeLa cells
only at 37 °C (see Figure S31 in Supporting Information), a
similar clear-cut trend in its temperature-dependent behavior
cannot be perceived. It can be postulated that the hydrophobic
dppz moieties of 3 intercalate into the mitochondria
membrane, thus impairing its potential. This, in turn, leads to
the release of the mitochondrial cytochrome c, that induces cell
permeabilization and apoptosis.
■ CONCLUSIONS
After platinum complexes, ruthenium compounds are the most
advanced metal-based anticancer drug candidates in medicinal
inorganic chemistry with two complexes, namely, NAMI-A24
and KP1019,21 already in clinical trials. However, for nearly all
ruthenium anticancer agents studied, a ligand exchange, often
with a biomolecule, is required for the antiproliferative activity.
In this study, we demonstrate that coordinatively saturated and
substitutionally inert polypyridyl Ru(II) compounds like 3 can
be also very eﬀective as anticancer drug candidates by
presenting one of the most detailed biological studies of a
cytotoxic inert Ru(II) complex. We could show, with 3 and 4 as
examples, that subtle structural changes can have a signiﬁcant
impact on both the cytotoxicity and cellular localization. Using
two diﬀerent techniques, namely, confocal microscopy and
atomic absorption spectrometry, 3 was shown to accumulate in
mitochondria. This correlation provides solid evidence for the
mechanism of action proposed in this study. Interestingly, while
3 was found to have IC50 values relatively close to those of the
well-known cisplatin on three cancer cell lines, and to be more
active on a cisplatin-resistant cell line than cisplatin itself, 4
presented signiﬁcantly higher IC50 values. We have also
demonstrated that 3 exerted its toxicity through a mitochondria
related pathway rather than the nuclear DNA mode of action
similar to cisplatin, as would have been presumed due the
presence of DNA intercalating ligands.
In summary, these promising ﬁndings provide great
encouragement to pursue the investigations toward the use of
inert Ru complexes in anticancer research.
■ EXPERIMENTAL SECTION
Materials. Ruthenium trichloride hydrate (Pressure Chemicals)
and other chemicals were either of reagent or analytical grade and used
as purchased from commercial sources. Analytical grade solvents were
degassed by purging with dry, oxygen-free nitrogen for at least 30 min
before use if necessary. Acetonitrile was dried by standing over calcium
hydride overnight. Deionized water was used for all reactions in
aqueous solution. All reagents and solvents were of HPLC grade,
purchased from Acros (Geel, Belgium), Aldrich/Sigma/Fluka
(Deisenhofen, Germany), Merck (Darmstadt, Germany) and IRIS
Biotech (Marktredwitz, Germany) and used without further
puriﬁcation. [Ru(CppH)(CO)2Cl2],
44 [Ru(Cpp-NH-Hex-COOH)-
(CO)2Cl2],
45 144 and 445 were synthesized according to the literature
procedures. All the characterization data was in agreement with
literature reports.44,45
Instrumentation and Methods. A vacuum line and Schlenk
glassware were employed when reactions had to be carried out under
an atmosphere of dry, oxygen-free nitrogen and assemblies were
protected from light if necessary by wrapping them with aluminum
foil. 1H and 13C NMR spectra were measured on Bruker AC200,
AM300 or DRX 400 spectrometers using the signal of the deuterated
solvent as an internal standard.89 The chemical shifts δ are reported in
parts per million (ppm) relative to tetramethylsilane (TMS) or signals
from the residual protons of deuterated solvents. Coupling constants J
are given in hertz (Hz). The abbreviations for the peak multiplicities
are as follows: s (singlet), d (doublet), t (triplet) and m (multiplet).
ESI mass spectrometry was performed using a Bruker Esquire 6000 or a
Micromass Platform II mass spectrometer ﬁtted with an ESI source
(capillary voltage was 3.5 eV and the cone voltage 35 V). In the
assignment of the mass spectra, the most intense peak is listed. High-
resolution accurate mass spectra were recorded with a Bruker BioApex II
47e FT-ICR MS ﬁtted with an Analytica Electrospray Source. Samples
were introduced by a syringe pump at a rate of 1 μL min−1 and the
capillary voltage was at 200 V. Infrared spectra were recorded on a
Perkin-Elmer 1600 Series FTIR spectrometer in the range 4000−500
cm−1 with a resolution of ±4.0 cm−1. Samples were measured as KBr
disks or neat as indicated. Microanalysis of inorganic compounds was
Figure 6. Eﬀect of 3 (20 μM) on the mitochondrial membrane potential in HeLa cells. Cells were treated for 2, 24, or 48 h with 3 at 37 °C and the
percentage of cells with depolarized mitochondrial membrane was determined. Valinomycin treatment was taken as positive control.
Journal of the American Chemical Society Article
dx.doi.org/10.1021/ja307288s | J. Am. Chem. Soc. 2012, 134, 20376−2038720382
carried out at Campbell Microanalytical Laboratory, University of
Otago, New Zealand. UV/vis spectra were recorded in 1 cm quartz
cuvettes using Varian Cary Bio 300 or 5G spectrophotometers.
Emission spectra were obtained following excitation at 450 nm on a
Fluoromax-4 spectroﬂuorometer (Horiba Jobin Yvon, Inc., France)
and were corrected for instrumental response using manufacturer
provided correction factors. The excitation and emission slit width
were set to 3.0 and 2.5 nm, respectively, for recording the emission
spectra of the complexes. Emission spectra for the DNA binding
evaluations were obtained following excitation at 440 nm on a Perkin-
Elmer Luminescence spectrometer LS 50 B and were corrected for
instrumental response using manufacturer provided correction factors.
The excitation and emission slit width were set to 5.0 and 10.0 nm,
respectively. Thin layer chromatography (TLC) was performed using
silica gel 60 F-254 (Merck) plates with detection of spots being
achieved by exposure to iodine or UV light or by using ninhydrin stain.
Column chromatography was done using Silica gel 60 (0.040−0.063
mm mesh, Merck) or activated neutral alumina (Brockmann l, Sigma-
Aldrich). Eluent mixtures are expressed as volume to volume (v/v)
ratios.
Electrochemical Measurements. Cyclic voltammetry measure-
ments were performed at (20 ± 2)°C in acetonitrile solutions
containing 0.1 M nBu4NPF6 as the supporting electrolyte, over the
scan rate range of 100−1000 mV s−1 using a BAS 100B (Bioanalytical
Systems) electrochemical workstation. Solutions used in electro-
chemical measurements were deoxygenated by purging with high
purity nitrogen for at least 10 min before commencing the
experiments. A conventional three electrode cell was employed
which comprised a glassy carbon working electrode (area = 0.0079
cm2), a large surface area Pt counter electrode and an Ag/Ag+ (0.1 M
AgNO3 in CH3CN) reference electrode. The potential of the Ag/Ag
+
reference electrode was frequently calibrated against that of ferrocene/
ferrocinium (Fc0/+) redox couple under the same conditions used for
voltammetric measurements with the Ru(II) complexes. The working
electrode was polished with an aqueous slurry of aluminum oxide (0.3
μm), then rinsed with acetone and dried before each voltammetric
experiment.
Synthesis and Characterization. [Ru(bipy)2(Cpp-NH-Hex-
COOH)](PF6)2·4H2O (2). Complex 2 was obtained as an orange solid
following the same method as for 4,45 using 2,2′-bipyridine (bipy)
(0.780 g, 5.00 mmol), trimethylamine-N-oxide dihydrate (1.00 g, 9.00
mmol), and [RuII(Cpp-NH-Hex-COOH)(CO)2Cl2] (1.10 g, 2.00
mmol) in 20 mL of deoxygenated 2-methoxyethanol. Yield: 1.50 g
(75%). Crystals of the perchlorate salt of 2, [Ru(bipy)2(Cpp-NH-Hex-
COOH)](ClO4)2·2H2O, suitable for X-ray structure determination
were obtained by slow evaporation of a solution prepared by dissolving
a sample of the PF6
− salt in an acetone/water mixture and then adding
aqueous NaClO4 solution (1 M). Anal. Calcd for C36H42F12N8O7P2Ru
(%): C, 39.68; H, 3.88; N, 10.28. Found: C, 39.81; H, 3.93; N, 10.29.
IR (KBr): ν 3103 (C−Harom), 2929 (C−Haliph), 2864 (C−Haliph), 1676
(CO), 1533, 1438, 1413, 1243, 1162, 1020, 841, 762, 731 cm−1. 1H
NMR (400 MHz, DMSO-d6): δ 9.55−9.52 (m, 1H, aromatic cpp),
9.32 (d, 3J = 7.5 Hz, 1H, aromatic cpp), 8.82−8.79 (m, 4H, aromatic
bpy), 8.28−8.24 (m, 2H, aromatic bpy), 8.20−8.14 (m, 4H, aromatic
cpp and bpy), 8.05 (d, 3J = 5.1 Hz, 1H, −NHCO-cpp), 7.95 (d, 3J =
5.9 Hz, 1H, aromatic cpp), 7.78−7.73 (m, 2H, aromatic bpy), 7.71−
7.65 (m, 3H, aromatic bpy), 7.56−7.51 (m, 3H, aromatic bpy), 7.49−
7.46 (m, 1H, aromatic cpp), 2.21 (t, 3J = 7.2 Hz, 2H,
−CH2CH2COOH), 1.63−1.51 (m, 4H, alkyl CH2), 1.38−1.30 (m,
2H, −NH(CH2)2CH2(CH2)2COOH) ppm. Two proton signals are
masked by residual water from DMSO-d6. MS (ESI
+): m/z 364.1 [M
− 2PF6]2+, 873.1 [M − PF6]+. HR-ESI mass spectrum (CH3CN/
MeOH 1:4): found 364.0902; calcd for [C36H34N8O3Ru]/z 364.0899.
ε440 = 12 900 M
−1·cm−1 (H2O in 0.2% DMSO).
[Ru(dppz)2(CppH)](PF6)2·4H2O (3). Complex 3 was prepared in a
similar manner to 2, using dipyrido[3,2-a:2′,3′-c]phenazine (dppz)
(0.212 g, 0.752 mmol), trimethylamine-N-oxide dehydrate (0.150 g,
1.35 mmol), and [RuII(CppH)(CO)2(Cl)2] (0.129 g, 0.301 mmol) in
12 mL of 2-methoxyethanol. The crude product was puriﬁed by
column chromatography on neutral alumina, gradually changing the
eluent from CH3CN/H2O/sat. KNO3 (16:3:1) to CH3CN/H2O/sat.
KNO3 (10:3:1). The dark orange band was collected, and the solvent
removed under reduced pressure. The concentrate was passed through
a Sephadex LH-20 column with acetonitrile as eluent to remove
inorganic salts. The intense orange band was collected, concentrated
and the residue suspended in water followed by dropwise addition of
HPF6 (60%) to complete the precipitation of the product as a
hexaﬂuorophosphate salt. The precipitate was collected by ﬁltration,
washed with hot toluene and dried in vacuo to obtain 3 as an orange
solid. Yield: 0.228 g (66%). Anal. Calcd for C46H35F12N11O6P2Ru (%):
C, 44.96; H, 2.87; N, 12.54. Found: C, 45.11; H, 2.98; N, 12.58. IR
(KBr): ν 1717 (CO), 1636, 1420, 1357, 1234, 1079, 844, 763, 729
cm−1. 1H NMR (400 MHz, DMSO-d6): δ 9.66−9.64 (m, 2H, aromatic
dppz), 9.57−9.54 (m, 2H, aromatic dppz), 8.94 (d, 3J = 7.8 Hz, 1H,
aromatic cpp), 8.63−8.61 (m, 1H, aromatic cpp), 8.52−8.46 (m, 4H,
aromatic dppz), 8.35−8.33 (m, 1H, aromatic cpp), 8.29−8.25 (m, 2H,
aromatic dppz), 8.23−8.16 (m, 5H, aromatic dppz), 8.12−8.06 (m,
3H, aromatic cpp and dppz), 7.91−7.85 (m, 3H, aromatic cpp and
dppz), 7.60−7.54 (m, 2H, aromatic dppz) ppm. MS (ESI+): m/z 433.3
[M − 2PF6]2+. HR-ESI mass spectrum (CH3CN/MeOH 1:4): found
433.5704; calcd for [C46H27N11O2Ru]/z 433.5696. ε440 = 19 650
M−1·cm−1 (H2O in 0.2% DMSO).
Distribution Coeﬃcients. The distribution coeﬃcient of each
complex, deﬁned as
=
+
⎛
⎝⎜⎜
⎞
⎠⎟⎟Dlog log
[solute]
[solute] [solute]o/w
octanol
water
ionized
water
neutral
was experimentally determined by using the “shake-ﬂask” method.
Brieﬂy, each complex was dissolved in a 10 mM phosphate buﬀer (pH
7.01), previously saturated with octanol, to give about 1 mL of a
solution with a concentration reported in Table 4 for each complex.
The same volume of octanol (previously saturated with 10 mM
phosphate buﬀer) was then added and the solution was shaken 100
times and equilibrated for 4.5 h. The concentration of the complex in
the aqueous phase was then evaluated by UV−vis spectroscopy, using
extinction coeﬃcients for PBS solutions of the complexes (Table 4).
The evaluation on each complex was repeated 3 times.
DNA Binding (UV−visible and Fluorescence Experiments).
DNA and Ru complexes concentrations were evaluated by spectros-
copy, using the extinction coeﬃcients presented in Table 4.
The absorption titrations were performed at room temperature in
10 mM phosphate buﬀer with 50 mM NaCl (pH 7.01). For every
sample, the Ru complex concentration was constant, between 3 μM
and 20 μM, depending on the compound, and a concentrated solution
of CT DNA (type I, ﬁbers) was added (ε260, CTDNA = 6600 M
−1 cm−1
per nucleotide). A reference cell loaded with buﬀer was necessary, in
which the DNA was added each time, to minimize the changes due to
the DNA in absorption at 260 nm. After every addition, samples were
incubated at room temperature for 10 min, and then the UV−visible
spectra were recorded. Additions of DNA were carried on until no
further changes in spectra were observed.
Fluorescent DNA titrations were performed in the same way, by
using Ru complex solution between 3 and 27 μM, depending on the
Table 4. Extinction Coeﬃcients (ε) of Ru(II) Complexes 1−
4
εmolar (M
−1 cm−1)
complex
λmax (nm)
[MLCT]
phosphate buﬀer (10 mM,
pH 7.01)a
H2O (0.2%
DMSO)b
1 444 12500 13400
2 440 12300 12900
3 451 17400 14500
4 451 17600 18200
a[1] = 50 μM, [2] = 50 μM, [3] = 42 μM and [4] = 37 μM.
b[complex] = 10 μM.
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complex, in the same buﬀer and by adding DNA until no more
changes were observed. In these cases, no reference cell was necessary.
DNA binding constant (Kb) was determined by ﬁtting the titration
data to the McGhee-Von Hippel equation, as previously reported.81,82
ε ε ε ε− − = − −b b K C s K C( )/( ) ( ( 2 [DNA]/ )) /2a f b f 2 b2 1/2 b
= + +b K C K s1 [DNA]/2b b
where [DNA] is the concentration of CT-DNA in nucleotides, εa is
the apparent extinction coeﬃcient of Ru complexes at a given DNA
concentration, εf is the extinction coeﬃcient of Ru complexes in
absence of DNA, εb is the extinction coeﬃcient of Ru complexes when
completely bound to DNA, C is the total Ru complex concentration,
and s is the binding site size in base pairs. From plots of (εa − εf)/(εb
− εf) versus [DNA], Kb values were calculated by ﬁtting the curves
with OriginLab 8.6.
DNA binding constants from emission data were determined by
ﬁtting the data with the same equation, but using Ia instead of εa, as the
luminescence intensity of ruthenium complexes at a given DNA
concentration, and If and Ib (instead of εf and εb), as the luminescence
intensity of complexes in their free and completely bound forms,
respectively.
DNA Binding (Gel Experiments). To test the DNA binding
ability of metal complexes, 0.5 μg of 1 kb DNA ladder (New England
BioLabs) was resolved on multiple lanes of a 1% agarose gel.
Individual lanes were excised and incubated with 2.5 μM ruthenium
complex solutions. As positive control, a lane of the agarose gel was
stained with ethidium bromide (EtBr). The reconstituted gel was
analyzed using an Alpha Innotech Imaging system with the EtBr
colorimetric ﬁlter (365 nm).
Protein Binding. To test the protein binding ability of metal
complexes, 3 μg of Broad Range Molecular Weight Markers (Bio-Rad)
were resolved on multiple lanes of an 8% SDS-gel. Individual lanes
were excised, ﬁxed with 30% ethanol/10% acetic acid and incubated
with 2.5 μM ruthenium complex solutions. Coomassie blue staining
was taken as a positive control. The reconstituted gel was analyzed
using an Alpha Innotech Imaging system using visible light as
illumination source.
Stability of 3 in Human Plasma. These experiments were
performed following a procedure recently described by our group.65
The human plasma was provided by the Blutspendezentrum, Zurich,
Switzerland. Diazepam (internal standard) was obtained from Sigma-
Aldrich. Stock solutions of 3 (20 mM) and diazepam (800 μM) were
prepared in DMSO. For a typical experiment, an aliquot of the
respective stock solutions and DMSO were then added to the plasma
solution (975 μL) to a total volume of 1000 μL and ﬁnal
concentrations of 20 μM for 3 and 10 μM of diazepam. The resulting
plasma solution was incubated for 72 h at 37 °C with continuous and
gentle shaking (ca. 300 rpm). The reaction was stopped by addition of
2 mL of methanol, and the mixture was centrifuged for 45 min at 650g
at 4 °C. The methanolic solution was evaporated and the residue was
suspended in 200 μL of 1:1 (v/v) acetonitrile/H2O solution. The
suspension was ﬁltered and analyzed using LC−MS. A total of 40 μL
of the solution was injected into the HPLC (Acquity Ultra
Performance LC, Waters) that was connected to a mass spectrometer
(Bruker Esquire 6000) operated in ESI mode. The Nucleosil 100-5
C18 (250 × 3 mm) reverse phase column was used with a ﬂow rate of
0.5 mL min−1 and UV-absorption was measured at 300 nm. The runs
were performed with a linear gradient of A (acetonitrile (Sigma-
Aldrich HPLC-grade) and B (distilled water containing 0.02% TFA
and 0.05% HCOOH): t = 0−3 min, 20% A; t = 7 min, 50% A; t = 20
min, 90% A; t = 23 min, 100% A; t = 25 min, 100% A; t = 28 min, 20%
A.
Cell Culture. Human cervical carcinoma (HeLa) cells were
cultured in DMEM (Gibco) supplemented with 5% fetal calf serum
(FCS, Gibco), 100 U/mL penicillin, 100 μg/mL streptomycin at 37
°C and 5% CO2. The human osteosarcoma cell line U2OS was
maintained in DMEM (Gibco) supplemented with 10% FCS (Gibco),
penicillin (100 U/mL), and streptomycin (100 μg/mL). The human
breast carcinoma MCF7 cell line was cultured in MEM medium
(Gibco) supplemented with 10% FCS (Gibco), 200 mM L-glutamine,
penicillin (100 U/mL), and streptomycin (100 μg/mL). The human
ovarian carcinoma A2780 cell line and a cisplatin-resistant subline
CP70 were cultured in RPMI-1640 medium (Gibco) supplemented
with 10% FCS (Gibco), penicillin (100 U/mL), and streptomycin
(100 μg/mL). The normal human fetal lung ﬁbroblast MRC-5 cell line
was maintained in F-10 medium (Gibco) supplemented with 10% FCS
(Gibco, penicillin (100 U/mL), and streptomycin (100 μg/mL).
In Vitro Fluorescence Evaluation. Cellular localization of
ﬂuorescent ruthenium complexes was assessed by ﬂuorescence
microscopy. HeLa cells were grown on 35 mm Cellview glass bottom
dishes (Greiner) or on 18 mm Menzel-glas̈er coverslips at a density of
1 × 105 cells/mL and incubated for 2 h with ruthenium complexes at
their IC50 or at 100 μM for nontoxic complexes. Cells were ﬁxed in 4%
formaldehyde solution (10% formaldehyde in 90% PBS) and either
mounted on slides for viewing by confocal microscopy or kept in water
for imaging on an Olympus IX 81 motorized inverted microscope
(Olympus, Hamburg, Germany), using 10× dry and 60× oil-
immersion lenses and digital camera. Alternatively, ﬁxed cells were
viewed on a CLSM Leica SP5 microscope. The ruthenium complexes
were visualized using the Cy3 ﬁlter set of the Olympus microscope
(ex., 550 nm; em., 570 nm) or using the red wavelength selection (ex,
458 nm; em, 600−650 nm) on the CLSM Leica SP5 microscope.
Mitochondrial Staining. Colocalization of ruthenium complex 3
with mitochondria was examined by means of Mitotracker green FM
(Molecular Probes), a mitochondria-speciﬁc dye.41 Brieﬂy, a 1 mM
Mitotracker Green FM stock solution made in DMSO was diluted to
10 μM working concentration in cell medium (DMEM, 5% FCS).
Staining of mitochondria was accomplished by adding a 50 nM ﬁnal
concentration of Mitotracker Green FM to the culture medium for the
last 45 min of ruthenium complex incubation. The medium was
removed and cells were ﬁxed in 4% formaldehyde solution before
being mounted on slides for viewing by confocal microscope.
Cytotoxicity Studies. Cytotoxicity studies were performed on six
diﬀerent cell lines, namely, HeLa, MCF7, U2OS, A2780, CP-70 and
MRC-5, by a ﬂuorometric cell viability assay using Resazurin
(Promocell GmbH). Brieﬂy, one day before treatment, cells were
plated in triplicates in 96-well plates at a density of 4 × 103 cells/well
in 100 μL. Upon treating cells with increasing concentrations of the
ruthenium complexes for 48 h, the medium was removed, and 100 μL
of complete medium containing resazurin (0.2 mg/mL ﬁnal
concentration) was added. After 4 h of incubation at 37 °C, the
ﬂuorescence of the highly red ﬂuorescent resoruﬁn product was
quantiﬁed at 590 nm emission with 540 nm excitation wavelength in a
SpectraMax M5 microplate Reader.
Flow Cytometry. HeLa cells suspensions were washed twice in 1×
PBS and centrifuged at 130g for 6 min to remove the medium and the
metal complex. The cellular uptake of ruthenium complex was
detected in the PE-Texas Red channel (excitation at 488 nm; emission
at 575/25 nm). JC-1 monomers used in determination of the
mitochondrial membrane potential health condition as well as annexin
V-FITC conjugate used in the detection of apoptotic cells were
detected in the FITC channel, whereas JC-1 aggregates were detected
in the APC channel. A total of 15 000 cells were collected for each
sample by the ﬂow cytometer CyAn ADP 9 and analyzed with Summit
4.3 software. Nonviable cells were excluded from the analysis. Data are
represented as mean ± SEM.
Uptake Studies. To determine the cellular uptake eﬃciency of
ruthenium complex 3, ﬂow cytometric analysis was performed. To this
end, 3 × 105 HeLa cells were seeded in 6 cm dishes one day before
treatment and incubated at 4, 23, and 37 °C and 5% CO2 for 6 h with
20 μM of 3. The cells were treated with trypsin, centrifuged, washed
twice in 1× PBS and ﬁnally resuspended in 1 tmePBS prior to ﬂow
cytometric analysis.
Evaluation of Mitochondrial Membrane Potential (ΔΨm).
The mitochondrial membrane potential was measured by the JC-1
(5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine
iodide) (Sigma-Aldrich). HeLa cells were seeded in 6-well plates at a
density of 4 × 105 cells one day before treatment and incubated for 2,
24, and 48 h with 20 μM 3 at either 4, 23, or 37 °C. Following this,
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cells were then treated with trypsin and resuspended in 5 mL of
complete medium. The cell suspension was then stained according to
the manufacturer’s instructions.
Intracellular ROS Measurement. The production of intracellular
ROS was detected by 2′,7′-dichloroﬂuorescin diacetate (H2DCF-DA,
Sigma-Aldrich), a cell-permeable nonﬂuorescent probe which is de-
esteriﬁed in cell and upon oxidation turns to highly ﬂuorescent 2′,7′
dichloroﬂuorescein. HeLa cells were seeded in white 96-well plates at a
density of 8 × 103 cells one day before treatment. The medium was
removed and H2DCF-DA (10 μM) was added to cells for 30 min at 37
°C in the dark. The cells were subsequently washed in serum-free
medium and treated for 30 min, 1 h, 2 h, or 6 h with 3, in presence or
absence of 10 mM NAC, an antioxidant. Fluorescence was quantiﬁed
at 530 nm emission with 488 nm excitation wavelength in a
SpectraMax M5 microplate Reader.
Apoptosis Detection. Apoptosis was detected by means of YO-
PRO (Molecular Probes) staining, a nucleic acid dye permeating
exclusively apoptotic cells. HeLa cells were seeded in 96-well plates at
a density of 5 × 103 cells one day before treatment. The medium was
replaced and cells were treated for 2, 24, 48, or 72 h with 3 (20 μM).
YO-PRO (2.5 μM ﬁnal concentration in 20 mM Na-citrate pH 4.0,
26.8 mM NaCl) was added to the culture medium for 10 min at 25 °C
in the dark. Fluorescence was quantiﬁed at 530 nm emission with 485
nm excitation wavelength in a SpectraMax M5 microplate Reader.
Finally, cells were lysed in 25 μL of lysis buﬀer (0.1% NP40, 5 mM
EDTA, 5 mM EGTA) for 30 min at 25 °C in the dark and
ﬂuorescence was quantiﬁed again. The ratio between the ﬂuorescence
measured before and after lysis equals the percentage of apoptotic cells
in the population examined.
Apoptosis was also detected by means of annexin V-FITC conjugate
purchased from BD Pharmingen (BD Bioscience), which has a high
aﬃnity binding for the membrane phospholipid phosphatidylserine,
translocated from the inner to the outer leaﬂet of the plasma
membrane during apoptosis. HeLa cells were seeded in 6 cm dishes at
a density of 4 × 105 cells one day before treatment. The medium was
replaced and cells were treated for 2, 24, 48, or 72 h with 3 (20 μM).
Cells were then stained with annexin V-FITC according to the
manufacturer’s instructions.
Caspase 3/7 Assay. Caspases 3/7 activity was assessed using the
Caspase-Glo 3/7 assay kit (Promega). HeLa cells were seeded in white
96-well plates at a density of 8 × 103 cells one day before treatment.
Cells were treated with 3 (20 μM) for 24 h or with 150 nM
staurosporin for 6 h at 37 °C. Caspase 3/7 activity was detected
according to the manufacturer’s instructions. Luminescence in RLUs
was quantiﬁed in a SpectraMax M5 microplate Reader.
Mitochondria Isolation from HeLa Cells. Mitochondria were
isolated by means of the Mitochondria isolation kit (Sigma Aldrich).
HeLa cells were cultured in 175 cm2 ﬂask at a density of 13 × 106 cells
and treated with 50 μM of 3. Mitochondria were then isolated from
whole cell extract according to the manufacturer’s instructions. Before
the isolation procedure, an aliquot was removed to determine the total
cellular ruthenium concentration. Mitochondria, as well as cell pellets,
were then lyophilized prior Atomic Absorption measurements.
HR-CS AAS Measurements. For metal quantiﬁcation, the
lyophilized samples were resuspended in 100 μL of deionized water
and 100 μL of storage buﬀer (1:5) for mitochondria pellets. An aliquot
of 10 μL was then removed to quantify the protein concentration of
the samples by Bradford method.64 A contrAA 700 high-resolution
continuum source atomic absorption spectrometer (AnalytikJena AG)
was used for the ruthenium quantiﬁcation at a wavelength of 349.900
nm. Aqueous standard samples of 3 were used for calibration purposes.
To 90 μL of all probes and standards each 9 μL Triton X-100 (1%)
and 9 μL hydrochloric acid (18%) were added. Samples were injected
at a volume of 25 μL into coated standard graphite tubes (“AAS IC-
Standardrohr, beschichtet”, AnalytikJena AG). A furnace program as
described in the literature was used.30 During the temperature
program, the graphite tube was purged with a constant argon gas ﬂow,
which was only halted during the zeroing and atomization steps. The
mean integrated absorbances of double injections were used
throughout the study. The results are expressed as nmol ruthenium
per milligram of protein. A percentage value of 3 accumulated in
mitochondria compared to the total cellular ruthenium concentration
was also calculated.
X-ray Crystallography. Intensity data for red crystals of 1 (0.20 ×
0.20 × 0.05 mm) and 2 (0.38 × 0.10 × 0.05 mm) were measured at
173 K on a Bruker Apex II CCD ﬁtted with graphite monochromated
Mo Kα radiation (0.71073 Å). The data were collected to a maximum
2θ value of 50° and processed using the Bruker Apex II software
package. Crystal parameters and details of the data collection are
summarized in Table S4 in the Supporting Information. Each structure
was solved by direct methods and expanded using standard Fourier
routines in the SHELX-97.90,91 All hydrogen atoms were placed in
idealized positions, except for the hydrogen on the oxygen atom of the
carboxylic group and the nitrogen atom (in 2) which were located on
the Fourier diﬀerence map and reﬁned with restrained O−H and N−
H distances. The isotropic thermal parameters for O−H and N−H
hydrogen atoms were ﬁxed at 1.2 times that of the respective oxygen
or nitrogen atom. A PF6
− counteranion in 1 and ClO4
− counteranion
in 2 were found disordered and reﬁned anisotropically using part
command. The hydrogen atoms associated with the water molecules of
crystallization could not be located on the Fourier Diﬀerence map. All
non-hydrogen atoms were reﬁned anisotropically.
Abbreviations. AAS, atomic absorption spectrometry; bipy, 2,2′-
bipyridine; Boc, tert-butoxycarbonyl; CppH, 2-(2′-pyridyl)pyrimidine-
4-carboxylic acid; Cpp-NH-Hex-COOH, 6-(2-(pyridin-2-yl)-
pyrimidine-4-carboxamido)hexanoic acid; CT-DNA, calf-thymus
DNA; dppz, dipyrido[3,2-a:2',3'-c]phenazine; DIPEA, diisopropyle-
thylamine; ESI-MS, electrospray ionisation mass spectrometry; Fmoc,
ﬂuorenylmethoxycarbonyl; Gly, glycine; HR-CS AAS, high-resolution
continuum source atomic absorption spectrometry; KP1019, trans-
[tetrachlorobis(1H-indazole)ruthenate(III)]; MALDI-TOF, matrix
assisted laser/desorption ionization−time of ﬂight; NAC, N-
acetylcysteine; NAMI-A, trans-[tetrachloro(dimethylsulfoxide)-(1H-
imidazole)ruthenate(III).
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1H NMR spectra of 2 and 3 (Figures S1−S2), absorption and
emission spectra of 1−4 (Figures S3−S4), thermal ellipsoid
plots of 1 and 2 (Figures S5−S6), molecular packing of 2
(Figure S7), selected bond lengths and angles for 1 and 2
(Table S1), plots of the Resazurin assays of 3, cisplatin and
dequalinium chloride hydrate (Figures S8−S10), ﬂuorescence
confocal microscopy images of 1−4 in HeLa cells (Figure S11),
UV traces (300 nm) of the LC−MS analysis of 3 in human
plasma at t = 0 and 72 h (Figure S12), ratios of peak areas of 3/
Diazepam in human plasma at t = 0 and 72 h (Table S2), ﬂow
cytometry dot plots of the uptake of 3 (Figure S13), eﬀect of
temperature on the uptake of 3 (Figure S14), cyclic
voltammetric data of 2−4 (Table S3), cyclic voltammograms
of 2−4 (Figures S15−S18), CT-DNA titration of 1−4 (Figures
S19−S24), gels for DNA and protein binding of 1−4 (Figures
S25−S26), annexin-V activity measurements of 3(Figure S27),
caspase 3/7 activity measurements of 3 (Figure S28), ROS
production measurements of 3 (Figure S29), ﬂow cytometry
dot plots of MMP of 3 in HeLa cells (Figure S30), eﬀect of 3
with temperature on mitochondrial potential of Hela cells
(Figure S31), crystallography collection and reﬁnement data of
1 and 2 (Table S4). X-ray crystallographic ﬁles for 1 and 2 in
CIF format. Video of the colocalization studies of 3 in avi
format. This material is available free of charge via the Internet
at http://pubs.acs.org.
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Baumann, K.; Wölfl, S.; Sheldrick, W. S.; Ott, I. Dalton Trans. 2013,
DOI: 10.1039/c2dt32319b.
(64) Bradford, M. M. Anal. Biochem. 1976, 72, 248−254.
(65) Patra, M.; Ingram, K.; Pierroz, V.; Ferrari, S.; Spingler, B.;
Keiser, J.; Gasser, G. J. Med. Chem. 2012, 55, 8790−8798.
(66) Puckett, C. A.; Ernst, R. J.; Barton, J. K. Dalton Trans. 2010, 39,
1159−1170.
(67) Puckett, C. A.; Barton, J. K. J. Am. Chem. Soc. 2007, 129, 46−47.
(68) Puckett, C. A.; Barton, J. K. Biochemistry 2008, 47, 11711−
11716.
(69) Liberman, E. A.; Topali, V. P.; Tsofina, L. M.; Jasaitis, A. A.;
Skulachev, V. P. Nature 1969, 222, 1076−1078.
(70) Johnson, L. V.; Walsh, M. L.; Chen, L. B. Proc. Natl. Acad. Sci.
U.S.A. 1980, 77, 990−994.
(71) Bard, A. J.; Faulkner, L. R. Electrochemical Methods,
Fundamentals and Application; 2nd ed.; Brisbane: Australia, 2001.
(72) Sevcik, A. Collect. Czech. Chem. Commun. 1948, 13, 349−377.
(73) Randles, J. E. B. Trans. Faraday Soc. 1948, 44, 322−327.
(74) Friedman, A. E.; Chambron, J.-C.; Sauvage, J.-P.; Turro, N. J.;
Barton, J. K. J. Am. Chem. Soc. 1990, 112, 4960−4962.
(75) Jenkins, Y.; Friedman, A. E.; Turro, N. J.; Barton, J. K.
Biochemistry 1992, 31, 10809−10816.
(76) Pyle, A. M.; Rehmann, J. P.; Meshoyrer, R.; Kumar, C. V.;
Turro, N. J.; Barton, J. K. J. Am. Chem. Soc. 1989, 111, 3051−3058.
(77) Fernandez-Moreira, V.; Thorp-Greenwood, F. L.; Coogan, M. P.
Chem. Commun. 2010, 46, 186−202 and references therein..
(78) Thorp-Greenwood, F. L.; Coogan, M. P.; Mishra, L.; Kumari,
N.; Rai, G.; Saripella, S. New. J. Chem. 2012, 36, 64−72.
(79) Zhang, A.-G.; Zhang, Y.-Z.; Duan, Z.-M.; Wang, K.-T.; Wei, H.-
B.; Bian, Z.-Q.; Huang, C.-H. Inorg. Chem. 2011, 50, 6425−6436.
(80) Carter, M. T.; Rodriguez, M.; Bard, A. J. J. Am. Chem. Soc. 1989,
111, 8901−8911.
(81) Dalton, S. R.; Glazier, S.; Leung, B.; Sanda Win, S.; Megatulski,
C.; Nieter Burgmayer, S. J. J. Biol. Inorg. Chem. 2008, 13, 1133−1148.
(82) Kalsbeck, W. A.; Thorp, H. H. J. Am. Chem. Soc. 1993, 115,
7146−7151.
(83) Angeles-Boza, A. M.; Bradley, P. M.; Fu, P. K.-L.; Wicke, S. E.;
Bacsa, J.; Dunbar, K. R.; Turro, C. Inorg. Chem. 2004, 43, 8510−8519.
(84) Nair, R. B.; Teng, E. S.; Kirkland, S. L.; Murphy, C. J. Inorg.
Chem. 1998, 37, 139−141.
(85) Sun, J.; Wu, S.; Han, Y.; Liu, J.; Ji, L.-N.; Mao, Z.-W. Inorg.
Chem. Commun. 2008, 11, 1382−1384.
(86) Idziorek, T.; Estaquier, J.; De Bels, F.; Ameisen, J.-C. J. Immunol.
Methods 1995, 185, 249−258.
(87) Adams, J. M. Genes Dev. 2003, 17, 2481−2495.
(88) Li, L.; Wong, Y.-S.; Chen, T.; Fan, C.; Zheng, W. Dalton Trans.
2012, 41, 1138−1141.
(89) Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. J. Org. Chem. 1997,
62, 7512−7515.
(90) SHELXS97: Program for Crystal Structure solution; Sheldrick, G.
M., Ed.; University of Göttingen: Göttingen, Germany, 1997.
(91) SHELXL97: Program for Crystal Structure Reﬁnement; Sheldrick,
G. M., Ed.l University of Göttingen: Göttingen, Germany, 1997.
Journal of the American Chemical Society Article
dx.doi.org/10.1021/ja307288s | J. Am. Chem. Soc. 2012, 134, 20376−2038720387
RESULTS' !
PHOTO+ACTIVATED'UNCAGING'OF'RU(II)'COMPLEXES'IN'CANCER'CELLS'(PACT)' !
 
 51 
2.1.3. BIS(DIPYRIDOPHENAZINE)(2-(2'-PYRIDYL)PYRIMIDINE-4-CARBOXILIC ACID) 
RUTHENIUM(II) HEXAFLUOROPHOSPHATE: A LESSON IN STUBBORNNESS 
In order to examine the influence of lipophilicity, charge, and size on the anticancer 
activity of the Ru(II) complex, a broad range of Ru(II) derivatives were synthetized 
and their toxicity and localization analysed. These modifications revealed the 
presence of carboxylic acid functionality as necessary to confer cytotoxicity to the 
Ru(II) complex. 
This chapter has been published in ChemMedChem. in 2014.44 Copyright © Wiley-
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Bis(dipyridophenazine)(2-(2’-pyridyl)pyrimidine-4-
carboxylic acid)ruthenium(II) Hexafluorophosphate: A
Lesson in Stubbornness
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Introduction
From the biological application point of view, research interest
in coordinatively saturated and substitutionally inert rutheniu-
m(II) polypyridyl complexes have seen considerable advance-
ment beyond their “popular” role as targeted biomolecular
probes. For example, the strong DNA interaction of RuII poly-
pyridyl scaffolds bearing ligands with extended planarity have
not only been exploited for imaging and sensing applications,
but have also been revisited as therapeutics.[1–11] With DNA
playing a central role in many cellular processes, assessing the
RuII polypyridyl complexes in a therapeutic role is certainly a ju-
dicious expansion of an already wide application window. Re-
search on RuII polypyridyl systems with a view to their applica-
tion as anticancer agents has, however, revealed that the DNA
binding interaction is not always essential for such complexes
to show promising cytotoxicity. For example, the activity could
also arise from such complexes accumulating in, or interfering
with, membrane function or otherwise inducing mitochondria-
mediated apoptosis.[12–19] This “nonconventional” mode of
action for some of the recently emerged cytotoxic mononu-
clear and dinuclear polypyridyl RuII complexes has guided
a new paradigm for anticancer research focused on RuII poly-
pyridyl chemistry.[1, 2,5]
Despite a similar octahedral coordination geometry, the cy-
totoxicity of RuII polypyridyl complexes can vary significantly
depending on several characteristic properties. An insight into
the molecular mechanism of their activity is crucial to the
future development of therapeutics.[20] A pool of studies have
been dedicated to understand the interplay between cellular
uptake mechanism, cellular localization, and lipophilicity in the
antiproliferative and apoptotic effects of polypyridyl RuII sys-
tems against various cancer cell types.[1,5,13–18] However, the
complexity of the interactions that can occur in the cellular mi-
croenvironment makes it challenging to outline a general
trend for the cytotoxic behavior of RuII polypyridyl complexes.
In our efforts to contribute to research in this direction, we re-
cently reported the cytotoxic behavior of [Ru(dppz)2(CppH)]
2+
(CppH=2-(2’-pyridyl)pyrimidine-4-carboxylic acid; dppz=di-
pyrido[3,2-a :2’,3’-c]phenazine), a bis(dppz)-RuII polypyridyl
complex (1, Figure 1).[18] This particular complex showed a cyto-
toxicity profile (against both specific cancer and noncancer
cells) similar to that of cisplatin, the most well-known plati-
num-containing anticancer drug. The cytotoxic effect of 1 was
linked to its accumulation in mitochondria, causing mitochon-
dria-mediated apoptosis.[18] Mitochondria are believed to play
a critical role in cell death by both apoptosis and necrosis.[21,22]
If this is indeed the case, drugs that target mitochondria can
be used for inducing apoptosis in cancerous cells or for manip-
ulating mitochondrial function upon demand, in general. How-
ever, this organelle is also a principal site of energy metabolism
and a primary source of ATP in cells, central to their function-
ing and survival; this is apart from several other primary roles
associated with mitochondria.[21,22] Thus, for RuII complexes
such as 1 to be effective as anticancer drugs in the near
future, it is essential for mitochondria-mediated apoptosis to
be controlled and rather selective. Restricting the intentionally
induced toxicity exclusively to cancer cells, and minimizing the
Ruthenium complexes are currently considered to be among
the most promising alternatives to platinum anticancer drugs.
In this work, thirteen structural analogues and organelle/recep-
tor-targeting peptide bioconjugates of a cytotoxic bis(dppz)-
RuII complex [Ru(dppz)2(CppH)](PF6)2 (1) were prepared, charac-
terized, and assessed for their cytotoxicity and cellular localiza-
tion (CppH=2-(2’-pyridyl)pyrimidine-4-carboxylic acid; dppz=
dipyrido[3,2-a :2’,3’-c]phenazine). It was observed that structural
modifications (lipophilicity, charge, and size-based) result in
the cytotoxic potency of 1 being compromised. Confocal mi-
croscopy studies revealed that unlike 1, the screened com-
plexes/bioconjugates do not have a preferential accumulation
in mitochondria. The results of this important structure–activity
relationship strongly support our initial hypothesis that accu-
mulation in mitochondria is crucial for 1 to exert its cytotoxic
action.
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inevitable collateral damage are indeed the highly desirable
objectives in anticancer drug discovery.[20,23]
As for the other substitutionally inert RuII polypyridyl com-
plexes, precise understanding of the exact mechanism behind
the anticancer efficacy of this complex is still developing. The
structure–activity correlations aimed to obtain additional in-
sight into the specificity displayed by 1 may serve as the basis
for development of bis(dppz)-RuII complexes with improved ef-
ficacy.[23] With this in mind, in this work, we evaluated the influ-
ence of the CppH ligand on the cytotoxicity of 1. The RuII poly-
pyridyl complexes of the CppH ligand have previously been
used by us for metalation of artificial nucleic acids.[6,24] A series
of bis(dppz)-RuII analogues of the lead complex 1 were synthe-
sized and screened for their cytotoxic properties (2–9,
Figure 1). In these complexes, either the pyrimidine carboxylic
acid framework of the original CppH ligand was replaced with
a substituted pyridine, or the carboxylic acid functionality was
derivatized to incorporate an ester/amide linkage or an alkyl
group. The observed cytotoxic effects were also compared
with those of 10 (Figure 1), a structurally related bis(dppz)-RuII
complex containing a hexyl spacer between the metal coordi-
nating Cpp unit and the carboxylic acid moiety, reported re-
Figure 1. Structures of bis(dppz)-RuII derivatives (racemic mixtures) investigated in this work (isolated as hexafluorophosphate salts).
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cently by us.[18] Furthermore, specific organelle/receptor-target-
ing peptide bioconjugates of 1 (11–15, Figure 1) were pre-
pared, and their cytotoxic potency was evaluated. These RuII-
peptide bioconjugates were investigated as part of an attempt
to further improve the selectivity and efficacy of 1 through its
short construct-promoted delivery to specific cell organelles.
This strategy was successfully adopted for the targeted deliv-
ery of RuII (and other metal) complexes to cellular compart-
ments.[4,25–29] However, despite all hypothesized advantages,
pursuing this approach in our case did not lead to any im-
provement in the cytotoxic potency of the parent RuII complex,
1 (see below).
Results and Discussion
Synthesis and characterization
The bis(dppz)-RuII derivatives 2–9 were prepared from their re-
spective ruthenium(II) cis-dicarbonyl precursors following
chemical decarbonylation methodology, as described in
Scheme 1. The coordination mode of the asymmetric 2-(pyri-
din-2-yl)pyrimidine unit in compounds 6–9 was established on
the basis of X-ray crystal structures of other bis(diimine)-RuII-2-
(2’-pyridyl)pyrimidine complexes previously prepared through
this decarbonylation route, showing the carboxylate group to
point away from the RuII center.[18,30] The desired complexes
were isolated as racemic mixtures and characterized by
1H NMR spectroscopy, mass spectrometry, and elemental analy-
sis. Furthermore, taking advantage of the carboxylic acid func-
tionality present in 1, the RuII-NLS (nuclear localization signal)
and RuII-MLS (mitochondrial localization signal) peptide bio-
conjugates 12 and 13 (Figure 1) were prepared, intending spe-
cific delivery of the active molecule to the nuclei and mito-
chondria, respectively.[31,32] In addition, a RuII-bombesin biocon-
jugate 11 (Figure 1) was also synthesized to evaluate its toxici-
ty toward HeLa cells. The truncated bombesin[33] sequence
(QWAVGHLM) was chosen for improved cellular internalization
of the RuII complex, as the peptide is known to have high rec-
ognition affinity for gastrin-releasing peptide receptors (GRPrs),
found to be overexpressed in HeLa cells.[33,34] As controls, 14
and 15, the random five-residue sequence (GPGVK) bioconju-
gates of complexes 1 and 10, were also prepared. The identity
and purity of the HPLC-purified RuII-peptide bioconjugates
were assessed by LC–MS (see Supporting Information).
Cytotoxicity studies
The cytotoxic action of the complexes 2–15 was evaluated on
human cervical cancer (HeLa) and noncancerous lung fibro-
blast (MRC-5) cell lines. Cell viability was quantified by resazur-
in-based fluorimetric assays. The
IC50 values obtained were com-
pared with those of the lead RuII
complex 1 and of cisplatin
(Table 1). Overall, the tested
complexes were found to be less
active toward the cancerous
(HeLa) and noncancerous (MRC-
5) cells than the parent proto-
type complex or cisplatin. Inclu-
sion of a 2,2’-bipyridyl or a 1,10-
phenanthroline ligand in 2 and
3, respectively, was found to se-
verely affect the cytotoxic poten-
cy of the corresponding bis-
(dppz) complexes (IC50~70 mm).
A similar cytotoxic response
toward both cell lines was ob-
served for 4, which incorporated
a (bis)methyl substituted 2,2’-bi-
pyridyl ligand, Me2bpy, in the
metal coordination sphere. Inter-
estingly, complex 5, in which
one of the methyl groups is re-
placed with a carboxylic acid
functionality, showed a twofold
improvement in cytotoxicity
toward HeLa cells (IC50=
33.3 mm). This particular complex
was also found to be selective in
its cytotoxic action; no IC50
values were reached up to the
Scheme 1. Chemical decarbonylation route for the preparation of 2–9 (racemic mixtures). Reagents and conditions :
a) dppz, Me3NO, 2-methoxyethanol, D, 4 h; 45–68%; b) SOCl2, EtOH, D, 24 h, 76%; c) benzyl alcohol 7/benzylamine
8, HATU, DMAP, Et3N, DMF, D, 24 h, ~50%.
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maximum tested concentrations of 100 mm toward the MRC-5
cell line.
When functional modifications were performed on the pyri-
midine ring of the CppH ligand, the resulting complexes 6–9
exhibited a broader cytotoxic response window. The IC50
values on HeLa cells of the tested complexes varied from
~34 mm (complex 7) to showing no inhibitory effect up to the
highest complex concentration
(100 mm) used in the case of
methyl-substituted complex 6.
Notably, none of the tested ana-
logues showed an improvement
in cytotoxicity against cancer
cells relative to the lead com-
pound 1, the most potent com-
plex 7 being almost threefold
less active. This observation is in
good agreement with our earlier
reports in which a similar de-
crease in activity was observed
with subtle changes in the struc-
ture for 1.[18] Also, much to our
surprise, relative to 1, peptide
conjugation lowered the cyto-
toxicity by at least fourfold in
the case of 12, the most active
RuII-peptide conjugate screened.
No IC50 values were obtained
from the highest concentration
(100 mm) of 14 and 15, the
random five-residue sequence
based 1 conjugates used as con-
trols, to which the cells were ex-
posed.
Cellular localization
Aiming to obtain a qualitative
correlation between the cytotox-
icity and intercellular localization
of the tested RuII complexes, the
in cellulo luminescence response
for the complexes was probed
with confocal laser scanning mi-
croscopy (CLSM; Figure 2). The
intrinsic capacity of the RuII-poly-
pyridyl complexes to produce lu-
minescence in the cellular micro-
environment was previously
shown to be highly relevant to
their application in cellular imag-
ing.[1,35–38] Furthermore, this char-
acteristic property has been ex-
ploited as an indirect measure of
their cellular uptake, which in
general finds good agreement
with the alternative techniques
explored for quantification,
alongside CLSM.[1,35] Specific to our lead complex 1, we could
previously show an extremely good correlation between the
mitochondrial uptake visually observed from the confocal mi-
croscopy studies and its quantification thereafter using high-
resolution continuum source atomic absorption spectrometry
(HR-CS AAS).[18]
Table 1. Cytotoxic activity data for RuII complexes 1–15 against human cervical cancer (HeLa) and noncancer-
ous fibroblast (MRC-5) cell lines.
Complex IC50 [mm]
[b] Formal charge logD[a]
HeLa MRC-5 (pH 7.0)
1[18] 10.0!1.3 15.1!2.2 1+ "1.74
2 63.5!8.7 72.0!0.1 2+ 1.96
3 69.0!5.6 68.5!0.3 2+ 2.29
4 70.2!1.2 65.4!0.9 2+ 2.98
5 33.3!3.9 >100 1+ "1.03
6 >100 >100 2+ 1.75
7 34.2!0.2 36.5!1.9 2+ 1.94
8 38.5!3.1 90.5!10.1 2+ 3.32
9 69.4!3.8 81.1!0.2 2+ 2.68
10[18] 57.5!4.8 66.3!8.1 1+ "1.22
11 71.8!4.2 >100 2+
12 43.1!0.1 ND 3+
13 >100 ND 3+
14 >100 ND 3+
15 >100 ND 3+
cisplatin 9.9!0.9 8.5!0.9
[a] Octanol–water distribution coefficient at pH 7.0 for the ligands was calculated using Calculator Plugins for
structure property prediction and calculation; Marvin 6.1.0, 2013, ChemAxon (http://www.chemaxon.com).
[b] Data are the average !SD of at least two independent experiments, each performed in triplicate per con-
centration level; ND: not determined.
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Prior to visualization by confocal microscopy, HeLa cells
were exposed to the test complex (at their respective IC50
values, or at 100 mm if no IC50 could be reached) for 2 h. In all
cases, the co-staining of DNA with 4’,6-diamidino-2-phenylin-
dole (DAPI), a commonly used fluorescent nuclear counter-
stain, was also performed for definitive evidence of nuclear in-
ternalization of the RuII complexes investigated as part of this
work. Although displaying varying emission intensities in cells
relative to the lead prototype 1, the tested complexes ap-
peared to be internalized in cells in a rather nonspecific
manner (Figure 2 and Figures S13–S23, Supporting Informa-
tion).
Imaging analysis of the fixed HeLa cells points toward the
presence of the complexes 2, 3, and 6 in the cytoplasm, along
with an intense luminescence signal in the nucleoli. Complexes
4, 5, and the ester derivatives 7 and 8 seemed to accumulate
mainly in the cytoplasm, showing a relatively weak lumines-
cence signal from the nucleoli, whereas the amide derivative 9
displayed a qualitatively homogenous spread in the cytoplasm
and nucleus. Distinct targeting of the nuclear membrane was
observed in the case of complex 4 (Figure S15, Supporting In-
formation), albeit at a relatively high concentration of 100 mm.
A rather interesting cellular accumulation pattern was ob-
served for the RuII-peptide conjugates 11–15. The bombesin
conjugation foreseen to increase the cellular uptake of 1 led to
an intense staining of the cytoplasmic region alongside the rel-
atively stronger nucleus-associated emission for 11 (Figure 2e).
Covalent linkage of the NLS peptide resulted in the cytoplasm
and nucleoli becoming the regions of accumulation for 12
(Figure 2 f). The MLS-conjugated RuII complex 13 also followed
a similar staining pattern, although with a much lower lumi-
nescence intensity (Figure S22, Supporting Information). Inter-
estingly, whilst incorporation of a hexyl spacer between the
randomly selected peptide and 1 in RuII-bioconjugate 15 deliv-
ered it exclusively to the cell nucleus, its direct attachment to
the CppH ligand in 14 showed almost no visible cellular
uptake up to the highest tested concentration (100 mm ; Fig-
ure S23, Supporting Information).
The relative hydrophobicity of ligands can play a crucial role
in the cellular uptake and localization of the RuII polypyridyl
complexes. Depending on whether the mechanism of cellular
uptake is exclusively energy dependent or independent, or
a combination of both, the localization in one cellular compart-
ment could be preferred over others.[1,35, 39–41] With only the
CppH ligand being a variable in the derivatives investigated in
this work, it can be rationally argued that the overall differen-
ces in the lipophilicity of the complexes should follow the
trend in lipophilicity of the individual 2,2’-bipyridyl- or pyrimi-
dine-ring-modified ligands. The theoretically calculated log
Doctanol/water values indicate that the ligands have increased lipo-
philic character over the CppH ligand (Table 1). It should be
noted that this theoretically predicted trend, which is based on
Figure 2. Fluorescence confocal microscopy images showing cellular staining patterns for HeLa cells incubated with RuII complexes a) 5 (40 mm), b) 6
(100 mm), c) 7 (30 mm), d) 8 (30 mm), e) 11 (70 mm), and f) 12 (40 mm) for 2 h.
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the lipophilic character of the individual 2,2’-bipyridyl- or pyri-
midine-ring-modified ligands, fits with the experimental log
Doctanol/water values for the dicationic Ru
II complexes 1 and 10
previously determined by shake-flask method ("0.21 vs.
"0.05).[18] As discussed earlier, in our case, in general the inves-
tigated derivatives mainly showed cytoplasmic staining, and
decreased nuclear targeting. Taking together these two obser-
vations, cellular uptake appears to occur by passive diffusion.
Notably, the CLSM studies were performed at different com-
plex concentrations. In addition, the polarity and water accessi-
bility of bis(dppz)-RuII complexes in the cellular microenviron-
ment could affect the intensity of the emission signals.[1, 37, 38]
Interestingly, however, the cytotoxic potency of the complexes
investigated in this work cannot be explained only in terms of
their lipophilicity. The overall cationic charge of complex 5 (+
1) at pH 7.0, and the hydrolytic susceptibility of the ester func-
tionalities in 7 and 8 could contribute to their observed
modest cytotoxic activity relative to 1. The precise reasons
cannot be explained with certainty at this stage, however, and
are a subject of our further investigations.
Conclusions
In summary, the studies conducted herein highlight the sensi-
tivity in cytotoxic action of a substitutionally inert bis(dppz)
RuII complex, 1. Subtle structural alterations in this lead proto-
type were found to have a detrimental effect on its cytotoxic
potency; at least a fourfold decrease in activity was observed
for the investigated analogues. Furthermore, CLSM studies re-
vealed that with lipophilicity, charge, and size-based modifica-
tions, the bis(dppz)-RuII complexes lose out on the preference
for mitochondrial accumulation previously observed for 1. In
conjunction, these results support our original hypothesis that
mitochondrial accumulation is crucial for the high cytotoxicity
of 1. More importantly, these findings establish 1 as a promis-
ing candidate for the future design of RuII-polypyridyl anticanc-
er prodrugs.[42] Overall, our results also underscore the difficulty
in finding a rationale between chemical structures and antipro-
liferative effect for substitutionally inert metal complexes.
Experimental Section
Materials : All chemicals were of reagent-grade quality or better,
obtained from commercial suppliers and used without further pu-
rification. Solvents were used as received or distilled using stan-
dard procedures. Deionized water was used for all reactions in
aqueous solution. Reagents and solvents for solid-phase peptide
synthesis were of HPLC grade and purchased from Acros (Geel, Bel-
gium), Aldrich/Sigma/Fluka (Deisenhofen, Germany), Merck (Darm-
stadt, Germany), and IRIS Biotech (Marktredwitz, Germany), and
were used without further purification. The preloaded polystyrene
resins were purchased from Rapp Polymers (T"bingen, Germany).
Unless otherwise mentioned, only l-amino acids were used
throughout. Thin-layer chromatography (TLC) was performed using
silica gel 60 F254 (Merck) plates with detection of spots by exposure
to iodine or UV light. Column chromatography was done using
silica gel 60 (0.040–0.063 mm mesh, Merck) or activated neutral
alumina (Brockmann l, Sigma–Aldrich). Eluent mixtures are ex-
pressed as volume to volume (v/v) ratios.
Instrumentation and methods : A vacuum line and Schlenk glass-
ware were employed when reactions had to be carried out under
an atmosphere of dry, oxygen-free nitrogen, and assemblies were
protected from light if necessary by wrapping them in aluminum
foil. 1H and 13C{1H} NMR spectra were measured on Bruker DRX 400
and 500 spectrometers at room temperature. Chemical shift values
(d) are reported in parts per million (ppm), using the signal of the
deuterated solvent as an internal standard.[43] The abbreviations for
the peak multiplicities are as follows: s (singlet), d (doublet), dd
(doublet of doublets), t (triplet), q (quartet), m (multiplet), and br
(broad). ESI mass spectrometry was performed using a Bruker Es-
quire 6000 spectrometer. In the assignment of the mass spectra,
the most intense peak is listed. Infrared spectra were recorded on
PerkinElmer FTIR spectrometer fitted with an ATR platform. Peak in-
tensities are given as broad (br), very strong (vs), strong (s),
medium (m) and weak (w). Microanalysis was performed on a Le-
coCHNS-932 elemental analyzer. HPLC purification of RuII-peptides
was performed on a Varian ProStar system equipped with a diode
array UV/Vis spectrometer equipped with Agilent Zorbax 300SB-C18
semi-prep (5 mm particle size, 300 # pore size, 250$9.4 mm; flow
rate: 4 mLmin"1) or Agilent Zorbax 300SB-C18 prep (5 mm particle
size, 300 # pore size, 150$21.2 mm; flow rate: 20 mLmin"1)
column. Chromatographic separations were performed with
a linear gradient of A (distilled H2O containing 0.1% v/v TFA) and B
(CH3CN (Sigma–Aldrich HPLC grade), containing 0.1% v/v TFA).
Preparative runs: t=0 min, 5% B; t=6 min, 30% B; t=15 min,
55% B; t=21 min, 81% B; t=25.5 min, 100% B; t=31 min, 100%
B; t=33 min, 5% B. The LC–MS spectra of metallopeptides were
measured on an Acquity Waters system equipped with a PDA de-
tector and an autosampler using an Agilent Zorbax 300SB-C18 ana-
lytical column (3.5 mm particle size, 300 # pore size, 150$4.6 mm).
The LC was coupled to an Esquire HCT from Bruker (Bremen, Ger-
many) for the MS measurements. The LC run (flow rate:
0.3 mLmin"1) was performed with a linear gradient of A (distilled
H2O containing 0.1% v/v formic acid) and B (CH3CN (Sigma–Aldrich
HPLC-grade), containing 0.1% v/v formic acid); t=0 min, 5% B; t=
3 min, 5% B; t=17 min, 100% B; t=20 min, 100% B; t=25 min,
5% B. The purity of all the RuII complexes and the Ru-peptide con-
jugates, as analyzed from microanalysis or the corresponding LC
traces, was found to be >95%.
Synthesis : Compounds 4-methyl-2-(pyridin-2-yl)pyrimidine
(Mpp),[30] dipyrido[3,2-a :2’,3’-c]phenazine (dppz),[44] [Ru(CO)2Cl2]n,
[45]
[RuII(bpy)(CO)2Cl2] ,
[45] [RuII(phen)(CO)2Cl2] ,
[45] [RuII(Me2bpy)(CO)2
Cl2] ,
[45] [Ru(dppz)2(CppH)](PF6)2 (1),
[18] and [Ru(dppz)2(MebpyCOOH)]-
(PF6)2 (5)
[46] were synthesized according to published procedures.
The characterization data were in agreement with the published
data.
[RuII(Mpp)(CO)2Cl2]: 4-methyl-2-(pyridin-2-yl)pyrimidine (Mpp)
(0.140 g, 0.82 mmol) was added to deoxygenated CH3OH (12 mL)
and heated at 60 8C until its complete dissolution was achieved.
[Ru(CO)2Cl2]n (0.230 g, 1.01 mmol) was added, and the reaction mix-
ture was held at reflux under nitrogen for 2 h. The solution was
cooled to 2 8C overnight to afford a yellow precipitate, which was
collected by filtration. The collected filtrate was restored at "4 8C
overnight for complete precipitation of the product, which was
collected by filtration, and washed with ice-cold CH3OH to obtain
the second crop as a yellow solid. Yield: 0.123 g (39%); 1H NMR
(500 MHz, [D6]DMSO): d=9.39 (d,
3J=5.5 Hz, 1H), 9.26–9.24 (m,
1H), 8.77–8.75 (m, 1H), 8.44–8.40 (m, 1H), 7.99–7.96 (m, 1H), 7.83
(d, 3J=6.0 Hz, 1H), 2.78 ppm (s, 3H); 13C NMR (125 MHz,
! 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 1419 – 1427 1424
CHEMMEDCHEM
FULL PAPERS www.chemmedchem.org
[D6]DMSO): d=197.0, 196.8, 172.5, 162.8, 160.4, 154.6, 153.5, 142.1,
130.9, 127.1, 124.5, 25.2 ppm; IR (ATR): n˜=3096 (C-Harom), 2059 (C#
O), 1987 (C#O), 1590 1578, 1412, 1322, 1031, 824, 773 cm"1; MS
(ESI+): m/z 542.9 [M+H]+ ; Anal. calcd for C12H9Cl2N3O2Ru (%): C
36.11, H 2.27, N 10.53, found: C 36.39, H 2.31, N 10.76.
[Ru(dppz)2(bpy)](PF6)2 (2): Complex 2 was obtained as a red solid
following the procedure described for [Ru(dppz)2(CppH)](PF6)2,
[18]
using dipyrido[3,2-a :2’,3’-c]phenazine (dppz) (0.170 g, 0.603 mmol),
trimethylamine-N-oxide dihydrate (0.130 g, 1.17 mmol), and [RuII-
(bpy)(CO)2(Cl)2] (0.100 g, 0.260 mmol) in 5 mL 2-methoxyethanol.
Yield: 0.189 g (65%); 1H NMR (400 MHz, CD3CN): d=9.75–9.72 (m,
2H), 9.65–9.62 (m, 2H), 8.59–8.57 (m, 2H), 8.51–8.46 (m, 4H), 8.31–
8.29 (m, 2H), 8.18–8.14 (m, 6H), 8.11–8.07 (m, 2H), 7.99–7.95 (m,
2H), 7.89–7.88 (m, 2H), 7.78–7.75 (m, 2H), 7.36–7.33 ppm (m, 2H);
MS (ESI+): m/z 411.0 [M"2PF6]2+ ; Anal. calcd for C46H28F12N10P2Ru
(%): C 49.69, H 2.54, N 12.60, found: C 49.87, H 2.54, N 12.28.
[Ru(dppz)2(phen)](PF6)2·1.5H2O (3): Complex 3 was isolated as
a red solid from dipyrido[3,2-a :2’,3’-c]phenazine (dppz) (0.242 g,
0.851 mmol), trimethylamine-N-oxide dihydrate (0.183 g,
1.65 mmol), and [RuII(phen)(CO)2(Cl)2] (0.150 g, 0.367 mmol) in 5 mL
2-methoxyethanol, using the same method as for 2. Yield: 0.251 g
(60%); 1H NMR (400 MHz, CD3CN): d=9.67–9.65 (m, 4H), 8.66–8.64
(m, 2H), 8.50–8.48 (m, 4H), 8.31–8.30 (m, 4H), 8.24–8.22 (m, 2H),
8.17–8.11 (m, 6H), 7.84–7.78 (m, 4H), 7.71–7.67 ppm (m, 2H); MS
(ESI+): m/z 423.0 [M"2PF6]2+ , 990.8 [M"PF6]+ ; Anal. calcd for
C48H28F12N10P2Ru·1.5H2O (%): C 49.58, H 2.69, N 12.05, found: C
49.63, H 2.45, N 11.76.
[Ru(dppz)2(Me2bpy)](PF6)2·3H2O (4): The synthesis was as de-
scribed for complex 2, but using dipyrido[3,2-a :2’,3’-c]phenazine
(dppz) (0.103 g, 0.528 mmol), trimethylamine-N-oxide dihydrate
(0.139 g, 1.25 mmol) and [RuII(Me2bpy)(CO)2(Cl)2] (0.103 g,
0.250 mmol) in 15 mL 2-methoxyethanol, affording the 4 as a red
solid. Yield: 0.193 g (68%); 1H NMR (400 MHz, CD3CN): d=9.73–
9.71 (m, 2H), 9.63–9.61 (m, 2H), 8.51–8.44 (m, 6H), 8.31–8.29 (m,
2H), 8.17–8.14 (m, 6H), 7.99–7.95 (m, 2H), 7.76–7.73 (m, 2H), 7.69–
7.67 (m, 2H), 7.19–7.17 (m, 2H), 2.54 ppm (s, 6H); MS (ESI+): m/z
425.2 [M"2PF6]2+ , 995.0 [M"PF6]+ ; Anal. calcd for
C48H32F12N10P2Ru·3H2O (%): C 48.29, H 3.21, N 11.73, found: C 48.38,
H 2.90, N 12.38.
[Ru(dppz)2(Mpp)](PF6)2 (6): Complex 6 was prepared using dipyri-
do[3,2-a :2’,3’-c]phenazine (dppz) (0.072 g, 0.255 mmol), trimethyla-
mine-N-oxide dihydrate (0.062 g, 0.558 mmol), and [RuII-
(Mpp)(CO)2(Cl)2] (0.050 g, 0.125 mmol) in 6.5 mL 2-methoxyethanol.
The synthesis was as for 2, with purification by silica gel column
chromatography (eluent polarity gradually changed from 100%
EtOAc to CH3CN/H2O/satd KNO3 (16:3:1)). The fractions containing
an intense orange band were combined, solvent was removed
under reduced pressure, and the residue was resuspended in
CH3CN and filtered. The filtrate was evaporated to dryness, and res-
idue was suspended in H2O (5 mL). The hexafluorophosphate salt
of the desired complex was precipitated by dropwise addition of
saturated aqueous solution of NH4PF6 to the aqueous suspension.
The precipitate was collected by filtration, washed with H2O and
Et2O, and dried under vacuum to obtain 6 as a red solid. Yield:
0.064 g (45%); 1H NMR (400 MHz, CD3CN): d=9.76–9.74 (m, 2H),
9.66–9.62 (m, 2H), 8.84–8.82 (m, 1H), 8.52–8.46 (m, 5H), 8.34–8.32
(m, 1H), 8.19–8.12 (m, 7H), 8.00–7.97 (m, 2H), 7.90–7.86 (m, 2H),
7.79–7.74 (m, 2H), 7.48–7.43 (m, 1H), 7.26–7.24 (m, 1H), 2.71 ppm
(s, 3H); MS (ESI+): m/z 418.5 [M"2PF6]2+ , 982.1 [M"PF6]+ ; Anal.
calcd for C46H29F12N11P2Ru (%): C 49.03, H 2.59, N 13.67, found: C
48.91, H 2.70, N 13.49.
[Ru(dppz)2(Cpp-OEt)](PF6)2·2H2O (7): [Ru(dppz)2(CppH)] (PF6)2
(0.020 g, 0.017 mmol) was added to anhydrous EtOH (8 mL, pre-
acidified by dropwise addition of SOCl2 (1.5 mL) at 0 8C), and the
reaction mixture was held at reflux under nitrogen for 24 h. The
solvent was evaporated in vacuo, and the residue was suspended
in H2O (3 mL). Saturated aqueous solution of NH4PF6 was added
dropwise until no further precipitation was observed. The orange
precipitate was collected by filtration, air-dried, and extracted with
10 mL CHCl3/CH2Cl2 (7:3 v/v) to remove unreacted [Ru(dppz)2-
(CppH)](PF6)2. The filtrate was evaporated to dryness, the residue
was dissolved in minimal volume of CH2Cl2 and layered with Et2O.
The precipitate so formed on standing at room temperature was
collected by filtration, washed thoroughly with CHCl3/Et2O (2:8 v/v)
and dried in vacuo to afford 7 as an orange solid. Yield: 0.015 g
(76%); 1H NMR (400 MHz, CD3CN): d=9.77–9.75 (m, 2H), 9.68–9.65
(m, 2H), 8.89 (d, 3J=7.8 Hz, 1H), 8.52–8.46 (m, 5H), 8.38–8.31 (m,
2H), 8.20–8.13 (m, 7H), 8.02–7.77 (m, 6H), 7.54–7.48 (m, 1H), 4.48
(q, 3J=7.1 Hz, 2H), 1.40 ppm (t, 3J=7.1 Hz, 3H); MS (ESI+): m/z
447.6 [M"2PF6]2+ ; Anal. calcd for C48H31F12N11O2P2Ru·2H2O (%): C
47.22, H 2.89, N 12.62, found: C 47.58, H 2.51, N 12.39.
[Ru(dppz)2(Cpp-OC6H5)](PF6)2·2H2O (8): A solution of [Ru(dppz)2-
(CppH)](PF6)2 (0.025 g, 0.022 mmol), benzyl alcohol (0.012 mL,
0.110 mmol), HATU (0.017 g, 0.044 mmol), DMAP (0.014 g,
0.110 mmol), and Et3N (0.006 mL, 0.044 mmol) in dry DMF (8 mL)
was heated at 80 8C under nitrogen atmosphere for 24 h. The sol-
vent was removed under reduced pressure, the residue was diluted
with H2O (3 mL), and an aqueous solution (satd) of NH4PF6 (1 mL)
was added to it, resulting in the formation of an orange precipi-
tate. The precipitate was collected by filtration on a sintered glass
frit, washed thoroughly with H2O and Et2O, and the washings were
discarded. The solid was extracted with 10 mL CHCl3/CH2Cl2 (7:3 v/
v) to remove unreacted [Ru(dppz)2(CppH)](PF6)2, the filtrate was
collected, and concentrated under reduced pressure. The residue
obtained was dissolved in minimal amount of CH2Cl2, layered with
Et2O and left standing at room temperature overnight. This result-
ed in the formation of a precipitate which was collected by suction
filtration, washed with Et2O/CHCl3 (8:2 v/v) and ether, and dried
under high vacuum to obtain 8 as an orange solid. (Note: alterna-
tively, silica gel column chromatography using CH3CN/H2O/satd
KNO3 (16:3:1) as eluent could be performed for a scale-up reac-
tion). Yield: 0.014 g (51%); 1H NMR (400 MHz, CD3CN): d=9.76–
9.74 (m, 2H), 9.67–9.63 (m, 2H), 8.86 (d, 3J=7.8 Hz, 1H), 8.51–8.45
(m, 5H), 8.38–8.30 (m, 2H), 8.19–8.13 (m, 7H), 8.00–7.94 (m, 2H),
7.91–7.89 (m, 1H), 7.84–7.75 (m, 3H), 7.51–7.49 (m, 3H), 7.44–7.38
(m, 3H), 5.48 ppm (s, 2H); MS (ESI+): m/z 478.6 [M"2PF6]2+ ; Anal.
calcd for C53H33F12N11O2P2Ru·2H2O (%): C 49.62, H 2.91, N 12.01,
found: C 49.38, H 2.52, N 11.93.
[Ru(dppz)2(Cpp-NHC6H5)](PF6)2·2H2O (9): The synthesis was carried
out as for 8, but using benzylamine (0.012 mL, 0.110 mmol) in
8 mL dry DMF (8 mL). The product was isolated as an orange solid.
Yield: 0.012 g (45%); 1H NMR (400 MHz, CD3CN): d=9.76–9.74 (m,
2H), 9.67–9.63 (m, 2H), 9.14–9.12 (m, 1H), 9.06–9.00 (m, 1H), 8.51–
8.43 (m, 5H), 8.35–8.28 (m, 2H), 8.20–8.11 (m, 7H), 8.00–7.90 (m,
4H), 7.81–7.76 (m, 2H), 7.52–7.48 (m, 1H), 7.43–7.35 (m, 4H), 7.32–
7.28 (m, 1H), 4.69 ppm (m, 2H); MS (ESI+): m/z 478.1 [M"2PF6]2+ ;
Anal. calcd for C53H34F12N12OP2Ru·2H2O (%): C 49.66, H 2.99, N
13.11, found: C 49.59, H 3.07, N 13.08.
Synthesis of RuII-peptide conjugates 11–15 : The Ru-peptide con-
jugates were prepared by manual Fmoc SPPS, following protocols
established for synthesis of other metal–peptide bioconjugates.[29]
The peptide sequences used were QWAVGHLM (11), RRDRK (12),
RDFK (13), and GPGVK for 14 and 15 (written from N to C termi-
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nus). Following the Fmoc deprotection of the last amino acid of
the desired peptide sequence, solid-phase insertion of 1 (or com-
plex 10 in the case of RuII-peptide bioconjugate 15) at the N-termi-
nus of the peptide sequence was achieved by reacting a solution
of the complex (5 equiv), pre-activated in an Eppendorf tube for
2 min with HATU (4.5 equiv), DIPEA and 2,6-lutidine (10 equiv
each), with the peptide preloaded polystyrene resin for 10 h at
400 rpm on a mechanical shaker. The RuII-peptide bioconjugates
were cleaved using a mixture of TFA/triisopropylsilane/phenol
85:5:10 (v/v/v) [3$400 mL (1.5 h each)] . Before cleavage, the resin
was contracted with CH3OH and dried. TFA was removed from the
resulting solutions under high vacuum before the crude oligomers
being precipitated with ice-cold ether. The solids were centrifuged
(10 min, 10000 g), washed with ice-cold ether and finally air dried.
The obtained crude products were purified with RP-HPLC and final-
ly characterized by ESIMS. The purity was assessed by LC–MS. Char-
acterization of 11: LC–MS: tR=12.5 min; ESIMS: m/z 894.3 [M]
2+ ,
596.7 [M+H]3+ . Characterization of 12 : LC–MS: tR=11.7 min;
ESIMS: m/z 731.2 [M]2+ , 487.8 [M+H]3+ , 366.1 [M+2H]4+ . Charac-
terization of 13 : LC–MS: tR=13.3 min; ESIMS: m/z 648.7 [M]
2+ ,
432.8 [M+H]3+ . Characterization of 14 : LC–MS: tR=13.5 min;
ESIMS: m/z 652.1 [M]2+ , 435.1 [M+H]3+ . Characterization of 15 :
LC–MS: tR=14.3 min; ESIMS: m/z 708.7 [M]
2+ , 472.9 [M+H]3+ .
Determination of Ru-peptide concentrations : Stock solutions of
the Ru-peptides 11–15 were prepared in nanopure water, and
molar concentrations were determined from the slope of the ab-
sorption (A450) versus concentration curve, using the e450 values cal-
culated for [Ru(dppz)2(CppH)](PF6)2.
[18]
Cell culture : Human cervical carcinoma cells (HeLa) were cultured
in DMEM (Gibco) supplemented with 5% fetal calf serum (FCS,
Gibco), 100 UmL"1 penicillin, 100 mgmL"1 streptomycin. The
normal human fetal lung fibroblast cell line (MRC-5) was grown in
F-10 medium (Gibco) supplemented with 10% FCS (Gibco), penicil-
lin (100 UmL"1), and streptomycin (100 mgmL"1). The cells were
cultured at 37 8C and in 5% CO2 humidified atmosphere.
Cytotoxicity determination : The toxicity of the RuII complexes and
the RuII-peptides toward HeLa and MRC-5 cells was evaluated
using a resazurin-based fluorimetric cell viability assay. Stock solu-
tions of the RuII complexes (20 mm) were either prepared in DMSO
or milli-Q H2O (for the Ru
II-peptides). The respective stock solutions
were further diluted with complete medium to the desired work-
ing concentrations. For a typical experiment, 100 mL aliquots of
cells in growth medium were seeded in 96-well plates (density of
4$103 and 7.5$103 cells per well for HeLa and MRC-5, respectively)
and incubated at 37 8C and 5% CO2. After 24 h incubation, cells
were treated with various concentrations (0.8–100 mm, 200 mL final
well volume) of the test compound and incubated for 48 h. There-
after, the medium was removed, 100 mL of freshly prepared resa-
zurin-containing complete medium (0.2 mgmL"1 final concentra-
tion) was added, and the cells were incubated at 37 8C for another
4 h. At the end of the incubation period, fluorescence of the highly
red fluorescent resorufin product (lex=540 nm, lem=590 nm) was
quantified using a SpectraMax M5 microplate Reader. The reported
cytotoxicity data are the average of at least two independent ex-
periments, each performed in triplicate per concentration level.
Final DMSO concentration in the wells was <0.5% (v/v). Control
experiments on cells treated with same amounts of DMSO in cul-
ture medium showed no cytotoxic effect (results not shown).
In vitro fluorescence evaluation : Cellular localization of lumines-
cent RuII complexes was assessed by confocal microscopy. As for
the cytotoxicity assays, stock solutions of the RuII complexes
(20 mm) were prepared in DMSO (for the RuII-peptides in milli-Q
H2O) and diluted to the desired concentrations with culture
medium. HeLa cells were grown on 18 mm Menzel–Gl%ser cover-
slips at a density of 1$105 cellsmL"1 in cell culture medium. Cells
were incubated with RuII complexes at their desired incubation
concentration (either IC50 values or at 100 mm for the nontoxic
complexes) for 2 h, at 37 8C under 5% CO2. The medium was dis-
carded, cells were fixed with a 4% formaldehyde solution in PBS
and mounted on slides for viewing by confocal microscopy. If re-
quired, co-staining of cell nuclei with DAPI was performed by
using a mounting solution containing DAPI (lex=402 nm, lem>
420 nm). Fixed cells were imaged on a Leica SP5 confocal laser
scanning microscope, using the red wavelength selection (lex=
458 nm, lem=600–650 nm).
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2.1.4. A BIS(DIPYRIDOPHENAZINE)(2-(2-PYRIDYL)PYRIMIDINE-4-CARBOXYLIC ACID) 
RUTHENIUM(II) COMPLEX WITH ANTICANCER ACTION UPON PHOTODEPROTECTION 
In a final step, this complex could be rendered inactive by masking the carboxylate 
functionality with a photolabile protecting group, allowing anticancer activity to be 
retrieved upon UV-A irradiation (2.58 J/cm2). 
This chapter has been published in Angew. Chem. Int. Ed. Engl. in 2014.45 
Copyright © Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
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A Bis(dipyridophenazine)(2-(2-pyridyl)pyrimidine-4-carboxylic
acid)ruthenium(II) Complex with Anticancer Action upon
Photodeprotection**
Tanmaya Joshi,* Vanessa Pierroz, Cristina Mari, Lea Gemperle, Stefano Ferrari, and
Gilles Gasser*
Abstract: Improving the selectivity of anticancer drugs
towards cancer cells is one of the main goals of drug
optimization; the prodrug strategy has been one of the most
promising. A light-triggered prodrug strategy is presented as an
efficient approach for controlling cytotoxicity of the substitu-
tionally inert cytotoxic complex [Ru(dppz)2(CppH)](PF6)2
(C1; CppH= 2-(2-pyridyl)pyrimidine-4-carboxylic acid;
dppz=dipyrido[3,2-a:2’,3’-c]phenazine). Attachment of
a photolabile 3-(4,5-dimethoxy-2-nitrophenyl)-2-butyl
(DMNPB) ester (“photocaging”) makes the otherwise active
complex C1 innocuous to both cancerous (HeLa and U2OS)
and non-cancerous (MRC-5) cells. The cytotoxic action can be
successfully unleashed in living cells upon light illumination
(350 nm), reaching similar level of activity as the parent
cytotoxic compound C1. This is the first substitutionally inert
cytotoxic metal complex to be used as a light-triggered prodrug
candidate.
Platinum- and ruthenium-based cytotoxic compounds are by
far the most exploredmetal-based anticancer agents.[1] For the
majority of such metal complexes, their anticancer activity
originates from the presence of a labile ligand and/or a redox-
active metal center.[2] (Organo)metallic complexes can, how-
ever, also exert anticancer activity in their inert intact form.[3]
The best examples are the substitutionally inert RuII scaffolds,
which have been found to not only act as potent kinase
inhibitors, but also as effective cytotoxic compounds.[2c,e, 4] The
mechanism of action for cytotoxic RuII polypyridyl com-
pounds is believed to be a complex function of inherent
physicochemical and pharmacological properties. As interest
in substitutionally inert metal complexes as anti-cancer drug
candidates has only recently regained momentum,[3a,4a,b,d,5] in
most cases only limited information is available on their
precise mode of action and metabolic activity. Moreover,
a scarcity of structure–activity relationship (SAR) studies
focusing on these aspects also implies that biochemical
understanding on most of these systems is still pre-
mature.[4a–c,6]
Nonetheless, targeting the cytotoxic aspects of one such
coordinatively saturated and substitutionally inert RuII com-
plex, [Ru(dppz)2(CppH)]2+ (C1; Scheme 1), we have demon-
strated that this particular bis(dppz) complex exerts its
cytotoxic action by disrupting the mitochondrial function.[7]
Through correlations from the detailed SAR studies, we could
deduce that structural alterations in this lead prototype can
significantly diminish its cytotoxic potency.[8] Furthermore,
with no decomposition of the complex in human plasma, it
was concluded that the intact RuII complex is responsible for
the cytotoxic activity.[7]
Taking the above findings into consideration, we explored
the potential of light-triggered prodrug strategy for tuning the
intracellular cytotoxic activity of the complex, while retaining
the structural integrity of the active parent complex. Such
molecules, which are rendered inactive through covalent
modification with a photocleavable moiety but can regain
biological activity upon light exposure, are commonly
referred to as “photocaged” compounds.[9] Light-activatable
pro-moieties allow the modulation of the release and activity
of a “photocaged” drug as a function of the wavelength,
duration, intensity, or location of illumination.[10] Whilst
photochemical control of activity (also referred to as “photo-
caging/uncaging”) has been widely explored with organic
drugs, application of this concept to metal coordination
complexes has been surprisingly limited.[9,11] Of note, metal
complexes were previously used in combination with light to
trigger biological activity.[3a,11,12] Specific to substitutionally
inert RuII complexes, photoactivation to date has primarily
revolved around the studies exploring their capacity to
undergo photoinduced ligand exchange/expulsion, DNA
binding, DNA cleavage, and cytotoxic effects.[3a,4a–c,13] To the
best of our knowledge, this work is the first example of a light-
triggered structurally inert metallo-prodrug candidate, with
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no “caged” variants of any substitutionally inert cytotoxic
metal complex been previously constructed.
For the proof-of-principle design of a light-activatable
RuII prodrug candidate, inspiration was drawn from the
recent structure–activity analysis on the lead prototype. The
results pointed towards the presence of the carboxylate
functionality on the pyrimidine ring as being essential for
cytotoxic activity of the complex, making it an ideal site for
attachment of a photocleavable moiety. 3-(4,5-Dimethoxy-2-
nitrophenyl)-2-butyl (DMNPB) ester was used as the photo-
cleavable moiety for derivatization of the carboxylic handle
(Scheme 1).[14] This ortho-nitrophenyl chromophore has pre-
viously been used for efficient photocontrolled release of l-
glutamate, a neurotransmitter, and for phototriggered cell
adhesion of “caged” RGD peptides, at near-UV wavelengths
(ca. 360 nm).[15] The synthesis of the aryl butyl esterified RuII
pro-moiety (C2) followed the route shown in the Supporting
Information, Scheme S1. The identity of C2 was confirmed by
1H NMR spectroscopy and mass spectrometry, and its purity
was determined by elemental analysis (see the Supporting
Information for more details).
The hydrolytic stability of C2 was evaluated by monitor-
ing a sample of this compound in phosphate-buffered saline
(PBS) at 25 8C in the dark. Over a time period of 24 h, aliquots
were examined by HPLC for the release of C1; formation of
about 7% C1 was observed over the time of experiment.
Photolytic stability of C2 was also assessed prior to perform-
ing the cytotoxicity experiments. The complex solution in PBS
(pH 7.2) was irradiated with 350 nm UV-A radiation, and
changes in the UV/Vis absorption spectra were monitored
over time (Figure 1). Upon light irradiation, the metal-to-
ligand charge transfer (MLCT) band centered at 478 nm is
hypsochromically shifted to a broad MLCT band centered at
451 nm. With time, a clear isosbestic point at 467 nm is
observed along with increasing absorption intensity in the
250–400 nm region. As the photolytic reaction proceeds,
a shoulder at about 318 nm that is characteristic of the free
complex C1 also appears, reflecting its photorelease from C2.
Furthermore, removal of DMNPB from the prodrug candi-
date C2 to release C1 could also be easily confirmed by
UPLC-MS (Supporting
Information, Figure S2).
With time, gradual disap-
pearance, upon light irradi-
ation, of the peak corre-
sponding to C2 (tR=
2.6 min) was seen along
with appearance of the
peak for free C1 (tR=
2.3 min); the observed
spectral changes are in
agreement with the
expected photolytic reac-
tion. After 20 min of light
irradiation (5.16 Jcm!2), an
almost quantitative amount
of C1 (" 92%) was photo-
released (Supporting Infor-
mation, Figure S3), as esti-
mated from UPLC analysis (see the Supporting Information
for more details). The calculated quantum yield for the
photorelease of C1, as determined by comparison with 1-(2-
nitrophenyl)ethyl phosphate (F= 54%),[16] was found to be
3.8%, indicating a modest photolytic efficiency (Supporting
Information, Figure S4).
Having confirmed the light-triggered removal of DMNPB
from the prodrug candidate C2 to release C1, the cytotoxic
evaluations were performed on cervical cancer (HeLa), bone
cancer (U2OS), and non-cancerous lung fibroblast (MRC-5)
cell lines. Resazurin based fluorometric assay was employed
for the cytotoxicity assessment of the prodrug candidate in the
dark and upon 350 nm light irradiation (Table 1). Different
concentrations of prodrug candidate C2 administered for 4 h
in the dark to both HeLa and U2OS cells, followed by
incubation at 37 8C in fresh cell culture media for additional
48 h, were found to be non-toxic up to the highest complex
concentration (100 mm) examined in this study. Similar
cytotoxic response was also observed on MRC-5 cells upon
Scheme 1. Chemical structures of the active bis(dppz)RuII complex C1 and its photolabile protected version C2
(isolated as racemic mixtures of hexafluorophosphate salts). The DMNPB group is released upon irradiation
at 350 nm.[14] CppH=2-(2-pyridyl)pyrimidine-4-carboxylic acid; dppz=dipyrido[3,2-a :2’,3’-c]phenazine.
Figure 1. Changes in absorption spectra of C2 (50 mm in PBS, pH 7.2)
as observed upon irradiation at 350 nm. Arrows indicate the direction
of change in absorbance with increasing periods of irradiation.
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incubation with C2. Interestingly, even extending the treat-
ment up to 48 h for prodrug candidate C2 did not induce any
cytotoxicity towards U2OS cells up to the highest dosed
complex concentration (100 mm), also causing no significant
change in its cytotoxic action towards HeLa and MRC-5 cells
(IC50# 85 mm). That prodrug candidate C2 shows a promising
lack of cytotoxicity toward both cells lines, in the dark, is in
stark contrast with the cytotoxic activity data obtained for the
active RuII complex, C1, for which the IC50 values against
HeLa, U2OS, and MRC-5 cell lines were determined to be
10.0 mm, 13.5 mm, and 15.1 mm, respectively. The parent
cytotoxic complex C1 losing its activity upon covalent
modification reflects similar findings previously reported by
us.[7,8] For example, the benzylic and ethyl ester derivatives of
C1 showed 3–4 times less activity on HeLa cells than the
parent complex.[8]
The effect of light irradiation on the cytotoxic action of
the prodrug candidate C2 was examined on HeLa and U2OS
cells. The cells were first incubated withC2 in the dark for 4 h,
before suspension in fresh cell culture media followed by
irradiation at 350 nm for 10 min (2.58 Jcm!2) and incubation
for additional 48 h. As anticipated, light irradiation of HeLa
and U2OS cells exposed to prodrug C2 restored the cytotoxic
effect (Table 1). An IC50 value of ca. 17.0 mm was obtained
when cells were subjected to light exposure. Notably, the
cytotoxicity level re-attained by the pro-moiety C2 upon light
irradiation is in excellent agreement with the cytotoxic
response observed for C1, in the dark, toward HeLa cells
(IC50= 16.0 mm) under similar conditions, with an almost
twofold increase in cytotoxicity against U2OS cells (Table 1).
Control light irradiation experiments performed onHeLa and
U2OS cells either in the absence of the complex or after
incubation with the photolabile group DMNPB showed no
toxic effect on the cells, ruling out their possible contributions
to the elevated cytotoxic effects observed upon light activa-
tion.
Tris(diimine)–RuII complexes can produce 1O2 upon light
irradiation and therefore induce 1O2-mediated DNA photo-
cleavage, and can also exert phototoxicity.[4b,c,13a,17] In our
case, the separately conducted measurements indeed con-
firmed the ability of C1 to produce singlet oxygen (see
Supporting Information) upon irradiation at 350 nm with the
determined quantum yield (F) of 0.81 and 0.06 in acetonitrile
and PBS (pH 7.2), respectively; the values indicating an
extremely efficient singlet oxygen production in lipophilic
environments. Given that the prodrug candidate C2 only
regains cytotoxic activity after light activation, it thus follows
that any cytotoxic effect introduced on light irradiation of C1
may have a role to play in the elevated cytotoxic potency of
the prodrug candidate C2. That the photoinduced toxicity of
C1 contributes to the observed light-triggered increase in
activity of C2 is supported by the fact that light irradiation at
350 nm of HeLa and U2OS cells dosed with C1 (4 h) further
led to up to about threefold increase in cytotoxicity compared
to those kept in the dark. Nevertheless, photolytic removal of
DMNPB fromC1 still remains the critical first step in the case
of C2 regaining cytotoxicity upon photolysis. Thus, it is
conceivable that as the complex C1 is photoreleased from the
prodrug candidate C2, the overall enhancement in exerted
cytotoxicity in HeLa cells is a cumulative effect of the direct
cytotoxic activity of C1 and the activity, in part, potentially
originating as a result of a cascade of photolytic reactions
involving the RuN6 coordination sphere of complexes C1 and
C2.
Furthermore, the effect of light irradiation on the cellular
localization of the prodrug candidate C2 was also probed
qualitatively using confocal laser scanning microscopy
(CLSM; Supporting Information, Figure S7). CLSM studies
on HeLa cells treated with C2 in the dark revealed a non-
specific manner of localization (Supporting Information,
Figure S7a). Intense luminescence signals were observed
from the cytoplasmic regions as well as the cell nucleoli.
Furthermore, a distinct sharp signal marking the periphery of
the nuclear membrane was also observed, which persisted
even after co-staining of cellular DNA with DAPI (4’,6-
diamidino-2-phenylindole; Supporting Information, Fig-
ure S7c). For the cells exposed to light irradiation (350 nm),
a relatively less-intense luminescence was observed in cells
(Supporting Information, Figure S7b). Nevertheless, from the
respective overlay image with DAPI staining (Supporting
Information, Figure S7d), accumulation appeared to mainly
occur in cytoplasmic organelles, with weak visual signs of red
emission from the nucleus under the conditions used for the
confocal microscopy experiments. However, a possibility that
the polarity and water accessibility of bis(dppz)–RuII com-
plexes in the cellular microenvironment is reflected in the
decreased intensity of the emission signals, cannot be ruled
out. This highlights the uncertainty on precise cellular
accumulation of metal complexes as assessed by confocal
microscopy. However, in case ofC1, we could previously show
that visually observed mitochondrial accumulation is highly
Table 1: Cytotoxic activity data (IC50) for C1, C2, DMPNB (4), and cisplatin against human cervical carcinoma (HeLa), human osteosarcoma (U2OS),
and non-cancerous lung fibroblast (MRC-5) cell lines.
IC50 [mm]
HeLa U2OS MRC-5
4 h
(dark)
4 h
(+ UV-A)[a]
48 h
(dark)
4 h
(dark)
4 h
(+ UV-A)[a]
48 h
(dark)
48 h
(dark)
C2 >100 17.0$0.8 85.8$5.8 >100 17.2$3.8 >100 85.3$0.2
C1 16.0$0.1 5.9$1.7 10.0$1.3[7] 30.5$1.1 13.5$2.1 13.5$2.5[7] 15.1$2.2[7]
DMPNB (4) >100 >100 >100 >100 >100 >100 >100
cisplatin 9.8$4.5 12.7$3.6 9.9$0.9 26.8$1.9 32.6$5.1 11.8$1.7[7] 8.5$0.9
[a] 10 min UV-A irradiation (350 nm, 2.58 Jcm!2).
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correlated to that determined using high-resolution contin-
uum source atomic absorption spectrometry (HR-CSAAS).[7]
In conclusion, we report on an efficient approach for
controlling cytotoxicity of a substitutionally inert cytotoxic
RuII complex. Attaching an appropriate photolabile moiety to
C1 makes the otherwise active complex innocuous to both
cancerous (HeLa and U2OS) and non-cancerous (MRC-5)
cells. Furthermore, the cytotoxic action of the pro-moiety C2
is controlled by light and can be regained upon illumination.
With light-induced (350 nm) liberation of C1 from the pro-
moiety, cytotoxic action of the prodrug on the cancer cells is
unleashed, reaching similar levels of cytotoxicity as for the
original complex in absence of light. Though still at the
prototype stage, this light-triggered prodrug strategy holds
tremendous potential for designing more sophisticated pro-
drug systems, where properties are tailored to produce
a controllable cytotoxic action in physiologically relevant
optical window. Efforts towards this end are currently under
investigation. It should be noted, however, that the UV-A
light dosage (2.58 Jcm!2) used to induce cytotoxicity in C2 is
comparable to that frequently employed for other UV-A
activated metal complexes.[11,12d,18]
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2.2. RU(II) COMPLEXES AS PROMISING PHOTOSENSITIZERS IN PDT 
 
2.2.1. CONTRIBUTION TO THE WORK 
V.P.: conducted all the experiments, except the Agarose gel in Figure 10.A 
performed by Dr. Riccardo Rubbiani. She also wrote the first draft of the manuscript.  
 
2.2.2. MECHANISM OF ACTION OF A DNA INTERCALATING RU(II) POLYPYRIDYL 
COMPLEX UPON UV-A IRRADIATION: FROM DNA CLEAVAGE TO APOPTOSIS 
 2.2.2.1. ABSTRACT 
We have previously reported the property of [RuII(bipy)2dppz]2+ derivatives to 
accumulate in the nucleus of HeLa cells, impairing cell viability upon UV-A 
irradiation. Here we confirm the ability of one derivative, namely [Ru(bipy)2-dppz-7-
methoxy][PF6]2 (Ru65 hereafter), to localize to the nucleus of cancer and normal cells 
and to selectively display cytotoxicity in response to UV-A irradiation. With regard to 
its molecular mechanism of action, we demonstrate that Ru65 intercalates in DNA 
and, in response to UV-A irradiation, generates singlet oxygen (1O2). The latter 
promotes oxidation of guanine in solution and in plasmid DNA, resulting in nicks in 
the double helix. With dedicated assays we confirm this mechanism of action in living 
cells and show that UV-A irradiation of Ru65 results in DNA double-strand breaks. 
At the molecular level, we observe an early and transient DNA damage response in 
cells treated with Ru65, which is followed by a more pronounced, delayed response, 
leading to accumulation in the S- and G2-phases of the cell cycle and followed by loss 
of viability and death by apoptosis.  
 
 2.2.2.2. INTRODUCTION 
Cancer therapy is still largely based on the use of DNA damaging agents, despite 
evident drawbacks such as their intrinsic genotoxic potential.31, 46 In recent years, the 
rational design of molecules targeting oncogenic pathways that are hyper-functional 
in cancer cells or to which cancer cells become addicted,46, 47 has provided an 
alternative approach to the use of “dirty” drugs. Although the introduction of “magic 
bullets” represented a great leap forward with respect to the use of chemotherapeutics, 
the well-documented adaptability of cancer cells to external insults, exemplified by 
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the induction of point mutations rendering the target protein resistant to first 
generation compounds,48 along with more general responses such as increased 
metabolization and extrusion of the drug from cells, continuously demands the 
implementation of novel strategies. The use of light to activate drugs has gained 
increasing attention as promising alternative to the treatment of a number of 
pathologies. Among the different medical techniques relying on light activation (e.g. 
photothermal therapy, photoactivated chemotherapy, etc.), photodynamic therapy 
(PDT) has been undoubtedly the most successful method reported so far. Initially 
used in the therapy of macular degeneration or bacterial infections, PTD has been 
increasingly successful in the treatment of a variety of cancers, including those of skin 
and prostate or, supported by the use of optic fibers to reach cavities, in targeting 
cancers of the lung and the esophagus.49, 50 More specifically, PTD relies on the 
activation of a photosensitizer (PS) by light at a defined wavelength, resulting in the 
production of reactive oxygen species (ROS), mainly consisting of singlet oxygen 
(1O2) that has an estimated half-life of 40 ns in a biological environment.51, 52 ROS will 
then rapidly react with biomolecules in close proximity of the PS, impairing 
metabolic functions and ultimately leading to cell death. The advantage of PDT over 
conventional chemotherapeutic treatments of solid tumors is its decreased toxicity, 
since generation of ROS is guided by light at defined locations as opposed to the mere 
uptake of an active drug in the cells. PTD appears also to be a better alternative to 
chemotherapy when used in combination with surgery.53 Indeed, local application of 
PDT upon surgical removal of portions of tissues or organs allows targeting the tumor 
while preserving healthy tissue, not last to the benefit of the aesthetic. Nonetheless, 
currently approved PSs (porphyrin, phtalocyanine) suffer from drawbacks inherent to 
their molecular structure, such as low solubility in water and a prolonged 
photosensitivity for patients treated with PSs.54 Good PSs should ideally display high 
solubility in water, good phototoxic dark/light index (PI), good singlet oxygen 
quantum yield upon activation with non-harmful light and little or no photosensitivity 
for the patient. In this respect, we recently described an excellent photosensitizer 
candidate, namely a substitutionally inert Ru(II) polypyridyl complex [Ru(bipy)2-
dppz-7-methoxy][PF6]2 (Ru65) (Figure 9).55  Ru65, whose phosphorescence can be 
turned on upon intercalation in a hydrophobic environment, showed nuclear 
localization in vivo and the ability to nick plasmid DNA in vitro, suggesting that it 
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intercalates between bases and damages DNA upon irradiation-induced 1O2 
production.55 
In the present study we set out to characterize in detail the mechanism of action of 
the Ru65 complex using a low-dose of UV-A irradiation as trigger. We observed that 
the normally innocuous complex efficiently localized to the nucleus and, upon UV-A 
irradiation, caused damage to DNA by oxidation of guanines and the generation of 
nicks in the double helix, triggering a DNA damage response. We observed that an 
initially weak but rapid response to Ru65-induced ssDNA breaks turned into a potent 
response characterized by the formation of dsDNA breaks and resulting in cell death. 
 
Figure 9. Structure of Ru65. 
 
 2.2.2.3. RESULTS  
 
Ru65 intercalates in DNA and photo-activation causes oxidative DNA damage  
 
We have previously reported that Ru65 generates 1O2 upon UV-A irradiation (350 
nm, 2.58 J/cm2) and that this results in relaxation of supercoiled plasmid DNA.55 To 
corroborate these findings and clarify the molecular mechanism of DNA damage, we 
examined binding of Ru65 to the plasmid pUC18. Treatment with Ru65 in the 
absence of UV-A irradiation caused retardation in the mobility of both supercoiled 
and nicked forms of the plasmid (Fig. 10A and 10B), an indication of the intercalating 
properties of RuII metal complexes in DNA. Incubation of pUC18 with Ru65 
followed by UV-A irradiation (350 nm, 0-65-2.58 J/cm2) confirmed a dose-dependent 
ability of the metal complex to nick plasmid DNA (Fig. 10A).  
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We reasoned that generation of ROS such as 1O2 in close proximity to DNA may 
cause damage to bases, with 8-oxo-guanine being a highly mutagenic lesion.56 
Incubation of pUC18 with Ru65 followed by UV-A irradiation and treatment with 
Formamido-pyrimidine DNA Glycosylase (Fpg or 8-oxoguanine DNA Glycosylase), 
an enzyme that releases damaged purines from dsDNA leaving a one-base gap, 
showed that supercoiled pUC18 was almost fully converted in the open circular form 
under these conditions (Fig. 10C). This indicates that activation of Ru65 intercalated 
in DNA led to oxidative damage of purines.  
 
Figure 10. Photo-activation of Ru65 causes DNA damage. A.The plasmid pUC18 (150 ng) was 
incubated with the indicated concentration of Ru65 for 30min, UV-A irradiated or kept in the dark, 
prior to run on a 1% agarose gel in the presence of EtBr. A linearized form of the plasmid was obtained 
by EcoRI digestion. The positions of supercoiled and nicked plasmid are indicated. B. DNA 
intercalation of Ru65. The plasmid pUC18 (150 ng) was incubated with the indicated concentration of 
Ru65 for 30min prior to run on a 1% agarose gel in the presence of EtBr. C. Purine oxidation was 
assessed by treating pUC18 (150 ng) with Ru65 and UV-A as indicated, followed by incubation with 
0.2 U of Fpg for 1h at 37°C. The products were loaded on a 1% agarose gel in the presence of GelRed. 
 
UV-A-mediated activation of Ru65 causes a DNA damage response 
 
We have previously observed by confocal microscopy that Ru65 preferentially 
accumulates into the nucleus of HeLa cells.55 To corroborate this finding, we 
examined the subcellular localization of Ru65 in additional cell lines using the same 
technique. Analysis of U2OS, MCF7, CAL33 cancer cells and the normal epithelial 
cell line RPE-1 incubated with Ru65 (100 µM) for 4h showed nuclear localization of 
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the metal complex (Fig. 11A). Time-course experiments showed increasing 
accumulation of the metal complex into the nucleus of U2OS cells over a 24h period, 
with detectable signal 30 min post-administration and substantial amounts of Ru65 
being internalized at 4h (Fig. 11B).   
 
Figure 11. Ru65 localizes in the cell nucleus. A. HeLa (a), U2OS (b), MCF7 (c), CAL33 (d) and 
normal RPE-1 cells (e) were treated with Ru65 (100µM) for 2h. After treatment, Ru65 was removed 
from the medium, cells were fixed and visualized by confocal microscopy. Scale bar = 20µm. B. Time 
course uptake of Ru65 (100µM) in U2OS. Cells were fixed and visualized as described in A. 
 
We have also previously shown that UV-A irradiation of HeLa or MRC5 cells 
treated with Ru65 led to a remarkable loss of viability if compared to non-irradiated 
cells.55 The UV-A dose used in our previous study (350 nm, 2.58 J/cm2) did not 
impact cell viability and was significantly below the dose administered by others 
working with similar metal complexes.57 Nonetheless, to directly assess the impact on 
DNA of distinct doses of the UV-A light used to trigger Ru65, we performed PFGE 
analysis of genomic DNA. The data showed that irradiation at 350 nm with a light 
RESULTS	   	  
RU(II)	  COMPLEXES	  AS	  PROMISING	  PHOTOSENSITIZERS	  (PDT)	   	  
 
 74 
dose of 2.58 J/cm2 in the absence of Ru65 caused per se the formation of significant 
amounts of double-strand breaks (DSBs) (Fig. 12A). Optimization studies on U2OS 
cells led us to conclude that at a lower dose of UV-A irradiation (1.29 J/cm2) caused 
minimal damage (Fig. 12A), compatible with the studies that we decided to 
undertake. 
To gain mechanistic insights into the cellular effect of activated Ru65, we 
examined the presence of γH2AX, an established marker of the DNA damage 
response (DDR). To this end, we used a flow cytometry-based method that couples 
quantification of DNA damage (γH2AX) with analysis of DNA content (DAPI), 
according to an established protocol.58 Control experiments, where U2OS cells were 
treated with 1.29 J/cm2 UV-A irradiation, showed only a transient phosphorylation of 
H2AX (Fig. 12B). 
 
Figure 12. The photosensitizer UV-A does not cause DNA damage. A. PFGE analysis of U2OS 
cells treated with the indicated amounts of UV-A (upper panel). Quantification of the signal 
corresponding to DSBs (lower panel) was obtained using ImageJ and normalized to the unsaturated 
signals of DNA retained in the wells. The fold change in DSBs was obtained by normalizing each 
treatment to the untreated control. Camptothecin (CPT 1µM, 4h) was used as positive control. B. Time-
course response of U2OS cells treated with UV-A (1.29 J/cm2). The phosphorylation of H2AX was 
determined by flow cytometry as described in Materials and Methods. Irradiation with UV-C (20 J/m2) 
was used as positive control. 
 
On the other hand, UV-A irradiation of U2OS cells pre-treated with Ru65 caused a 
~16-fold increase in γH2AX foci 16 h post-irradiation in comparison to cells treated 
with either Ru65 or UV-A alone (Fig. 13A). Immunofluorescence (Fig. 13B and 13C) 
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confirmed the generation of DNA damage upon activation of Ru65. Similar results 
were obtained using CAL33 cells (Fig. 13E). 
Damage to DNA triggers a checkpoint response that arrests cell cycle progression 
and orchestrates repair at the site of damage.59 To assess effects on the cell cycle, we 
performed studies using flow cytometry. The cell cycle profile of U2OS cells treated 
with Ru65 in the absence of UV-A irradiation showed no difference with respect to 
that of untreated cells, indicating that the presence of Ru65 did not disturb cell cycle 
progression (Fig. 13D). On the other hand, UV-A irradiation of Ru65 showed a 
marked accumulation of cells in the S- and G2-phases of the cell cycle at 16 h post-
irradiation (Fig. 13D), a time when γH2AX foci were clearly detectable in cells (Fig. 
13A). 
Figure 13. UV-A activated Ru65 triggers a DNA damage response. A. U2OS cells were treated 
with Ru65 (50µM) and UV-A (1.29 J/cm2) as indicated. Upon fixation, cells were probed with anti-
γH2AX antibody and examined by flow cytometry. B. Representative images of U2OS cells left 
untreated (a), UV-C irradiated (b) or treated with Ru65 and UV-A (c). Cells were immuno-stained with 
γH2AX antibody and visualized by confocal microscopy. C. Quantification of foci detected in the cells 
described in B. n = 200 cells, error bars = SEM. D. U2OS cells treated as in A were fixed and stained 
with DAPI. DNA was examined by flow cytometry. E. Dot plots of Ru65 (50µM) treated CAL33 cells 
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irradiated with UV-A (1.29 J/cm2) and allowed to recover for the time indicated. Cells were probed 
with anti-γH2AX antibody and examined by flow cytometry. 
 
Photo-activation of Ru65 leads to the formation of DSBs in DNA 
 
To elucidate the molecular mechanism of action of Ru65 and assess the impact of 
the damage caused to DNA, we performed a set of analyses on living cells The exact 
nature of the DNA damage caused by Ru65 was assessed by alkaline Single Cell Gel 
Electrophoresis (SCGE) or comet assay, which allows detecting DSBs, single-strand 
breaks (SSBs), abasic sites and DNA adducts.60, 61 By measuring the % DNA in the 
tail, we first quantified the increase of DNA damage resulting from UV-A activation 
of Ru65 over control treatments. An initial response occurring 30 min upon light 
irradiation was enhanced at the 16 h time point (Fig. 14A and 14B, see also Fig. 13A). 
To assess whether Ru65 would cause base oxidation in living cells similarly to what 
observed on isolated plasmid DNA, cells treated with Ru65 were agarose-embedded, 
incubated with Fpg and examined in alkaline comet assays. The increased pattern of 
DNA damage observed upon Fpg treatment (Fig. 14C) confirmed that Ru65 operates 
in living cells with the same mechanism of action described above for plasmid DNA.  
Finally, to assess whether staggered base damage occurring on the two DNA 
strands would result in the formation of DSBs, we examined the status of DNA in 
control or Ru65-treated cells by pulsed-field gel electrophoresis. The data confirmed 
that UV-A mediated activation of Ru65 resulted in the formation of DSBs after 24h 
(Fig. 14D). To substantiate this observation, we treated U2OS cells with higher doses 
of Ru65 and activating UV-A radiation. The data showed that, under these conditions, 
the extent of DSBs was proportionally increased and, particularly, that in respect to 
camptothecin, activated Ru65 caused an evident fragmentation of DNA upon UV-A 
irradiation and 24h recovery (Fig. 14E). 
Taken together, these data indicate that UV-A triggered formation of ROS by Ru65 
results in DNA base damage that is further processed to single- and double-strand 
breaks 
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Figure 14. UV-A-activated Ru65 causes base oxidation and double-strand breaks. DNA damage in 
U2OS cells treated with Ru65 and UV-A irradiation as indicated, was assessed by alkaline comet 
assay. A. The % of DNA in tail was quantified for each cell using the software Comet Assay IV 
(Perceptive Instruments). Each spot represents a single cell; 60 comet images were taken for each 
treatment. B. Representative micrographs of fluorescent DNA stain. C. The extent of oxidative damage 
in DNA upon treatment of U2OS cells with Ru65 and UV-A irradiation was visualized by incubating 
cells embedded in agarose plugs with 0.2 U of Fpg for 1h at 37°C and resolving cells by alkaline comet 
assay. H2O2 was used as positive control. The % of DNA in tail was quantified as described in A. 
PFGE of U2OS cells treated as indicated and allowed to recover for 0.5 or 24h (D) and for 24h (E). 
Camptothecin (CPT 1µM, 4h) was used as positive control. 
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Photo-activation of Ru65 causes loss of viability and death by apoptosis 
 
To evaluate the effect the mid-term cellular response to photo-induced activation of 
Ru65 we performed MTT assays on a set of cell lines. The data showed that Ru65 
caused loss of viability in all cell lines tested (Table 1). To extend these observations, 
we decided to assess the long-term cellular response to Ru65 by clonogenic survival 
assays.62 Consistent with the data above, cytotoxicity was observed only upon UV-A 
irradiation of Ru65 (Fig. 15A). Dose-response studies confirmed a decrease of 
survival at increasing Ru65 doses (Fig. 15B). 
 
Table 1.  IC50 values determined upon incubation of a set of cell lines with Ru65 in the dark for 4h 
and upon 4h incubation followed by UV-A irradiation. Cisplatin was used as comparison. 
Figure 15. Activated Ru65 causes apoptosis. A. U2OS cells were treated with Ru65 (50 µM) for 4h 
and UV-A (1.29 J/cm2) as indicated prior to trypsinization and re-seeding at low density. Single 
colonies were stained after 12-14 days and the survival fraction determined by the ratio of plating 
efficiency for treated and untreated cells. Plotted values are the average of triplicates from 3 
independent experiments with indication of standard error of the mean (SEM). B. U2OS cells were 
treated with increasing amounts of Ru65 as indicated and examined as described in A. 
 
 
 
4 h (dark) 4 h (UV-A)a 4 h (dark) 4 h (UV-A)a 4 h (dark) 4 h (UV-A)a 4 h (dark) 4 h (UV-A)a
Ru65 > 100 20.0 ± 6.1 > 100 30.5 ± 2.9 > 100 17.4 ± 5.3 > 100 35.4 ± 3.3
Cisplatin 30.9 ± 3.6 27.4 ± 2.3 26.8 ± 1.9 21.6 ± 0.3 30.2 ± 7.2 25.0 ± 4.2 62.3 ± 9.7 64.1 ± 3.8
RPE-1 hTERT
a 5 min UV-A irradiation (350 nm, 1.29 J cm−2).
CAL33
IC50 (µM)
HeLa U2OS
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 2.2.2.4. DISCUSSION  
The application of RuII complexes in cell imaging as well as their potential in 
therapy is well documented.30, 63 With regard to their molecular mode of action, the 
ability of Ru complexes to bind canonical and non-canonical DNA structures has been 
reviewed at length.63 We have recently reported the synthesis, characterization, 
photophysical properties and biological evaluation of a set of substitutionally inert 
polypyridyl RuII complexes. Notably, we have demonstrated the ability of such 
complexes to produce singlet oxygen (1O2) in response to irradiation at a defined 
wavelength and proposed their application as photosensitizers in PDT.55 In the study 
reported here, we examined in detail the molecular mechanism of action of one such 
complexes (Ru65) upon intercalation in DNA. We observed that Ru65 is efficiently 
internalized in a number of cell lines, that it mainly localizes to the nucleus and exerts 
specific cytotoxicity upon irradiation with UV-A. The dose of UV-A irradiation used 
in our experiments is ~4-fold lower than what reported by Gicquel et al. and it is 
comparable to what is locally employed in combination with psoralen for the 
treatment of psoriasis, which is generally innocuous for skin types >II.57, 64  
Mechanistically, using a set of biochemical and biological assays we demonstrate 
that activated Ru65 causes the oxidation of purines on isolated plasmid DNA as well 
as in living cells. Among purines, guanine is characterized by a low redox potential 
and can be easily oxidized.65 8-oxo-7,8-dihydroguanine (8-oxo-G) is one of the most 
stable and miscoding lesions caused by ROS that originate from endogenous cellular 
processes or are produced by external sources like ionizing or UV radiation.56 Such 
lesion is normally rapidly removed by the pathway of Base Excision-Repair (BER), 
with DNA glycosylase OGG1 being the enzyme responsible for recognition and 
excision of 8-oxo-G when it is regularly paired to cytosine.66 
Using structurally similar DNA intercalating RuII polypyridyl complexes, Gicquel 
and colleagues have argued that their complexes must cause single- and double-strand 
breaks, based on the ability of specific DNA repair proteins to bind the DNA 
structures that were generated.57 In our study, using comet assays as well as pulse-
field gel electrophoresis and a by far lower amount of activating UV-A radiation, we 
provide formal and direct demonstration for the ability of activated Ru65 to generate 
DNA double-strand breaks.  
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In analogy to the response to DNA mismatches generated by S(N)1-type alkylating 
agents that were previously described in studies conducted at IMCR, we speculate 
that cells treated with Ru65 may cope with the presence of residual base damage 
during the first cycle of cell division and that unaddressed damage becomes critical 
during the S-phase of the second cell cycle when it is converted in double strand 
breaks.67 We speculate that the latter may originate either from staggered base 
oxidations on opposite DNA strands that are not fully addressed in the first wave of 
repair or from replication-dependent conversion of nicks, that result from the effective 
removal of oxidized bases, into double-strand breaks. These hypotheses explain the 
cell cycle profile data and the late pattern of γH2AX foci formation in response to 
UV-A activated Ru65.  
In conclusion, our study highlights the mechanism of action of RuII-based metal 
complexes as DNA targeting molecules that can be activated at will with innocuous 
UV-A irradiation and formally demonstrates that activated Ru65 causes DNA double-
strand breaks ultimately resulting in cell death. Taken together, our observations open 
the perspective of using RuII-based metal complexes in the photodynamic therapy of 
cancer.55, 57  
 
2.2.2.5. FUTURE WORK BASED ON PRELIMINARY RESULTS 
Understanding the mechanism involved in the repair of the DNA damage triggered 
by UV-A activation of Ru65 is crucial to define the most likely application for this 
drug candidate. Indeed, a tumor lacking the specific machinery that addresses repair 
of the damage caused by Ru65 would be more vulnerable to the treatment, as opposed 
to a tumor proficient in such pathway, which would rather survive and acquire further 
mutations, resulting in resistance to therapy and more pronounced malignancy. To 
this end, the repair machinery involved, the mechanism of cell death and possible 
genome threats could be investigated. 
 
A. To dissect the contribution of established signaling pathways to the observed 
pattern of γH2AX foci, we can envisage to examine by immunoblotting markers for 
the ATM or ATR pathways, namely the phosphorylation status of ATM, KAP1 for 
the former and ATR, CHK1 for the latter. Additionally, we could employ specific 
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inhibitors of the three apical PI-3K-like kinases and check the pattern of γH2AX foci 
by flow cytometry. 
Considering ATR, preliminary data obtained by Western blot analysis where we 
looked at its direct downstream target (CHK1), indicate that the ATR pathway is 
activated already 30 min after Ru65-UV-A treatment and remains activated up to 8 h. 
The involvement of ATR could be explained with the fact that unrepaired DNA single 
strand breaks at early stage of the response to Ru65 result in higher amount of 
γH2AX foci, marker of double strand break at later stage. This could support the 
hypothesis that primary SSBs left unrepaired, lead to DSBs at later times. On the 
contrary, the data indicated that the ATM pathway is not induced in Ru65 treated 
U2OS cells after irradiation, since no phosphorylation of its downstream target KAP1 
could be detected by Western blot, even at late time points (16-24 h) when most 
γH2AX appears. Similarly, inhibition of ATM with a specific compound showed no 
differences in γH2AX foci in comparison to non-inhibited conditions. Hence, the 
appearance of γH2AX foci mainly at 16-24 h in the absence of a detectable ATM 
activation remains puzzling. 
 
B. A possible explanation of the death consequent to Ru65 activation is the 
occurrence of futile cycles of repair. These result from the inability of the base 
excision repair (BER) pathway to process oxidized bases, thus leading to the 
formation and persistence of base mismatches. To test this hypothesis we can consider 
to down-regulate OGG1, which would lead to an increase of unrepaired 8-oxoG 
lesions in DNA, possibly causing cell death at earlier time points. 
 
C. To explore the mechanism triggering cell death upon photo-activation of Ru65, 
we would like to complement our cell cycle studies (Fig. 13D) with the analysis of 
apoptotic, necrotic and autophagic markers.   
Apoptosis could be investigated via caspase 3/7 activation and Annexin-V 
expression at the cell surface, two specific assays detecting apoptosis in biological 
samples. Simultaneously, necrotic pattern would also be studied, together with 
Annexin-V exposure, using Propidium Iodide (PI) staining. Preliminary Annexin-
V/PI staining results showed only a slight increase in the amount of early-stage 
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apoptotic cells at 30 min and at 24 h after combined treatment compared to Ru65 only 
treated cells. Moreover, no PI positive cells were detected, a pattern that possibly 
excludes death by necrosis. 
These negative results and the highly vacuolated status of the cytoplasm of the 
treated and irradiated cells starting already 1 h after Ru65 activation lead us to 
consider other forms of programmed cell death. Indeed, Ru65 treated and irradiated 
cells show massive vacuolization in the cytoplasm that leads to cell detachment and 
blebbing prior to cell death. Early experiments investigating autophagy are 
undertaken. Known inhibitors (Wortmannin, SB202190) would be used, and vacuole 
formation, as well as presence of LC3B-II protein, would be monitored. At this stage, 
we cannot exclude a simultaneous or sequential death process and we even consider 
that Ru65 could trigger its own paraptotic-like cell death. To exhaustively describe 
the death pathway, we can imagine to check for different additional known pattern 
occurring during cell death in a time-lapse approach, such as nuclear fragmentation, 
chromatin condensation, mitochondria swelling, DNA fragmentation, PARP cleavage, 
presence of LC3B-II in vacuole membranes or if vacuoles are made of endoplasmic 
reticulum membranes. 
Should Ru65 trigger its own paraptotic-like cell death, this would be of great 
interest for the treatment of apoptotic resistant cancer cells, for instance.      
 
D. Finally, since the Ru65 complex damages DNA, investigation of possible 
chromosomal aberrations (breaks, fusion) could be undertaken, in order to assess if 
the compound represents a threat to genome stability.  
 
2.2.2.6. MATERIALS AND METHODS 
Antibodies, chemicals and enzymes – Rabbit polyclonal antibodies to 
phosphorylated histone H2AX (S139), was purchased from Cell Signaling Technology 
(Beverly, MA, USA). HRP-conjugated anti-mouse and anti-rabbit secondary 
antibodies were obtained from Amersham-Biosciences/GE-Healthcare (Otelfingen, 
Switzerland). The Alexa Fluor® 488 anti-rabbit secondary antibody was from Cell 
Signaling Technology. Formamido-pyrimidine DNA Glycosylase (Fpg) was 
purchased at New England Biolabs. The CometAssay® kit was from Trevigen (USA). 
Crystal violet was obtained from Sigma-Aldrich (Switzerland). 
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Cell culture - U2OS osteosarcoma cells and hTERT-immortalized retinal pigment 
epithelial cells RPE-1 hTERT were cultured in DMEM (Gibco, Life Technologies, 
USA) supplemented with 10% fetal calf serum (FCS) (Gibco). HeLa cervical 
carcinoma cells were maintained in DMEM containing 5% FCS. MCF-7 breast 
carcinoma cells were grown in MEM (Gibco, Life Technologies, USA) supplemented 
with 10% FCS and 200 mM L-Glutamine. CAL-33 squamous cell carcinoma were 
cultured in RPMI (Gibco, Life Technologies, USA) without phenol red supplemented 
with 10% FCS and 1% Glutamax (Gibco, Life Technologies, USA). All cell lines 
were complemented with penicillin (100 U/mL), and streptomycin (100 μg/mL) and 
stored in a humidified incubator containing 5% CO2 at 37 °C. 
 
Photo-irradiation settings - UV-A treatment was performed in a Rayonet RPR-
200 photochemical reactor (Rayonet Corp., USA) containing 6 bulbs (14 W each) 
emitting in the 300-400 nm range (350 nm maximum intensity). Light intensity (55 
W/m2) was determined using a X11 optometer (Gigahertz-Optik, Germany). 
 
Cell viability and colony formation assays - Cytotoxicity of the Ru(II) complex 
was assessed by a fluorometric cell viability assay using resazurin (Promocell, 
Germany). Briefly, one day before treatment, cells were seeded at a density of 4x103 
cells/well in 100 µl in 96-well plates and the next day incubated for 4 h with either 
Ru65 complex or cisplatin. Upon replacement of the medium and UV-A irradiation 
(1.29 J/cm2), cells were returned to incubator for 48 h and viability assessed as 
previously described 68. 
For colony formation assays cells were seeded at 3 x 105 cells/ml in a 6 cm dish and 
the next day treated and irradiated as above. Cells were trypsinized and re-seeded in 
triplicate in 6 well dishes. Colonies were stained with a crystal violet/ethanol solution 
(0.5%/20%) after 12-14 days of culturing and counted. 
 
Immunofluorescence staining and analysis - Cellular localization of fluorescent 
ruthenium complex was assessed by fluorescence microscopy. Cells were grown on 
18 mm Menzel-Gläser cover slips (Menzel-Gläser, Germany) at a density of 2.5 × 105 
cells/ml and incubated for 2h with 100 μM Ru65 at 37 °C. Cells were fixed in 4% 
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formaldehyde and mounted on slides for viewing by confocal microscopy on a CLSM 
Leica SP5 microscope (Leica Germany). Ru65 was visualized using the red 
wavelength selection (ex, 458 nm; em, 600−650 nm) on the CLSM Leica SP5 
microscope. 
U2OS cells were seeded at a density of 3 x 105 cells/ml in a 6 cm dish containing 
cover slips. The next day, cells were treated for 4h with Ru65 (50 μM), the medium 
was replaced and cells were UV-A irradiated (1.29 J/cm2). For control UV-C 
treatment, cells were set in a Stratalinker 1800 (Stratagene, Agilent Technologies, 
USA) and irradiated with 20 J/m2. After treatment, cells were placed back to the 
incubator for 30min or 24h. Cells were fixed for 15min at RT °C in 4% formaldehyde, 
permeabilized in 0.1 % Triton X-100 for 5min at 4°C, blocked in 3% milk/PBS and 
incubated over night at 4°C with anti- γH2AX antibody. After washing in 3% 
milk/PBS, Alexa Fluor 488 goat-anti rabbit antibodies (1:1000) were added for 1h at 
37°C. After washing in PBS and rinsing in ddH2O, coverslips were mounted on slides 
with DAPI containing mounting solution (Vectashield) and visualized with CLSM 
SP5 microscope. 
 
Flow Cytometry - Cells were seeded at a concentration of 3 x 105 cells/ml in a 6 
cm dish one day before treatment. The next day cells were treated and irradiated as 
indicated above, fixed in 4% formaldehyde for 15 at room temperature (RT) and 
permeabilized in 0.1% Triton-X100/PBS for 10 min on ice. Upon washing with 1% 
BSA/PBS cells were resuspended in 1% saponin dissolved in 1% BSA/PBS buffer 
containing the primary antibody (rabbit anti γH2AX 1:250) for 2h at RT. Cells were 
washed with saponin/BSA/PBS and the secondary antibody (anti-rabbit Alexa Fluor 
488 1:50) was added in the same buffer for 30 min at RT in the dark. Cells were 
washed with saponin/BSA/PBS followed by 1% BSA/PBS before resuspension in 1% 
BSA/PBS containing 0.1 mg/ml RNase and 1µg/ml DAPI at RT in the dark 30min. 
Alexa Fluor 488 and DAPI signals were acquired on 10’000 cells / sample using a 
CyAn ADP 9 flow cytometer (Dako) and analyzed with Summit 4.3 software. Data 
are represented as mean ± SEM. 
  
Pulse-field gel electrophoresis – Sub-confluent cultures of U2OS were treated with 
vehicle alone (DMSO), camptothecin (CPT 1µM) or Ru65 (50 µM) in the dark or 
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upon UV-A irradiation. Cells were harvested by trypsinization, and agarose plugs of 
106 cells were prepared in a disposable plug mold (BioRad). Plugs were incubated in 
lysis buffer (100 mM EDTA, 1% (w/v) sodium lauryl sarcosyl, 0.2% (w/v) sodium 
deoxycholate, 1mg/ml proteinase K) at 37 oC for 72h and washed four times in 20 
mM Tris-HCl pH 8.0, 50 mM EDTA before loading onto an agarose gel. 
Electrophoresis was performed for 23h at 14 oC in 0.9% (w/v) Pulse Field Certified 
Agarose (BioRad) containing Tris-borate/EDTA buffer according to the conditions 
described in 70 and adapted to a BioRad CHEF DR III apparatus. The gel was finally 
stained with ethidium bromide (EtBr) and analyzed using an Alpha Innotech Imaging 
system. 
 
Alkaline comet assay – Alkaline comet assays were performed using the 
CometAssay Reagent Kit (Trevigen), according to the manufacturer's instructions. 
Briefly, U2OS cells were seeded at a concentration of 3 x 105 cells/ml in a 6 cm dish 
one day before treatment. The next day cells were treated and irradiated as indicated 
above and let recover for 30min or 16h. After resuspension in PBS at a concentration 
of 1 x 105 cells/ml and combined with LM Agarose at a ratio of 1:10 (v/v), 50 µl of 
the mixture was loaded onto CometSlide and placed at 4 °C for 30 min. Embedded 
cells were lysed in a bath at 4 °C for 30 min, slides were immersed in alkaline 
unwinding solution for 20 min at RT, prior to alkaline electrophoresis (21 V, 30 min, 
in alkaline electrophoresis solution). Following two baths in H2O of 5 min and one of 
70% EtOH of 5 min, samples were dried at 37 °C and stained with SYBR green for 
30 min. A total of 60 cells were scored using Comet Assay IV analysis system 
(Perceptive Instruments, UK) and an epifluorescence microscope (Leica) with 20x 
magnification objective. Results are presented as mean values for % of DNA in tail. 
 
 
	  
  
 
 
3. Discussion and Outlook 
 
 
 
 
 
 
 
Advantages of using photo-activatable metal-based anticancer agents over 
conventional anticancer drugs. 
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3.1. ADVANTAGES OF PDT OVER CONVENTIONAL CHEMOTHERAPY  
Research in the field of light-activated prodrugs is rapidly expanding since this 
strategy offers the possibility of overcoming several drawbacks of traditional 
chemotherapeutics. The advantages of photoactivatable prodrugs consist in:  
(i) Spatial and temporal control of drug activity 
The fact that the generated toxicity does not originate from the drug itself, but from 
the ROS produced upon a specific light, is crucial to overcome systemic toxicity and 
side effects (nausea, nephrotoxicity, ototoxicity); since the toxicity is sequestered to 
the irradiated area. 
(ii) Light as a trigger 
- Light is easily applicable and economically affordable in the clinic.  
- The use of optic fibres allows reaching internal areas located in cavities or 
colorectal and oesophageal areas. Such fibres can also treat solid cancer located in the 
core of organs by incisions and insertions into the organ. Therefore, PDT could 
potentially substitute removal surgery in the case of cancers located in areas that are 
easily reachable with fibres (cavities) or in areas where esthetical outcome matters 
(i.e. head and neck cancer). As an example, TOOKAD, a photosensitizer, currently in 
clinical trials, accumulates preferentially into prostate cancer tissues. The local 
treatment of the tumor with fibres permits to avoid total resection of the prostate, as 
currently performed in the clinic.73   
- Porphyrin photosensitizers absorb light in the red (600-800 nm), allowing light to 
penetrate the dermis of the skin.74 Research to tune molecules for near infra-red 
(NIR)(>800 nm) absorbance are ongoing, since such wavelengths penetrate deeper 
into the skin, and will allow for treatment of cancer located deeper in the tissue 
without surgery. According to the location of the cancer, it may be of interest to 
modulate the light penetrability of the skin, and thereby the activation of the drug. 
Indeed, if the layer of skin underlying the tumor is at risk or need to be protected, the 
use of a topical or short skin entrance (UV-A) is relevant (optical properties of the 
skin in Figure 8) 
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Figure 16. Propagation of light in the tissue according to its wavelength. Taken from ref 74. 
 
(iii) Photodynamic Therapy and Photodiagnosis 
5-Aminolevulinic acid (ALA), is metabolized via the heme biosynthetic pathway 
and results in the endogenous photosensitizer protoporphyrin IX (PpIX). The latter 
photosensitizer can also be used as a fluorescence cancer marker for the detection of 
cancer, combining PDT and photodiagnosis.75 The advantage of such a molecule is 
that combined to surgery, remaining cancer tissue can be visualized and treated. 
(iv) Substitute to surgery 
For safety reasons, during removal surgery of a solid tumor, a large surrounding 
area, mostly composed of healthy tissue is also sacrificed. The use of PDT would be 
aesthetically preferable, where removal of large skin areas, for example, on the head, 
will lead to bad esthetical outcomes or skin difficulty to reattach. As mentioned 
above, the use of fibres in an organ to locally treat tumor tissues instead of the total 
ablation could benefit to the patient, as illustrated by the prostate case.  
 
3.2. ADVANTAGES OF RU COMPLEXES OVER TRADITIONAL PORPHYRIN 
BASED PHOTOSENSITISERS 
 Nowadays, most of the photosensitizers clinically used in PDT are porphyrins-
based. However, they suffer several drawbacks that non-porphyrin based Ru 
complexes could tackle.  
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(i) Poor solubility 
The poor water solubility of porphyrins makes them difficult to synthesize, mostly 
because of the purification step. The same is true in biological solution, raising the 
issue for bloodstream administration. Research towards increasing solubility is on 
going with the so-called 2nd PS generation. To this end, one of the strategies examined 
is the insertion of a metal fragment, such as Zn or Ru, to inter alia increase the 
solubility of the conjugated porphyrin.30 
(ii) Extended photosensitivity in patient skin 
An other important drawback from with patients suffer, is the prolonged 
photosensitivity of current PS like Photofrin.54 Therefore, using PS with non-
porphyrin structure could be a way to reduce photosensitivity. 
 
3.3. ADVANTAGES OF THE CAGING AND TRIGGERED-RELEASE 
STRATEGY IN CANCER THERAPY  
(i) Reduced systemic toxicity 
In the field of targeted therapy, the selective and located delivery of biologically 
active compounds into living cells is highly attractive. The control derived from such 
a strategy permits to concentrate the action of the drug at a given location, reducing 
though the systemic toxicity of the latter molecule. The availability of existing cages 
permit the use of internal or external trigger, the latter one offering additional 
temporal control on the drug activity. 
(ii) Use of endogenous and exogenous triggers  
Are considered endogenous trigger, all the events derived from diseased cellular 
tissues, such as ROS level, specific pH change or presence of a tissue-specific 
enzyme. More appealing is the use of an external trigger to activate the release of the 
molecule, since it offers complete control on the release. Different sort of cages exist. 
They respond to specific events such as light, magnetic field or temperature. The most 
interesting trigger is light, since, as explained earlier, it is cheap and the range of 
wavelength allows for tuning the skin permeability.  
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3.4. FUTURE DIRECTION 
The next step in this research field would be to increase the targeting efficiency of 
PDT agents. Although the enhanced permeability and retention effect of PS in cancer 
tissues favors the accumulation of the latter in tumor over healthy cells,76 this feature 
could be improved by the attachment of a targeting molecule to the PS. As example, a 
specific biomolecule could be used as a targeting moiety since it is known that several 
receptors at the surface of cancer cells are overexpressed.  
More work needs also to be done in order to find efficient PS complexes with 
absorption in the near-IR, to targets tumors localized deeper in the skin without 
surgery.  
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Figure S1. 1H NMR spectrum of [Ru(bipy)2(Cpp-L-OH)](PF6)2 (2) in DMSO-d6. 
 
Figure S2. 1H NMR spectrum of [RuII(dppz)2(CppH)](PF6)2 (3) in DMSO-d6. 
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Figure S3. Absorption spectra for 10 ȝM solutions of Ru(II) complexes. Solid traces represent 
the spectrum in acetonitrile and dotted traces show spectra in H2O/0.2% DMSO solutions.  
 
 
 
 
Figure S4. Emission spectra recorded on excitation of 10±1 ȝM acetonitrile solutions of 1-4 at 
450 nm. 
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Figure S5. Thermal ellipsoid representation of the cationic unit [Ru(bipy)2(CppH)]2+, in 1 
(probability ellipsoids drawn at 50%; selected hydrogen atoms, counter PF6Ǧanions and water 
molecules omitted for clarity). 
 
Figure S6. Thermal ellipsoid representation of a cationic unit, 
[Ru(bipy)2(Cpp-NH-Hex-COOH)]2+, of 2 (probability ellipsoids drawn at 50%; selected 
hydrogen atoms, counter ClO4Ǧ anions and water molecules omitted for clarity). 
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Figure S7. Molecular packing diagram for [Ru(bipy)2(Cpp-NH-Hex-COOH)](ClO4)2 (2) 
showing hydrogen-bonding interactions (shown in dashed bonds) and C-H….ʌ interactions 
present in the crystal lattice, as viewed along the ‘b’ axis.  
 
Table S1. Selected bond lengths [Å] and angles [°] for 1 and 2. 
1 2 
  
            Ru(1)-N(4)                    2.048(3)  
            Ru(1)-N(6)                    2.051(4)  
            Ru(1)-N(5)                    2.054(3)  
            Ru(1)-N(2)                    2.058(4)  
            Ru(1)-N(8)                    2.057(3)  
            Ru(1)-N(1)                    2.069(4) 
            C(30)-O(1)                    1.239(7) 
            C(30)-O(2)                    1.261(7) 
            Ru(1)-N(4)                    1.947(4)  
            Ru(1)-N(2)                    1.951(4)  
            Ru(1)-N(3)                    2.053(3)  
            Ru(1)-N(8)                    2.058(4)  
            Ru(1)-N(7)                    2.178(4)  
            Ru(1)-N(1)                    2.184(4) 
            C(36)-O(7)                    1.340(7) 
            C(36)-O(8)                    1.268(6) 
            C(30)-O(9)                    1.193(5) 
  
            N(4)-Ru(1)-N(6)           88.54(13)  
            N(4)-Ru(1)-N(5)         173.85(13)  
            N(6)-Ru(1)-N(5)           95.40(13)  
            N(4)-Ru(1)-N(2)           95.65(14)  
            N(6)-Ru(1)-N(2)           78.60(15)  
            N(5)-Ru(1)-N(2)           89.77(14)  
            N(4)-Ru(1)-N(8)           97.60(14)  
            N(6)-Ru(1)-N(8)         172.29(14)  
            N(5)-Ru(1)-N(8)           78.89(13)  
            N(2)-Ru(1)-N(8)           96.07(15)  
            N(4)-Ru(1)-N(1)           78.75(13)  
            N(6)-Ru(1)-N(1)           97.64(14)  
            N(5)-Ru(1)-N(1)           96.01(13)  
            N(2)-Ru(1)-N(1)         173.40(14)  
            N(8)-Ru(1)-N(1)           88.18(13)  
            O(1)-C(30)-O(2)             124.8(5) 
            N(4)-Ru(1)-N(2)          174.10(15) 
            N(4)-Ru(1)-N(3)            78.88(14) 
            N(2)-Ru(1)-N(3)            96.76(14) 
            N(4)-Ru(1)-N(8)            96.45(14) 
            N(2)-Ru(1)-N(8)            88.28(14) 
            N(3)-Ru(1)-N(8)          172.63(15) 
            N(4)-Ru(1)-N(7)            87.05(14) 
            N(2)-Ru(1)-N(7)            97.34(16) 
            N(3)-Ru(1)-N(7)            94.93(14) 
            N(8)-Ru(1)-N(7)            79.03(14) 
            N(4)-Ru(1)-N(1)           97.07(15)  
            N(2)-Ru(1)-N(1)           78.70(16)  
            N(3)-Ru(1)-N(1)           87.90(13)  
            N(8)-Ru(1)-N(1)           98.40(14)  
            N(7)-Ru(1)-N(1)         175.40(13) 
            O(8)-C(36)-O(7)             123.1(6) 
             
   
S6 
 
    
 
Figure S8. Cytotoxicity of 3 on HeLa, MCF-7, U2OS, A2780, CP-70 and MRC-5 cells 
measured by the resazurin assay.  
 
 
Figure S9. Cytotoxicity of Cisplatin on HeLa, MCF-7, U2OS, A2780, CP-70 and MRC-5 cells 
measured by the resazurin assay.  
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Figure S10. Cytotoxicity of dequalinium choride hydrate on HeLa, MCF-7, U2OS, A2780, 
CP-70 and MRC-5 cells measured by the resazurin assay. 
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Figure S11. Fluorescence microscopy images of living HeLa cells incubated with: a) 1 (100 
ȝM, 2 h); b) 2 (15 ȝM, 4 h); c) 3 (20 ȝM, 2 h) and d) 4 (70 ȝM, 15 min). Images show cellular 
staining of ruthenium compounds, phase contrast and the overlay. 
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Figure S12. UV traces (300 nm) for LC-MS analysis of human blood plasma incubated with 
3 (20 ȝM) at t = 0 and 72 h (Diazepam was used as internal standard).  
 
Table S2. Ratio of peak areas of 3/diazepam at t = 0 and 72 h. 
Time (h) Ratio of peak area (3/Diazepam) 
0  21.54 
72 20.17 
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Figure S13. Flow cytometry dot plots showing the effect of the temperature on the uptake of 3 
(20 PM) after 6 h in HeLa cells. Green spots represent cells that have taken up 3 in A) control 
untreated cells or cells treated at B) 4 qC, C) 23 qC, and D) 37 qC. 
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(a) 
 
 
 
(b) 
 
Figure S14. Effect of temperature on: (a) uptake of 3 {HeLa cells were incubated with 3 
(20 ȝM, 6h) at 4 °C, 23 °C or 37 °C and the amount of compound taken up was determined by 
flow cytometry}; (b) mitochondrial membrane potential of untreated HeLa cells incubated for 6 h 
at 4 °C, 23 °C or 37 °C {Valinomycin was used a positive control (6 h at 37 °C)}. 
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Table S3.  Cyclic voltammetric data obtained as a function of scan rate (Ȟ) at a glassy carbon 
electrode from the oxidation of 2-4 (1.0 mM) in MeCN (0.1 M nBu4NPF6) at (20 ± 2) ºC. 
Complex ȃ 
(mVs-1) 
Epox (mV)a,b Epred (mV)a,b ¨Ep (mV)a,b Em (mV)a,b |ipox/ipred|a,c Diffusion 
coeff 
(cm2s-1) 
(x10-5)d 
2 100 1010 930 80 970 1.09 1.03±0
.1 
200 1010 930 80 970 1.07  
300 1010 930 80 970 1.07  
400 1020 930 90 975 1.06  
500 1020 930 90 975 1.05  
700 1020 930 90 975 1.04  
1000 1020 930 90 975 1.02  
        
3 
 
100 1130 1070 60 1100 0.91 1.05±0
.1 
200 1140 1070 70 1105 0.92  
300 1140 1070 70 1105 0.93  
400 1140 1070 70 1105 0.93  
500 1140 1070 70 1105 0.93  
700 1140 1070 70 1105 0.94  
1000 1140 1070 70 1105 0.95  
        
4 100 1100 1030 70 1065 0.92 1.12±0
.1 
200 1100 1030 70 1065 0.93  
300 1100 1020 80 1060 0.94  
400 1100 1020 80 1060 0.95  
500 1100 1020 80 1060 0.93  
700 1100 1020 80 1060 0.93  
1000 1100 1020 80 1060 0.93  
        
 
aOxidation peak potential = Epox; reduction peak potential = Epred; Em = (Epox+Epred)/2 versus 
the Fc0/+ couple; oxidation peak current = ipox; reduction peak current = ipred. bMeasured peak 
potentials have an error of ±5 mV versus Fc0/+. cThe ratios of peak currents associated with the 
oxidation and reduction of the complexes were calculated according to the empirical method 
derived by Nicholson.1 dDiffusion coefficient data obtained from the linear plot of ipox versus 
Ȟ1/2, employing the Randles-Sevcik equation.2-4 
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Figure S15. Cyclic voltammograms obtained at a glassy carbon electrode using a scan rate of 
100 mV s-1 for the oxidation of 1 mM Ru(II) complexes in MeCN (0.1 M nBu4NPF6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S16. Cyclic voltammograms obtained at a glassy carbon electrode for the oxidation of 
1 mM 2 in MeCN (0.1 M nBu4PF6) as a function of scan rate. 
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Figure S17. Cyclic voltammograms obtained at a glassy carbon electrode for the oxidation of 
1 mM 3 in MeCN (0.1 M nBu4PF6) as a function of scan rate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S18. Cyclic voltammograms obtained at a glassy carbon electrode for the oxidation of 
1 mM 4 in MeCN (0.1 M nBu4PF6) as a function of scan rate. 
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Figure S19. Changes in absorption spectra of 3 (3.96 ȝM) in 10 mM phosphate buffer (pH = 
7.01, 50 mM NaCl) with increasing concentrations of CT-DNA until [DNA]/[Ru] = 4. Arrows 
show spectral changes upon increasing DNA concentrations. In the inset: plot of (İa - İf)/(İb - İf) 
vs [DNA] and the non-linear fit of the titration data. 
 
 
Figure S20. Changes in absorption spectra of 4 (4.62 ȝM) in 10 mM phosphate buffer (pH = 
7.01, 50 mM NaCl) with increasing concentrations of CT-DNA until [DNA]/[Ru] = 3. Arrows 
show spectral changes upon increasing DNA concentrations. In the inset: plot of (İa - İf)/(İb - İf) 
vs [DNA] and the non-linear fit of the titration data. 
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Figure S21. Changes in absorption spectra of 1 (20 ȝM) in 10 mM phosphate buffer (pH = 
7.01, 50 mM NaCl) with increasing concentrations of CT-DNA until [DNA]/[Ru] = 6. 
 
 
 
Figure S22. Changes in absorption spectra of 2 (5.48 ȝM) in 10 mM phosphate buffer (pH = 
7.01, 50 mM NaCl) with increasing concentrations of CT-DNA until [DNA]/[Ru] = 9. 
   
S17 
 
 
Figure S23. Changes in emission spectra (ʄex = 440 nm) of 3 (3.96 ȝM) in 10 mM phosphate 
buffer (pH = 7.01, 50 mM NaCl) with increasing concentrations of CT-DNA until 
[DNA]/[Ru] = 4. Arrows show spectral changes upon increasing DNA concentrations. In the 
inset: plot of (Ia - If)/(Ib - If) vs [DNA] and the non-linear fit of the titration data. 
 
 
Figure S24. Changes in emission spectra (ʄex = 440 nm) of 4 (4.62 ȝM) in 10 mM phosphate 
buffer (pH = 7.01, 50 mM NaCl) with increasing concentrations of CT-DNA, until [DNA]/[Ru] 
= 3. Arrows show spectral changes upon increasing DNA concentrations. In the inset: plot of 
(Ia - If)/(Ib - If) vs [DNA] and the linear fit of the titration data. 
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Figure S25. Slices of a 1% agarose gel containing 0.5 ȝg of 1kb DNA ladder were incubated 
with ruthenium compounds (2.5 ȝM) for 40 minutes and visualized by UV (365 nm). Ethidium 
bromide was taken as positive control.  
 
 
Figure S26. Slices of a 8% SDS-gel containing 5 ȝL of Bio-Rad Broad Range Protein Markers 
(0.25 µL) were resolved on a 8% SDS-gel and individual lanes were incubated with ruthenium 
compounds (2.5 ȝM) for 40 minutes, analyzed with ethidium bromide colorimetric filter. 
Coomassie blue was taken as positive control.  
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Figure S27. Apoptosis assay. (A) Scattergrams of HeLa cells (forward vs. side scatter; left 
panels), histograms of cells stained with annexin V-FITC after treatment with 3 (20 ȝM) for 
2, 24, 48 or 72 h: annexin-positive cells are shown in the R2 gate (middle panels) and cells 
stained with 3 in the R4 gate (right panels). FITC and Ruthenium fluorescence were analyzed 
in the FITC and in the PE-Texas Red channels, respectively. (B) Quantification table of 
apoptotic cells. 
 
 
Figure S28. Caspase 3/7 activity measurements. HeLa cells were incubated with 3 (20 µM, 
24 h) or staurosporin (150 nM, 6 h) at 37 °C and the extent of substrate cleavage by caspase 
3/7 was determined. 
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Figure S29. ROS production measurements. HeLa cells were incubated with 3 for 30 min, 
1 h, 2 h or 6 h at 37 °C in presence or absence of NAC (10 mM).  
 
 
Figure S30. Flow cytometry dot plots showing the effect of 3 (20 ȝM) on the mitochondrial 
membrane potential (MMP) in HeLa cells. A) control unstained cells, B) untreated cells 
displaying normal MMP, C) cells treated with valinomycin, D), E) and F) cells treated with 3 for 
2 h, 24 h or 48 h, respectively. 
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Figure S31. Effect of temperature on the mitochondrial membrane potential of HeLa cells 
incubated with 3 (20 ȝM). Cells were incubated for 6 h at 4 °C, 23 °C or 37 °C and the 
percentage of cells with depolarized mitochondrial membrane was determined.  
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Table S4. Crystallography collection and refinement data of 1 and 2. 
Compound 1 2 
empirical formula C30H23F12N7O4P2Ru C36H34Cl2N8O13Ru 
M/g mol-1 936.56 958.68 
crystal system  Monoclinic Monoclinic 
space group P21/c P21/c 
a/Å 11.6446(6) 15.8449(7) 
b/Å 24.0079(11) 14.7672(8) 
c/Å 13.3326(6) 16.7863(9) 
ȕ/deg 99.087(2) 99.325(3) 
V/Å3 3680.5(3) 3875.8(3) 
Z 4 4 
T/K 173(2) 173(2) 
Ȝ/Å 0.71073 0.71073 
Dalcdc/g cm-3 1.690 1.643 
M(Mo KĮ)/mm-1  0.620 0.620 
no. data measured 26656 36905 
unique data (Rint)  6440 (0.0421) 6850 (0.0611) 
observed data [I > 2(ı)I] 5389 5149 
final R1, wR2 (obsd data) 0.0488a, 0.1309b 0.0529a, 0.1321b 
final R1, wR2 (all data) 0.0598, 0.1401 0.0760, 0.1445 
ȡmin, ȡmax/e Å-3  -0.768, 1.202 -0.630, 0.770 
a R = Ȉ(|Fo | - |Fc|)/ Ȉ |Fo |. b R’ = [Ȉ w(|Fo | - |Fc|)2/ Ȉ Fo2]1/2, where w = [ı2(Fo)]-1.  
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Figure S1. 1H NMR spectrum of 2 in CD3CN. 
 
 
Figure S2. 1H NMR spectrum of 3 in CD3CN. 
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Figure S3. 1H NMR spectrum of 4 in CD3CN. 
 
 
Figure S4. 1H NMR spectrum of 6 in CD3CN. 
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Figure S5. 1H NMR spectrum of 7 in CD3CN. 
 
Figure S6. 1H NMR spectrum of 8 in CD3CN. 
 S4  
 
Figure S7. 1H NMR spectrum of 9 in CD3CN. 
 
 
 
 
Figure S8. LC-MS spectrum of 11.  
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Figure S9. LC-MS spectrum of 12 (two major peaks in the LC spectrum show a similar MS 
pattern). 
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Figure S10. LC-MS spectrum of 13 (two major peaks in the LC spectrum show a similar MS 
pattern). 
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Figure S11. LC-MS spectrum of 14.  
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Figure S12. LC-MS spectrum of 15.  
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Figure S13. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 2 (60 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
 
 
 
Figure S14. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 3 (60 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
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Figure S15. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 4 for 2 h. Images show (1) DAPI staining, (2) cellular staining of 
ruthenium compounds, and (3) the overlay. 
 
 
Figure S16. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 5 (40 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
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Figure S17. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 6 (100 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
 
 
 
 
Figure S18. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 7 (30 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
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Figure S19. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 8 (30 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
 
 
Figure S20. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 9 (70 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
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Figure S21. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 12 (40 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
 
 
Figure S22. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with 13 (100 μM) for 2 h. Images show (1) DAPI staining, (2) cellular 
staining of ruthenium compounds, and (3) the overlay. 
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Figure S23. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with (a) 14 (100 μM), and (b) 15 (100 μM) for 2 h.  
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 S2  
Experimental Section 
Materials. All chemicals were of reagent grade quality or better, obtained from commercial 
suppliers and used without further purification. Solvents were used as received or distilled 
using standard procedures. Deionised water was used for all reactions in aqueous solution. 
Thin layer chromatography (TLC) was performed using silica gel 60 F-254 (Merck) plates 
with detection of spots being achieved by exposure to iodine or UV light. Column 
chromatography was done using Silica gel 60 (0.040-0.063 mm mesh, Merck) or activated 
neutral alumina (Brockmann l, Sigma-Aldrich). Eluent mixtures are expressed as volume to 
volume (v/v) ratios.  
Instrumentation and methods. A vacuum line and Schlenk glassware were employed 
when reactions had to be carried out under an atmosphere of dry, oxygen-free nitrogen and 
assemblies were protected from light if necessary by wrapping them with aluminium foil. 1H 
and 13C{1H} NMR spectra were measured on Bruker DRX 400 and 500 spectrometers, at 
room temperature. The chemical shifts, G, are reported in parts per million (ppm), using the 
signal of the deuterated solvent as an internal standard.[1] The abbreviations for the peak 
multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q 
(quartet), m (multiplet), and br (broad). ESI mass spectrometry was performed using a Bruker 
Esquire 6000 spectrometer. In the assignment of the mass spectra, the most intense peak is 
listed. Microanalysis was performed on a LecoCHNS-932 elemental analyser.  
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Synthesis.  
 

Scheme S1. Synthetic route for preparation of the prodrug candidate C2 (racemic mixture). 
Reagents and conditions: (a) NaH, dry THF, MeI, 0 °C–rt, 2 h, 96%; (b) NaBH4, 
THF/isopropanol (1:2 v/v), rt, 1 h, 98%; (c) Cu(NO3)2•3H2O, Ac2O, rt, o/n, 68%; (d) HATU, 
Et3N, DMF, DMAP, 65 °C, 18 h, 76%. 
 
Compound 3-(3,4-dimethoxyphenyl)-butan-2-ol (3) [2] (isolated as a mixture of erythro/threo 
isomers) and [Ru(dppz)2(CppH)](PF6)2 (C1)[3] were synthesised according to the literature 
procedure. The characterisation data were in agreement with the published data.  
 
3-(4,5-dimethoxy-2-nitrophenyl)butan-2-ol (DMPNB, 4). A mixture of 3-(3,4-
dimethoxyphenyl)-butan-2-ol (0.476 g, 2.27 mmol) and Cu(NO3)2•3H2O (0.657 g, 2.72 
mmol) in 20 mL acetic anhydride was stirred under nitrogen for 12 h. The reaction mixture 
was diluted with water (20 mL) and aqueous solution was extracted with dichloromethane (3 
× 60 mL). The combined organics were washed with 2 N NaOH (2 × 30 mL), water and 
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brine, dried over Na2SO4, filtered and concentrated under reduced pressure. Purification of the 
crude product by silica gel column chromatography using ethylacetate/hexane (3:7 v/v) as 
eluent, yielded an erythro-threo isomeric mixture of 4 as a yellow solid. Yield: 0.395 mg 
(68%). Rf = 0.43 in ethylacetate/hexane (2:3 v/v). The characterisation data for 4 was found to 
be in agreement with that earlier reported.[2] 
 
[Ru(dppz)2(Cpp-ODMPNB)](PF6)2 (C2). The reaction was performed under the exclusion 
of light. HATU (0.013 g, 0.035 mmol), DMAP (0.06 g, 0.044 mmol), triethylamine (0.006 
mL, 0.044 mmol) and 4 (0.010 g, 0.040 mmol) were added to a solution of 
[Ru(dppz)2(CppH)](PF6)2 (0.025 g, 0.022 mmol) in dimethylformamide (5 mL), and the 
reaction solution was heated at 65 °C under a nitrogenous atmosphere for 18 h. After removal 
of the solvent under reduced pressure, the residue was purified using column chromatography 
(SiO2, eluent gradually changed from 100% EtOAc to CH3CN/H2O/sat. KNO3 (16:3:1)). The 
bright orange band was collected and evaporated to dryness. The concentrate was suspended 
in minimum chloroform and filtered to remove insoluble KNO3 salt. The filtrate was 
evaporated to dryness, and the residue was resuspended in saturated aqueous solution of 
NH4PF6, sonicated for 2 min and stored (2 h) at 2 °C for complete precipitation of the 
product. The precipitate was collected by filtration, washed with water and ether, and dried in 
vacuo. This yielded the desired complex C2 as an orange solid. Yield: 0.023 g (76%).  Anal. 
calcd. for C58H42F12N12O6P2Ru (%): C, 49.97; H, 3.04; N, 12.06. Found: C, 50.06; H, 2.97; N, 
11.99. 1H NMR (400 MHz, CD3CN): į 1.26–1.45 (m, 6H), 3.61–3.86 (m, 7H), 5.46–5.54 (m, 
1H), 6.97–7.06 (m, 1H), 7.22 (min) and 7.30 (maj) (s, 1H), 7.43–7.59 (m, 2H), 7.76–7.82 (m, 
2H), 7.87–7.91 (m, 1H), 7.94–8.02 (m, 2H), 8.13–8.22 (m, 7H), 8.27–8.31 (m, 2H), 8.41–8.43 
(m, 1H), 8.46–8.52 (m, 4H), 8.79–8.81 (m, 1H), 9.64–9.68 (m, 2H), 9.75–9.77 (m, 2H) ppm. 
MS (ESI+): m/z 552.1 [M-2PF6]2+.  
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Photolysis evaluation. For photolysis measurements, 1 mL PBS (pH 7.2) solution of C2 (50 
PM) in a 1 cm quartz luminescence cuvette was irradiated at 350 nm, in a RPR100 Rayonet 
Chamber Reactor (Southern New England Ultraviolet Company), equipped with 6 lamps. 
UV-Vis spectra were recorded after different irradiation times (t = 0, 5, 10, 15, 20 minutes) 
and 70 PL aliquots were collected to evaluate the photouncaging of the compound by UPLC-
MS analysis. A total of 5 PL of the solution was injected into the UPLC (Acquity Ultra 
Performance LC, Waters) that was connected to a mass spectrometer (Bruker Esquire 6000) 
operated in ESI mode. The Waters ACQUITY UPLC ® BEH C18 1.7 mm (2.1 × 50 mm) 
reverse phase column was used with a flow rate of 0.6 mL miní1 and UV-absorption was 
recorded at 275 nm. The runs were performed with a linear gradient of A (acetonitrile (Sigma 
Aldrich HPLC-grade)) and B (distilled water containing 0.02% TFA and 0.05% HCOOH): t = 
0í0.25 min, 5% A; t = 4.5 min, 100% A; t = 5.5 min, 100% A. 
To obtain the quantum yield of photorelease (ĭ), a solutions of C2 (50 PM in PBS) and a 
reference compound, 1-(2-Nitrophenyl)ethyl phosphate (57 PM in PBS) with known quantum 
yield ()ref = 54%)[4], were irradiated at 350 nm for different irradiation times, in a quartz 
luminescence cuvette in the Chamber Reactor equipped with 2 lamps. Samples were collected 
until 20% of the caged compound was decomposed, and 30 PL of the collected sample was 
injected into the VWR HITACHI Chromaster HPLC system. Reference sample was analyzed 
with a MACHEREY NAGEL EC 250/3 Nucleosil 100-5 C18 reverse phase column with a 
flow rate of 1 mL min-1, with a linear gradient of A (acetonitrile (Sigma Aldrich HPLC-grade 
and B (distilled water containing 0.1% TFA): t = 0–3 min, 5% A; t = 3–15 min, 86.4% A; 15–
16 min, 100% A; 16–17.5 min, 100% A; 17.5–18.5 min, 5% A. C2 samples were analyzed 
with a MACHEREY NAGEL EC 150/3 Nucleosil 100-5 C18 reverse phase column with a 
flow rate of 1 mL min-1, with a linear gradient of A (acetonitrile (Sigma Aldrich HPLC-grade 
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and B (distilled water containing 0.1% TFA): t = 0–3 min, 20% A; 3–7 min, 50% A; 7–17 
min, 73.1% A; 17–18 min, 100% A. From the HPLC chromatograms recorded at 300 nm, the 
area of the uncaged products was evaluated and plotted against the irradiation time for both 
the reference and the complex. The data were fitted with linear regression to derive slope (S) 
(Figure S3).  
The photorelease quantum yields (ĭsample) were determined using the equation:  
ĭsample = ĭref (Ssample / Sref) (Iref  / Isample)   
where Ssample and Sref are the slope for the linear fit of the absorbance vs. irradiation time plots 
for the sample and reference, respectively, and Isample and Iref are the integrated light 
absorption of the sample and reference, respectively, calculated as:  
 I = I0 (1 – 10-A(Ȝ))     
where, I0 is the light intensity of the irradiation source in the irradiation interval and AO is the 
absorbance of the sample at wavelength Ȝ. 
 
 
Singlet Oxygen Evaluation. The singlet oxygen measurements were performed following 
our previously published procedure,[5] using two different methods. 
 Near-IR luminescence (direct evaluation): Luminescence measurements were performed on a 
Fluorolog-3 Spectrofluorometer (Jobin Yvon Horiba, Model FL3-11) with a 450 W xenon 
lamp light source and single-grating excitation and emission spectrometers. For high beam 
intensity, the excitation slits were set to a maximum value of 29.4 nm. A colored glass filter 
was placed between the sample and the detector to cut off the light below 695 nm. The 
emission signal between 1200–1350 nm was collected at right angle to the excitation path, 
with an IR-sensitive liquid nitrogen cooled germanium diode detector (Edinburgh 
Instruments, Model EI-L). The detector was biased at -160 V. The signal-to-noise ratio of the 
 S7  
detected signals was improved with a lock-in amplifier (Stanford Research Systems, model 
SR510) referenced to the chopper frequency of 126 Hz, and the data-acquisition was done 
with DataMax. Samples in aerated acetonitrile were prepared at an optical density of 0.4 at the 
irradiation wavelength (365 nm), in 1 cm luminescence quartz cuvette. Four different 
transmittance filters were used to vary the intensity of the irradiation beam. Integrated area of 
the singlet oxygen luminescence was plotted against the intensity of irradiation (Figure S4), 
and slope for the linear fit was calculated (Ssample). 
N,N-dimethyl-4-nitrosoaniline/histidine assay (indirect evaluation): Air-saturated PBS 
buffer solution containing the complex (OD = 0.15 at the irradiation wavelength), p-
nitrosodimethyl aniline (RNO) (20 ȝM), histidine (10 mM) was irradiated in a 1 cm 
luminescence quartz cuvette at 350 nm, in a RPR100 Rayonet Chamber Reactor (Southern 
New England Ultraviolet Company) with 12 lamps, for different time intervals. For each 
sample, the absorbance of the irradiated solution was recorded and variation in the absorbance 
at 440 nm (A0-A, where A0 is the initial absorbance before irradiation) was plotted against the 
total irradiation time (Figure S5). Slope for the linear fit was calculated (Ssample) and used for 
quantum yield determination. 
For both methods, phenalenone (ĭref(1O2) = 95%) was used as a reference compound to 
obtain Sref. 
The singlet oxygen quantum yields (ĭsample) were determined using the equation:  
ĭsample = ĭref (Ssample / Sref) (Iref  / Isample)   
where Ssample and Sref are the slope for the linear fit of the absorbance vs. irradiation time plots 
for the sample and reference, respectively, and Isample and Iref are the integrated light 
absorption of the sample and reference, respectively, calculated as:  
 I = I0 (1 – 10-A(O))     
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where, I0 is the light intensity of the irradiation source in the irradiation interval and AO is the 
absorbance of the sample at wavelength O. 
 
Cell Culture. Human cervical carcinoma cells (HeLa) were cultured in DMEM (Gibco) 
supplemented with 5% fetal calf serum (FCS, Gibco), 100 U/mL penicillin, 100 ȝg/mL 
streptomycin. The human osteosarcoma cell line (U2OS) was maintained in DMEM (Gibco) 
supplemented with 10% FCS (Gibco), penicillin (100 U/mL), and streptomycin (100 ȝg/mL). 
The normal human fetal lung fibroblast cell line (MRC-5) was grown in F-10 medium 
(Gibco) supplemented with 10% FCS (Gibco), penicillin (100 U/mL), and streptomycin (100 
ȝg/mL). The cells were cultured at 37 °C and in 5% CO2 humidified atmosphere. 
Cytotoxicity Determination. The toxicity of the Ru(II) complexes to HeLa, U2OS and 
MRC-5 cells, in the dark and upon light (350 nm) irradiation, was evaluated using Resazurin 
based fluorometric cell viability assay. Stock solutions of the Ru(II) complexes (20 mM) were 
prepared in DMSO, and stored in the dark. The respective stock solutions were further diluted 
with complete medium to the desired working concentrations. For a typical experiment, 
100 ȝL aliquots of cells in growth medium were seeded in 96-well plates (density of 4 × 103 
cells/well for HeLa and U2OS, and 7.5 × 103 cells/well for MRC-5) and incubated at 37°C 
and 5% CO2. After 24 h of incubation, cells were treated with different concentrations (0.8–
100 µM, 200 µL final well volume) of the test compound and incubated for 4 h or 48 h, in the 
dark, as required. For experiments with compounds, cells were treated for 4 h, the medium 
was replaced thereafter, followed by incubation for additional 48 h. For light irradiation 
experiments, cells were exposed to light (350 nm) for 10 min (2.58 J cm-2) prior to their 48 h 
incubation (for calculation purposes, the light dose intensity delivered was corrected for 
absorption by the 96-well plate lids). Thereafter, for all experiments, the medium was 
removed, 100 µL of freshly prepared resazurin containing complete medium (0.2 mg/mL final 
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concentration) was added, and cells were incubated at 37 oC for additional 4 h. At the end of 
the incubation period, fluorescence of the highly red fluorescent resorufin product (Ȝex = 540 
nm), at 590 nm, was quantified using a SpectraMax M5 microplate Reader. The reported 
cytotoxicity data is an average of at least two independent experiments, with triplicate 
determinations for each drug concentration. Final DMSO concentration in the wells was less 
than 0.5% (v/v). Control experiments on cells treated with same amount of DMSO in culture 
medium showed no cytotoxic effect (results not shown).  
,Q YLWUR Fluorescence Evaluation. Cellular localization of luminescent ruthenium(II) 
complexes was assessed by confocal microscopy. As for the cytotoxicity assays, stock 
solutions of the Ru(II) complexes (20 mM) were prepared in DMSO and diluted to the desired 
concentrations with culture medium. HeLa cells were grown on 18 mm Menzel-gläser 
coverslips at a density of 1 × 105 cells/mL in cell culture medium. Cells were incubated with 
ruthenium(II) complexes at defined  incubation concentration (either IC50 values or at 100 ȝM 
for the non-toxic complexes) for 2 h, at 37 °C under 5% CO2. The medium was removed, 
cells were fixed with a 4% formaldehyde solution in PBS and mounted on slides for viewing 
by confocal microscopy. For light irradiation experiments, the cells were exposed to light 
(350 nm) for 10 min (2.58 J cm-2), in fresh complete cell culture medium, prior to their 
fixation. Co-staining of cell nuclei with DAPI was performed by using a mounting solution 
containing DAPI (Ȝex = 402 nm, Ȝem > 420 nm). Fixed cells were imaged on a Leica SP5 
confocal laser scanning microscope, using the red wavelength selection (Ȝex = 458 nm, Ȝem = 
600–650 nm). 
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Figure S1. 1H NMR spectrum of C2 in CD3CN. 
 
 
Figure S2. UPLC chromatograms for photolysis of C2 upon irradiation for different time 
intervals. 
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Figure S3. Exponential fit for photorelease of C1(Ɣ) from the prodrug C2 (ż). 
 
Figure S4. Linear fitting of the photorelease of C1 for the calculation of the quantum yield. 
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Figure S5. Near-IR luminescence spectra for singlet oxygen production from C1 in 
acetonitrile (inset shows integrated area of the singlet oxygen luminescence with changing 
irradiation intensity). 
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Figure S6. Absorption spectra for singlet oxygen production from C1 in PBS buffer, as 
determined by RNO/histidine assay (indirect method), with the inset showing change in 
absorbance (440 nm) with increasing irradiation time.  
 
Table S1. Singlet oxygen evaluation. 
 
 
 
 
 
 
 
 
Figure S7. Fluorescence confocal microscopy images showing cellular staining patterns for 
HeLa cells incubated with C2 (20 ȝM) for 2 h. Images show cellular staining in cells 
maintained in the dark (a), and exposed to light irradiation (b), and their respective overlays 
Complex Acetonitrilea PBSb 
C1 81.1% 5.7% 
ameasured by near-IR luminescence (direct method). bmeasured by 
RNO/histidine assay (indirect method).  
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with DAPI staining ((c) and (d)). For light irradiation experiments, the cells were irradiated at 
350 nm for 10 min (2.58 J cm-2) prior to confocal imaging.  
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